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ABSTRACT OF THE DISSERTATION 
Integrative Analysis to Investigate Complex Interaction in Alzheimer’s Disease 
by 
Zeran Li 
Doctor of Philosophy in Biology and Biomedical Sciences 
Neurosciences 
Washington University in St. Louis, 2019 
Carlos Cruchaga, Chair 
Alzheimer’s disease (AD) is a neurodegenerative disorder featuring progressive cognitive 
and functional deficits. Pathologically, AD is characterized by tau and amyloid β protein 
deposition in the brain. As the sixth leading cause of death in the U.S., the disease course usually 
last from 7 to 10 years on average before the consequential death. In 2019 there are estimated 5.8 
million Americans living with AD affecting 16 million family members. At certain stage of the 
disease course, patients with inability of maintaining their daily functioning highly depend on 
caregivers, primarily family caregivers, that incur estimated 18.4 billion unpaid hours of cares, 
which is equivalent to 232 billion dollars. These huge economic burdens and inevitable 
emotional distress on the family and the society would also increase as the number of AD 
affected population could triple by 2050.  
Altered cellular composition is associated with AD progression and decline in cognition, 
such as neuronal loss and astrocytosis, which is a key feature in neurodegeneration but has often 
been overlooked in transcriptome research. To explore the cellular composition changes in AD, I 
developed a deconvolution pipeline for bulk RNA-Seq to account for cell type specific effects in 
brain tissues. I found that neuronal and astrocyte relative proportions differ between healthy and 
xvii 
diseased brains and also among AD cases that carry specific genetic risk variants. Brain carriers 
of pathogenic mutations in APP, PSEN1, or PSEN2 presented lower neuron and higher astrocyte 
relative proportions compared to sporadic AD. Similarly, the APOE ε4 allele also showed 
decreased neuronal and increased astrocyte relative proportions compared to AD non-carriers. In 
contrast, carriers of variants in TREM2 risk showed a lower degree of neuronal loss compared to 
matched AD cases in multiple independent studies. These findings suggest that genetic risk 
factors associated with AD etiology have a specific effect on the cellular composition of AD 
brains. The digital deconvolution approach provides an enhanced understanding of the 
fundamental molecular mechanisms underlying neurodegeneration, enabling the analysis of large 
bulk RNA-sequencing studies for cell composition. It also suggests that correcting for the 
cellular structure when performing transcriptomic analysis will lead to novel insights of AD. 
With deconvolution methods to delineate cell population changes in disease condition, it 
would help interpret transcriptomics results and reveal transcriptional changes in a cell type 
specific manner. One application demonstrated in this dissertation work is to use cell type 
proportion as quantitative trait to identify genetic factors associated with cellular composition 
changes. I performed cell type QTL analysis and identified a common pathway associated with 
neuronal protection underlying aging brains in the presence or absence of neurodegenerative 
disease symptoms. A protective variant of TMEM106B, which was previously identified with a 
protective effect in FTD, was identified to be associated with neuronal proportion in aging 
brains, suggesting a common pathway underlying neuronal protection and cognitive reservation 
in elderly. This extended analysis yield from deconvolution results demonstrated one promising 
direction of using deconvolution followed by cell type QTL analysis in identifying new genes or 
pathways underlying neurodegenerative or aging brains. 
xviii 
To understand the complexity of the brain under disease condition, network analysis as a 
large-scale system-level approach provides unbiased and data-driven view to identify gene-gene 
interactions altered by disease status. Using network analysis, I replicated and reconfirmed the 
co-expression pattern between MS4A gene cluster and TREM2 in sporadic AD, from which 
further evidence was inferred from Bayesian network analysis to show that MS4A4A might be a 
potential regulator of TREM2 that is validated by in-vitro experiments. In Autosomal Dominant 
AD (ADAD) cohort, disrupted and acquired genes were identified from PSEN1 mutation 
carriers. Among these genes, previously identified AD risk genes and pathways were revealed 
along with novel findings. These results demonstrated the great potential of applying network 
approach in identifying disease associated genes and the interactions among them.  
To conclude the dissertation work from methodological, empirical, and theoretical levels, 
deconvolution pipeline for bulk RNA-Seq, cell type QTL analysis, and network analysis 
approaches were applied to understand transcriptome changes underlying disease etiology. From 
which previous AD related findings were replicated that validated the methods, and novel genes 
and pathways were identified as potential new therapeutic targets. Based on prior knowledge and 
empirical evidence observed from this dissertation work, a model is proposed to explain how 
genetic factors are assembled as a highly interconnected interactome network to affect 
proteinopathy observed in neurodegenerative disorders, that cause cellular composition changes 
in the brain, which ultimately leads to cognitive and functional deficits observed in AD patients.
1 
  
 
 
 
 
Chapter 1: Introduction and Overview 
  
2 
1.1 The Alzheimer’s Disease discovery and its impact nowadays 
In 1901, Alois Alzheimer, a German psychiatrist and a lecturer at the Munich University 
Hospital received a patient case of a 51 years female named Auguste D[129]. She was sent by 
her husband describing her symptoms as paranoid, progressive sleep and memory disturbance, 
aggressiveness, crying, and confusion. This lady was admitted to the Community Psychiatric 
Hospital at Frankfurt am Main, and remained impatient until her death in 1906. The brain 
material of her autopsy was sent to Alzheimer for examination, from which he observed 
distinctive plaques and neurofibrillary tangles in the histology, which were later identified as 
pathological hallmarks of Alzheimer’s disease. In 1906, Alzheimer presented his finding of this 
“peculiar” dementia case in the 37th Meeting of South-West German Psychiatrists in Tubingen. 
Although at the meeting it did not spur much interests from the audience, Alzheimer’s finding 
was included as “Alzheimer's disease” in the 3th edition of his coworker Emil Kraepelin’s text 
‘Psychiatrie’ in 1910[129].  
For the past one hundred years since its first diagnosis, Alzheimer’s Disease (AD) is like 
a shadow that never leaves, and it also grows larger as human life expectancy increases as age 
being its most important risk factor. In 2019, there are estimated 5.8 million Americans living 
with AD affecting 16 million family members. At certain stage of the disease course, patients 
with inability of maintaining their daily functioning highly depend on caregivers, primarily 
family caregivers, that incur estimated 18.4 billion unpaid hours of cares, which is equivalent to 
232 billion dollars[15, 69]. These huge economic burdens and inevitable emotional distress on 
the family and the society would also increase as the number of AD affected population could 
triple by 2050[121].  
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As the sixth leading cause of death in the U.S., the disease course usually last from 7 to 
10 years on average before the consequential death[133]. Due to progressive neuronal death in 
the affected brain regions, apart from cognitive functions it will also disable movement functions 
of the patients with the results being long term bed-bound and later having swallowing problems 
that ultimately lead to organ failure or lethal aspiration pneumonia[15]. 
1.2 Cognitive deficits as the primary clinical symptoms and related 
measurements 
Among all the neurodegenerative disorder that would result in dementia, Alzheimer’s 
Disease is the most common form[23]. Impaired declarative memory is usually the first 
noticeable sign but sometimes it could also be other executive functions such as planning or 
problem-solving skills. More detailed cognitive deficit rating scales, such as the clinical 
dementia rating[189] (CDR), have been developed to further categorize cognitive performance 
for both clinical and research purposes. CDR = 0 is considered as normal without dementia; 
CDR = 0.5 is very mild dementia; CDR = 1 is mild dementia; CDR = 2 is moderate dementia; 
CDR = 3 is severe dementia.  
As our knowledge about neurodegenerative disorders accumulates, neuropsychological 
tests also evolve to optimize their diagnostic and prognostic utilities. Efforts have been spent on 
ensuring the test construct validity and stability with appropriate norms[88]. Test construct 
validity hinges heavily on an accurate and unambiguous design that projects the clinical batteries 
to their designated cognitive domains to ensure they are measuring what they are designed to 
measure. The assessment criteria of AD developed by the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) integrates evidence from multiple modalities including clinical, 
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behavioral, demographical, neuropsychological, neuropathological, neuroimaging, family 
history, and postmortem materials to standardize and ensure accurate diagnosis[91]. 
1.3 Diagnostic evidence from genetic, imaging, blood and CSF 
biomarkers 
Symptoms, such as memory loss or difficulties with executive functions, are usually what 
AD patients first complained to the physicians, however, pathologic changes have developed 
decades (10-20 years) before cognitive symptoms onsets[138, 211]. To capture preclinical stages 
and the disease development trajectory and dynamics, a variety of biomarkers or diagnostic 
evidence based on genetic, CSF, blood, and imaging biomarkers have been developed to 
facilitate early detection and differentiation among different dementia sub forms. 
1.3.1 Genetics 
Amyloid β is one of the two pathological hallmarks of AD, which was first isolated from 
a late onset AD (LOAD) patient[105]. Later, the same authors isolated cerebrovascular amyloid 
protein from Down’s syndrome, a disease caused by the presence of all or part of a third copy of 
chromosome 21(trisomy 21). Because of the close resemblance of the two proteins and the 
cerebrovascular amyloid protein discovery in Down’s syndrome, the authors accurately predicted 
that the amyloid β gene might be located on chromosome 21[104]. Three amyloid β related 
genes amyloid-beta precursor protein (APP), presenilin 1 (PSEN1), presenilin 2 (PSEN2) were 
identified associated with familial AD with in a Mendelian dominance pattern and high 
penetrance[148]. Then an amyloid cascade was hypothesized (Figure 1.1) suggesting over 
accumulation or failed clearance of amyloid β is the central event in the pathogenesis of AD, 
which led to neuronal and synaptic dysfunction, and ultimately to cognitive deficits[106]. Many 
statements surround the amyloid centered theory have been fulfilled but one issue raised 
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regarding whether amyloid β being the cause or the consequence of AD. If amyloid 
accumulation is the leading cause, then drugs targeting clearance of amyloid should ameliorate 
the symptom. However, so far, none of the drug developments targeting amyloid pathway is 
successful, which may suggest the alternative hypothesis that amyloid accumulation might be the 
consequence or by-product of AD.  
A second doubt surround the amyloid pathway comes from the differences in inheritance 
mechanism between sporadic and familial AD. Unlike familial AD which has a clear Mendelian 
inheritance pattern with three major gene players and an early onset of disease manifestation, 
sporadic AD is late onset and attributed to complex traits with multiple risk genes located 
throughout the genome[162]. It seems that genes with rare variants such as APP, PSEN1, PSEN2 
in familial AD exert high risk effects to familial AD, whereas many genes with common variants 
exert medium or low risk effects to sporadic AD (Figure 1.2). For sporadic AD, apolipoprotein 
E (APOE) is the gene with the largest and dosage dependent effect[84]. APOE has three major 
Figure 1.1 Amyloid cascade hypothesis. Image reproduced from Blennow et al.[29] with permission. 
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alleles, protective allele ε2, common allele ε3, and risk allele ε4. In Caucasian cohorts, carriers of 
two ε4 alleles have increased risk of 14.9 relative to two ε3 alleles. Walking down to the risk 
ladder, one ε4 allele renders increased risk of 2.6 for ε2/ε4, and increased risk of 3.2 for ε3/ε4. 
Carriers with protective allele ε2 have reduced risk of 0.6 in both ε2/ε2 and ε2/ε3[84]. APOE 
influence LOAD risk in an amyloid dependent manner[235, 252]. The rare TREM2 variant 
p.R47H (rs75932628) carriers exhibit increased AD risk by a range from 1.7-fold to 3.4-
fold[112, 212]. This gene is related to microglia and immune system through 
neuroinflammation[79]. The involvement of immune system leads to another hypothesis for AD 
surround inflammation and infection with microbial triggers, for example herpes infection[219] 
and oral P. gingivalis infection[75, 203]. Instead of thinking genetic variants as disease causing 
factors, is it possible that the genetic vulnerability that failed to protect the brain from insult is 
the cause of sporadic AD? For example, the vulnerability of blood brain barrier[254] and 
neuroinflammation triggered by microbial, stress, or even lack of sleep[68] initiate amyloid 
protein accumulation, then leads to neuronal death and subsequent cognitive deficits. The shift of 
thinking paradigm may drive therapeutic strategy and drug design switching from amyloid 
clearance to anti-inflammation or boost immune resilience to insults. Apart from researches 
focusing on protein coding genes, investigation of non-coding RNA in neurodegeneration[232] 
and 3D spatial structure of genome[218] may also shed light on figuring out the mechanism 
underlying AD.   
As shown in Figure 1.2, AD has a substantial but heterogeneous genetic component. The 
rare mutations in the APP, PSEN1 and PSEN2[64, 238] that cause autosomal dominant AD 
(ADAD) only account for 1-2% of overall AD cases. There are also early-onset AD cases with 
unknown genetic risk factors that remain elusive. Apart from early-onset AD, the most common 
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manifestation of AD presents late-onset (LOAD) and accounts for the majority of the cases (90-
95%). Despite appearing sporadic in nature, a complex genetic architecture underlies LOAD 
risk. APOE ε4 as discussed above is the most common genetic risk factor. In addition, recent 
whole genome and whole exome analysis have identified rare coding variants in TREM2[26, 
113], PLD3[58], ABCA7[65, 249]  and SORL1[86, 226] that are associated with AD and confer 
risk comparable to that of carrying one APOE ε4 allele. Besides age at onset, the clinical 
presentations of LOAD and ADAD are remarkably similar with an amnestic and cognitive 
impairment phenotype[230, 258]. A minor fraction of cases of ADAD have additional 
neurological findings, sometimes also seen in LOAD[230, 258]. Twin studies have estimated 
that the heritability of Alzheimer's disease is about 0.74 and argued that unexplained variance is 
due to environmental factors[101]. So far, genetic studies have identified around 30 common and 
rare genetic variants that contribute to the AD phenotypes; however, these genes with disease 
susceptibility only explain a small proportion of the genetic heritability of the AD population. 
The remaining unexplained heritability has been named as missing heritability[80, 177, 178]. In 
Chapter 4, an omnigenic model will be discussed from a network perspective to explain a 
potential cause of the missing heritability problem.  
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1.3.2 CSF and plasma biomarkers 
 Biomarkers are objective measures of biological or pathogenic changes that can be used 
as diagnostic, prognostic, or disease progression measurement tools. Cerebrospinal fluid (CSF) is 
a clear and colorless fluid that the brain and spinal cord are immersed in.  Due to its direct 
contact with the extracellular space of the brain, it is optimal as a biomarker to capture biological 
or pathogenic changes in the brain. CSF biomarkers can be divided to basic and core biomarkers. 
Basic biomarkers measure basic brain function that might be changed in AD condition but not 
specific to AD, which include measurements of blood brain barrier and immune system response 
to chronic inflammation (Table 1.1 basic biomarker section). The core biomarkers measure AD 
specific molecular pathology that is specific to AD, including APP metabolism and amyloid 
deposition, tau phosphorylation and axonal degeneration (Table 1.1 core biomarker section).  
Figure 1.2 AD gene risk allele frequency and risk effect. Image from Karch and Goate[148] with 
permission. 
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Amyloid β proteins of different length are cleaved from APP protein by beta-secretase 
and gamma-secretase (Figure 1.3), and Aβ40, Aβ42, and Aβ40:42 ratios are primarily measured as 
biomarkers. Six different tau isoforms can be divided through alternative splicing from exon 2, 3, 
and 10 of MAPT gene (Figure 1.4a). There are a number of phosphorylation sites of threonine 
and serine across the tau isoforms but the commonly referred as phosphorylated tau levels are 
measured from Thr181 or Thr231 phosphorylation sites (Figure 1.4b). Other CSF biomarkers 
related to neuronal and synaptic proteins, for example, visinin-like protein 1 (VLP-1) and 
synaptosomal-associated protein 25 (SNAP-25), and oxidative stress markers such as F2-
isoprostanes were also be able to differentiate AD from controls.  
Figure 1.3 APP protein cleavage and amyloid β proteins. 
Image from Blennow et al.[29] with permission. 
Biomarker Pathogenic process Biomarker level change in AD
CSF cell count inflammation unchanged
CSF: serum albumin ratio BBB function Pure AD: unchanged; AD with cerebrovascular pathology: increase
IgG or IgM index or oligoclonal bands Intrathecal immunoglobin production unchanged
Aβ 1-42 APP metabolism and plaque formation AD and prodromal AD: reduction
p-tau181 and p-tau231 Tau phosphorylation AD and prodromal AD: increase
total tau Axonal degeneration AD and prodromal AD: increase
Core biomarker
Basic biomarker
Table 1.1 CSF biomarkers 
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CSF biomarkers have shown great potential in measuring pre-symptomatic changes 
before the plaque becomes too widespread or the proceeding of irreversible neurodegeneration. 
However, collection of CSF through lumbar puncture is invasive with potential risks of post-
lumbar puncture headache, back discomfort or pain, bleeding, and brainstem herniation. 
Therefore, developments of non-invasive biomarkers, such as plasma derived biomarker, have 
been pursuit to look for alternative sources other than CSF, for example plasma Aβ1-42[180], 
Aβ40 to Aβ42 ratio[109], APP669–711 to Aβ42 ratio[195], α 2-Macroglobulin (α2M) and 
complement factor H (CFH)[135], neurofilament light protein (NFL)[179].  
1.3.3 Imaging  
As amyloid β aggregation being directly related to AD and potentially a predictor of AD 
decades before cognitive deficits, Aβ PET imaging has been used clinically as a diagnosis tool 
and prognosis measurement[270]. Although the Aβ’s role in AD is still under debate, it has been 
shown that amyloid β deposition proceeds neuronal loss or cerebral atrophy observed on MRI. 
Five different amyloid β tracers showed that the frontal, temporal and posterior cingulate cortices 
Figure 1.4 Tau isoforms. a) Tau protein isoforms and b) 
phosphorylation sites. Image from Blennow et al.[29] with 
permission. 
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showed the highest retention rate for Aβ (Figure 1.5) that correlates with regional amyloid β 
plaque density and the sequence of amyloid β deposition found in post-mortem brains in 
sporadic AD[32]. Noticeably, the pattern of amyloid β tracer retention in familial AD mainly 
located in striatal region which is different from the patterns of sporadic AD. Based on the 
retention patterns observed, amyloid β imaging could also be used to differentiate sporadic AD 
from dementia with Lewy bodies (DLB) and early-onset AD from frontotemporal lobar 
degeneration (FTLD), because DLB exhibits a posterior retention pattern that sporadic AD does 
not have, and FTLD should not have C-PIB retention. However, it is worth noticing that about 
25% cognitive normal elderly also have fibrillary Aβ deposition[185], which had been observed 
long before the amyloid β PET imaging era[216].   
 
 
 
 
 
Figure 1.5 Amyloid β PET radiotracer imaging. 
Surface projection images obtained from five AD patients 
with different amyloid beta PET radiotracer. Five images 
showed consistent pattern with highest retention in 
frontal, temporal and posterior cingulate cortices 
representing amyloid β deposition in the brain. Image 
from Villemagne et al.[270] with permission. 
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Similar to amyloid β imaging, tau imaging also showed consistent tau tracer retention 
pattern (Figure 1.6) with post-mortem studies, besides it is more correlated with neuronal injury 
markers. As opposed to amyloid β imaging which focusing on total amyloid β load, regional tau 
distribution in terms of density and topological distribution of tau provide more information in 
disease progression than total tau load. 
 Apart from tracers based PET that requires tracer injection into the patients, gradient 
recalled echo MRI based approach post-processing method, Gradient Echo Contrast Imaging 
(GEPCI), has been developed utilizing transverse relaxation rate constant to avoid tracer 
injection. The GEPCI metrics showed strong correlation with both amyloid β accumulation 
measured from PET and cognitive performance[292]. Another non-tracer imaging technique 
based on functional connectivity MRI also showed success in differentiating APOE4+ from 
APOE4- carriers in the absence of amyloid deposition[240] suggesting early genetic effect can 
be measured with functional connectivity MRI. Strong evidences suggested the default mode 
network is strongly associated with AD[17, 111, 116, 241]. 
 Since 2011, the diagnosis guideline for AD in the U.S. had been revised from the 1984 
diagnostic criteria, which was mainly based on the clinical judgement of the patient’s symptoms, 
to incorporate biomarker tests[15]. An A/T/N system have been proposed to integrate multiple 
biomarker modalities: “A” refers to β-amyloid related biomarker including amyloid PET or CSF 
A42; “T” refers to tau related biomarker including CSF phosphor tau or tau PET; and “N” 
refers to non-specific neurodegeneration or neuronal injury biomarkers including 18F-FDG PET, 
structural MRI or CSF total tau[137]. With either positive or negative binary traits defined by 
respective cutoffs within each category, a biomarker profile integrating multimodal 
measurements can be established for the subject to inform diagnosis[136]. As mentioned above, 
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tau imaging result is highly correlated with neuronal function biomarker 18F-FDG PET, thus one 
potential problem with ATN is that the integrative approach includes highly correlated metrics 
may incur a cost of redundant tests or repetitive information. Besides, the binary traits may over 
simplify the complexity of AD manifestation as opposed to a more quantitative approach. 
 
 
 
1.4 Neuropathological verification for postmortem assessment of AD 
Mostly for research purposes, neuropathological assessments are performed during 
autopsy on post mortem materials to verify the clinical diagnosis of AD. The CERAD 
neuropathology criteria contains gross and microscopic findings focusing on hippocampus, 
amygdala and various cortical regions[91, 186]. They use a semi-quantitative approach to assess 
frequency of senile plaques, including both neuritic plaques relative to the patent’s age and 
diffuse plaques, neurofibrillary tangles, and others such as cerebrovascular changes. From those 
Figure 1.6 Tau radiotracer imaging. Representative PET images with three different tau 
radiotracers. Top row is sagittal view; center row is transverse view; bottom row is coronal view. 
Compared to healthy elderly controls (HC), AD patients showed tracer retention in mesial temporal, 
temporoparietal and posterior cingulate cortical regions. 18F-THK5351-PET and 18F-flortaucipir-PET 
in HC show ‘off-target’ retention in the stratum. 18F-THK5351-PET also show tracer retention in the 
striatum. Image from Villemagne et al.[270] with permission.  
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together with clinical history, a categorical assessment result will be derived to report the 
certainty of AD diagnosis, and they are definite, probable, possible, or no evidence of AD.  
Other commonly used neuropathological assessment with slightly different focuses are 
Braak and Braak[34], Khachaturian[150], NIA-Reagan Institute[5], and the Tierney A3[259] 
criteria. Braak and Braak staging focuses on the distribution patterns of neurofibrillary tangles 
and neuropil threads[34], which is divided into six stages – stage I and II are characterized by 
either mild or severe alteration of the transentorhinal region; stage III and IV are marked by 
conspicuous changes in both transentorhinal region and entorhinal cortex; stage V and VI 
include destruction of all isocortical associated regions. Khachaturian[150] documented 
consensus criteria of AD diagnosis reached upon by the neuropathology panel at the “research 
workshop on the diagnosis of Alzheimer’s Disease” organized by National Institute of Aging 
(NIA) in 1983.  These criteria focus on microscopic findings in frontal, temporal, and parietal 
lobes, the amygdala, the hippocampal formation, the basal ganglia, the substantia nigra, the 
cerebellar cortex, and the spinal cord. The number of amyloid plaque and neurofibrillary tangles 
per field for different age ranges are specified for AD diagnosis.  Another more recent consensus 
recommendation of postmortem diagnostic criteria for AD are proposed to reassesses the 
previous criteria documented in Khachaturian[150]. This meeting was led by both NIA and 
Nancy Reagan Institute of the Alzheimer's Association. This NIA-Reagan Institute[5] criteria 
emphasize on the heterogeneous clinicopathological characteristics of AD, thus the diagnosis are 
only probabilistic rather than deterministic statements in any given patient based on both 
CERAD and Braak and Braak staging criteria. Besides, there might be other pathological process 
involved along with AD that contribute to dementia, for example stroke, Parkinson’s disease, 
progressive supranuclear palsy, and etc. A study that compared different pathological criteria 
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found the CERAD category of definite AD closely resemble the cases that fulfil the Tierney 
A3[259] AD criteria[194].  
1.5 Relation to other neurodegenerative disorders 
Under the umbrella term of neurodegenerative disease resulted from neuronal loss, 
patients suffering from various cognitive or motor deficits are categorized into different 
arbitrarily defined diseases based on their clinical manifestations. Despite distinct symptoms and 
affected brain regions (Table 1.2), different neurodegenerative diseases share some common 
features that may suggest potential shared mechanisms underlying disease etiology[99]. For 
example, the two major clinical manifestations, cognitive deficit and motor deficit, divide the 
realm into two halves. Age is the most important risk factor for all of the neurodegenerative 
diseases. Aggregation and progression of misfolded proteins are also involved in all of them, 
although being the cause or the result of the disease is still under debate. The common features 
suggest common pathways being altered in neurodegenerative diseases, including protein quality 
control, the autophagy-lysosome pathway, mitochondria homeostasis, protein seeding and 
propagation of stress granules, and synaptic toxicity and network dysfunction[99]. Genetically, 
MAPT gene (microtubule associated protein tau) only plays a modest role in sporadic AD but a 
substantial role in Frontotemporal Dementia (FTD) and Progressive Supranuclear Palsy (PSP). 
The most important susceptibility region for late-onset AD surrounding the APOE gene is 
involved in non-AD neurodegenerative disorders and conditions[62], such as Lewy body 
dementias(LBD)[25, 284], Parkinson's disease (PD)[40], amyloid angiopathy[25, 110, 285], 
TDP-43 proteinopathy[283], hippocampal sclerosis[25, 83, 283].  
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1.6 Dissertation Overview  
As discussed above, unlike the rare familial Mendelian dominant AD, late onset AD 
inherited as complex traits are more common in the population and resulted from dozens of 
variants involving genes distributed across the whole genome. To tackle the complex interaction 
in AD, the primary purpose of this dissertation is to apply integrative analysis approaches to 
demystify and obtain a more accurate and comprehensible picture of AD etiology.  
Alzheimer’s disease is characterized by neuronal loss and astrocytosis in the cerebral 
cortex. However, the specific effects that pathological mutations and coding variants associated 
with AD have on the cellular composition of the brain are often ignored. In chapter 2, to 
investigate cerebral cortex cell-type population structure I developed an in-silico deconvolution 
method to infer cellular composition from RNA-Seq. I firstly assembled a reference panel to 
model the transcriptomic signature of neurons, astrocytes, oligodendrocytes and microglia. The 
panel was created by analyzing expression data from purified cell lines. I evaluated alternative 
digital deconvolution methods and selected the best performing ones for my primary analyses. I 
tested the digital deconvolution accuracy on induced pluripotent stem cell (iPSC) derived 
neurons/microglia cells and neuronal Translating Ribosome Affinity Purification followed by 
RNA-Seq. Finally, I verified its accuracy by creating artificial admixture with pre-defined 
Major 
Symptoms
Cerebral 
Cortex
Basal 
Ganglia
Thalamus Hippocampus Cerebellum Brain Stem Protein Aggregation 
AD Cognitive Affected Affected Affected Affected - - Aβ, tau
FTD Cognitive Affected Affected Affected - - - TDP-43, tau, FUS
LBD Cognitive Affected - - Affected - Affected Aβ, tau, α-synuclein
ALS Motor - - - - - Affected TDP-43, FUS, UPS
HD Motor Affected Affected - - - - polyglutamine protein
PD Motor - Affected Affected - - - α-synuclein
MSA Motor - Affected - - Affected Affected α-synuclein
Table 1.2 Neurodegenerative diseases comparison
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cellular proportions. Once the deconvolution approach was optimized, I calculated the cell 
proportion in AD cases and controls from the different brain regions of LOAD and ADAD 
datasets. I found that neuronal and astrocyte relative proportions differ between healthy and 
diseased brains and also among AD cases that carry specific genetic risk variants. Brain carriers 
of pathogenic mutations in APP, PSEN1 or PSEN2 presented lower neurons and higher 
astrocytes relative proportions compared to sporadic AD.  Similarly, the APOE ε4 allele also 
showed decreased neuronal and increased astrocyte relative proportions compared to AD non-
carriers.  On the contrary, carriers of variants in TREM2 risk showed a lower degree of neuronal 
loss than matched AD cases in multiple independent studies. These findings suggest that genetic 
risk factors associated with AD etiology have a specific imprinting in the cellular composition of 
AD brains. 
 In chapter 3, I utilized cell-type proportions inferred from deconvolution procedure as 
disease status proxy to identify new genetic variants related to AD. Instead of using disease 
phenotype, studies which used endo-phenotypes, such as CSF APOE levels[59], CSF amyloid-β, 
tau, and phosphorylated tau (ptau181)[71], and AD proxy[174] have successfully uncovered other 
variants associated with AD. Using cell type composition inferred from RNA-Seq data as a 
disease status proxy, I performed cell type association analysis to identify potential new locus 
that are related to cellular population changes in disease cohort. We imputed and merged 
genotyping data from seven studies (five centered on neurodegeneration; two focused on 
schizophrenia and multiple tissue controls), and derived major CNS cell type proportions as 
described in chapter 2 from cortical RNA-Seq data. Neuronal proportion were normalized by 
subtracting the mean from each tissue deconvolution results after removing outliers. I identified a 
variant rs1990621 located in the TMEM106B gene region significantly associated with neuronal 
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proportion in cortical RNA-Seq dataset. This variant is in high LD with rs1990622 (r2 = 0.98) 
which was previously identified as a protective variant in FTD cohorts[266]. In conclusion, I 
have identified a variant associated with neuronal proportion with potential protective effect in 
neurodegeneration disorders.  
In Chapter 4, using network analysis I replicated and reconfirmed the co-expression 
pattern between MS4A gene cluster and TREM2 in sporadic AD, from which further evidence 
was inferred from Bayesian network analysis to show that MS4A4A might be a potential 
regulator of TREM2 that is validated by in-vitro experiments. In Autosomal Dominant AD 
(ADAD) cohort, disrupted and acquired genes were identified from PSEN1 mutation carriers. 
Among the genes, previous identified AD related gene and pathways were revealed together with 
novel findings. These results demonstrated the great potential of applying network approach in 
identifying disease associated genes and the interactions among them.  
In conclusion, contribution from this dissertation work to AD research is summarized in 
Chapter 5, and future directions in research to facilitate diagnosis, intervention, and disease-
modifying therapies are also discussed in the context of this dissertation work.  
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Chapter 2: Genetic variants associated with 
Alzheimer’s disease confer different cerebral 
cortex cell-type population structure 
 
 
 
 
 
 
 
 
 
This chapter was adapted from:  
Li Z, Del-aguila JL, Dube U, et al. Genetic variants associated with Alzheimer's disease confer 
different cerebral cortex cell-type population structure. Genome Med. 2018;10(1):43
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2.1 Abstract 
Background: Alzheimer's disease (AD) is characterized by neuronal loss and astrocytosis in the 
cerebral cortex. However, the specific effects that pathological mutations and coding variants 
associated with AD have on the cellular composition of the brain are often ignored. 
Methods: I developed and optimized a cell-type-specific expression reference panel and 
employed digital deconvolution methods to determine brain cellular distribution in three 
independent transcriptomic studies. 
Results: I found that neuronal and astrocyte relative proportions differ between healthy and 
diseased brains and also among AD cases that carry specific genetic risk variants. Brain carriers 
of pathogenic mutations in APP, PSEN1, or PSEN2 presented lower neuron and higher astrocyte 
relative proportions compared to sporadic AD. Similarly, the APOE ε4 allele also showed 
decreased neuronal and increased astrocyte relative proportions compared to AD non-carriers. In 
contrast, carriers of variants in TREM2 risk showed a lower degree of neuronal loss compared to 
matched AD cases in multiple independent studies. 
Conclusions: These findings suggest that genetic risk factors associated with AD etiology have a 
specific imprinting in the cellular composition of AD brains. My digital deconvolution method 
provides an enhanced understanding of the fundamental molecular mechanisms underlying 
neurodegeneration, enabling the analysis of large bulk RNA-sequencing studies for cell 
composition and suggests that correcting for the cellular structure when performing 
transcriptomic analysis will lead to novel insights of AD.  
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2.2 Introduction 
2.2.1 Altered cellular composition confounds downstream transcriptomic 
analysis 
Altered cellular composition is associated with AD progression and decline in cognition. 
Neuronal loss in the hippocampus is characteristic in the initial stages of AD, which could 
explain early memory disturbances[205, 282]. As the disease progresses, neuronal death is 
observed throughout the cerebral cortex. Furthermore, ~25% of individuals who die by ~75 years 
of age who were cognitively normal also presented substantial cerebral lesions that resemble AD 
pathology, including amyloid plaque, NFTs, and neuronal loss[132]. Thus, the identification of 
the brain cellular population structure is essential for understanding neurodegenerative disease 
progression[107]. However, stereology protocols for counting neurons can be tedious, require 
extensive training and are susceptible to technical artifacts which may lead to biased 
quantification of cell-type distributions[107]. 
Recently there has been a growing interest in understanding the transcriptomic changes 
attributed to AD[9, 46, 98, 184, 197, 206, 247, 287], as these may point to underlying molecular 
mechanisms of disease. These studies are typically designed to analyze the expression profiles of 
large cohorts ascertained from homogenized regions of the brain (e.g. bulk RNA-Seq) of affected 
and control donors. However, bulk RNA-Seq captures the gene expression of all of the 
constituent cells in the sampled tissue, and the altered cellular composition associated with AD 
has been reported to confound downstream analyses[247].  
2.2.2 Digital deconvolution approach 
Digital deconvolution approaches enhance the interrogation of expression profiles to 
identify the cellular population structure of individual samples, alleviating the requirement of 
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additional neurostereology procedures. These approaches have been developed, tested and 
applied to ascertain cellular composition altered in many traits[157, 199, 242, 293]. However, 
digital deconvolution has not been applied to identify the cellular population structure from 
RNA-Seq from human brain of AD cases and controls. Technical constraints restrict the 
dissociation of cells from the brains for very specific conditions[38, 290, 291]. Nevertheless, a 
limited number of RNA-Seq from isolated cell populations from the brain have been 
generated[38, 290, 291]. Using these resources, I am now able to generate a reference panel for 
digital deconvolution of human brain bulk RNA-Seq data. 
I sought to investigate the cellular population structure in AD by analyzing RNA-Seq 
from multiple brain regions of LOAD participants.  To do so, I assembled a novel brain reference 
panel and evaluated the accuracy of digital deconvolution methods by analyzing additional cell-
type specific RNA-Seq samples and by creating synthetic admixtures with defined cellular 
distributions. Then I analyzed large cohorts of pathologically confirmed AD cases and controls 
(N = 613) and verified that it predicts cellular distribution patterns consistent with 
neurodegeneration. Finally, I generated RNA-Seq from the parietal lobe of participants from the 
Charles F. and Joanne Knight Alzheimer's Disease Research Center  (Knight-ADRC)[153], 
including non-demented controls, LOAD cases, with enriched proportions of carriers of high-risk 
coding variants associated with AD, and also ADAD from The Dominantly Inherited Alzheimer 
Network[72] (DIAN). I compared the cell composition in ADAD and LOAD; and also evaluated 
differences among carriers of coding high-risk variants in PLD3, TREM2 and APOE ε4. My 
findings indicated that cell-type composition differs among carriers of specific genetic risk 
factors, which might be revealing distinct pathogenic mechanisms contributing to disease 
etiology.  
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2.3 Methods 
2.3.1 Subjects and Samples 
DIAN and Knight-ADRC  
Parietal lobe tissue of post-mortem brain was obtained with informed consent for 
research use and were approved by Washington University in St. Louis review board. RNA was 
extracted from frozen brain using Tissue Lyser LT and RNeasy Mini Kit (Qiagen, Hilden, 
Germany).  RNA-Seq Paired end reads with read length of 2×150bp were generated using 
Illumina HiSeq 4000 with a mean coverage of 80 million reads per sample (Table 2.1; Table 
2.2). RNA-Seq was generated for 19 brains from The Dominantly Inherited Alzheimer Network 
(DIAN), 84 brains with late-onset AD and 16 non-demented controls from The Charles F. and 
Joanne Knight Alzheimer's Disease Research Center (Knight ADRC)[153]. The AD brains 
selected from the Knight-ADRC are enriched for carrier of variants in TREM2 (N=20; Table 
2.2) and PLD3 (N=33; Table 2.2). The clinical status of participants was neuropathologically 
confirmed[187].  We identified three additional participants from the Knight-ADRC study with 
PSEN1 (p.A79V, p.I143T and p.S170F) mutations. CDR scores were obtained during regular 
visits throughout the study prior to the subject’s decease[190]. A range of other pathological 
measurement were collected during autopsy including Braak staging, as previously 
described[35].  
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RNA was extracted from frozen brain tissues using Tissue Lyser LT and RNeasy Mini 
Kit (Qiagen, Hilden, Germany) following the manufacturer’s instruction. RIN (RNA integrity) 
and DV200 were measured with RNA 6000 Pico Assay using Bioanalyzer 2100 (Agilent 
Technologies). The RIN is determined by the software on the Bioanalyzer taking into account 
the entire electrophoretic trace of the RNA including the presence or absence of degradation 
products. The DV200 value is defined as the percentage of nucleotides greater than 200nt. RIN 
and DV200 for all the samples can be found on Table 2.2. The yield of each sample is 
determined by the Quant-iT RNA Assay (Life Technologies) on the Qubit Fluorometer (Fisher 
Scientific). The cDNA library was prepared with the TruSeq Stranded Total RNA Sample Prep 
with Ribo-Zero Gold kit (Illumina) and then sequenced by HiSeq 4000 (Illumina) using 2×150 
paired end reads at McDonnell Genome Institute, Washington University in St. Louis with a 
Mayo
a
MSBB
b DIAN Knight-ADRC
Sample Size 191 300 19 103
Age 83 ± 7.77 83.3 ± 7.55 50.6 ± 7.06 85.1 ± 9.78
% Male 45.5 36 68.4 38.8
% APOE  ε4+ 33.2 31.7 14.3 45.6
Brain weight - - 1187.7 ± 184.5 1138.1 ± 142.5
AD
c 82 135 19 87
PA
d 29 0 0 0
Control 80 85 0 16
CDR
e
 = 0 - 40 0 13
CDR = 0.5 - 40 0 9
CDR = 1 - 30 2 11
CDR = 2 - 44 4 14
CDR = 3 - 146 1 56
Table 2.1 Demographics and disease status of cohorts from four brain bank resources.
a
 Mayo stands for Mayo Clinic.
b
 MSBB stands for Mount Sinai Brain Bank.
c
 AD stands for Alzheimer’s Disease.
d
 PA stands for pathological aging (amyloid plaques but no tau tangles).
e
 CDR stands for clinical dementia rating for available samples.
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mean of 58.14 ± 8.62 million reads. Number of reads and other QC metrics can be found in 
Table 2.2. 
Mayo Clinic Brain Bank 
Mayo Clinic Brain Bank RNA-Seq was accessed from the AMP-AD portal (synapse ID = 
5550404; accessed January 2017) (Table 2.1). Paired end reads of 2×101bp were generated by 
Illumina HiSeq 2000 sequencers for an average of 134.9 million reads per sample. 
Neuropathology criteria, quality control procedures, RNA extraction and sequencing details are 
explained elsewhere[9]. 
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Total DIAN & ADAD vs LOAD 
ADAD LOAD Control Knight-ADRC t-tests p-value
RIN 5.69 ± 1.13 6.44 ± 1.16 6.71 ± 1.18 6.34 ± 1.19 9.04×10
-03
DV200 86.59 ± 4.12 89.48 ± 3.85 91.19 ± 2.54 89.18 ± 3.97 5.82×10
-03
PMI 14.57 ± 10.29 13.05 ± 6.66 10.52 ± 6.09 12.99 ± 7.4 5.16×10
-01
Age 51.27 ± 11.13 85.72 ± 6.83 87.08 ± 10.2 79.69 ± 15.67 2.61×10
-13
Male % 0.64 0.39 0.38 0.43 4.68×10
-02
APOE4+ % 0.3 0.52 0.06 0.44 1.94×10
-01
CDR 2.2 ± 0.79 2.37 ± 0.93 0.22 ± 0.31 2.04 ± 1.14 5.42×10
-01
Braak 5.94 ± 0.24 4.84 ± 1.29 1.93 ± 0.88 4.61 ± 1.62 8.81×10
-10
Number of Total Reads (Million) 60.92 ± 5.6 57.7 ± 9.28 56.6 ± 7.98 58.14 ± 8.62 4.47×10
-02
Uniquely Mapped Reads % 79.72 ± 4.28 80.74 ± 4.49 81.06 ± 5.96 80.6 ± 4.65 3.32×10
-01
Mapped to Multiple Loci Reads % 16.39 ± 2.1 15.56 ± 2.2 15.08 ± 3.3 15.64 ± 2.36 1.07×10
-01
Disease Status 22 84 16 122 -
   APP 3 0 0 3 -
   PSEN1 18 0 0 18 -
   PSEN2 1 0 0 1 -
   TREM2 0 20 0 20 -
   PLD3
a 0 33 0 33 -
   UNC5C
a 0 4 0 4 -
   Sporadic AD 0 29 0 29 -
Table 2.2 Demographics and AD mutation carriers of DIAN and Knight-ADRC cohorts.
a 
There are two Knight-ADRC subjects that carry both PLD3  and UNC5C  variants.
DIAN & Knight-ADRC
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RNA-Seq based transcriptome data was generated from post-mortem brain tissue 
collected from cerebellum (189 samples) and temporal cortex (191 samples) of Caucasian 
subjects[2, 9]. RNA was extracted using Trizol® reagent and cleaned with Qiagen RNeasy. RIN 
measurement was performed with Agilent Technologies 2100 Bioanalyzer. Samples with RIN 
greater than 5 were included. Library was prepared by Mayo Clinic Medical Genome Facility 
Gene Expression and Sequencing Cores with TruSeq RNA Sample Prep Kit (Illumina). 
Mount Sinai Brain Bank  
Mount Sinai Brain Bank RNA-Seq study was downloaded from the AMP-AD portal 
(synapse ID = 3157743; accessed January 2017) (Table 2.1). Single end reads of 100 nucleotides 
was generated by Illumina HiSeq 2500 System (Illumina, San Diego, CA) for an average of 38.7 
million reads per sample[3].   
This dataset contains 1030 samples collected from four post-mortem brain regions of 300 
subjects: anterior prefrontal cortex (BA10), superior temporal gyrus (BA22), parahippocampal 
gyrus (BA36), and inferior frontal gyrus (BA44). RNA-Seq was generated using the TruSeq 
RNA Sample Preparation Kit v2 and Ribo-Zero rRNA removal kit (Illumina, San Diego, CA)[3].  
iPSC-derived neurons  
 Dermal fibroblasts were obtained from skin biopsies from research participants in the 
Knight-ADRC (Fibroblast lines: F11362, F12455, and F13504). Human fibroblasts were 
reprogrammed into iPSC using non-integrating Sendai virus carrying OCT3/4, SOX2, KLF4, and 
cMYC[255, 265]. iPSCs were manually selected and expanded on Matrigel in mTesR1 
(StemCell Techologies). iPSCs were characterized for expression of pluripotency markers by 
immunocytochemistry and quantitative PCR (qPCR). qPCR with probes specific to Sendai virus 
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were used to confirm the absence of virus in the isolated clones. All cell lines were confirmed to 
have a normal karyotype based on G-band karyotyping. To generate cortical neurons, iPSCs 
were plated in a v-bottom plate in neural induction media (StemCell Technologies; 65,000 per 
well) to form highly uniform neural aggregates. After 5 days, neural aggregates were transferred 
onto PLO/laminin-coated tissue culture plates. Neural rosettes formed over 5-7 days. The 
resulting neural rosettes were then isolated by enzymatic selection (StemCell Technologies) and 
cultured as neural progenitor cells (NPCs). NPCs were then differentiated by culturing in neural 
maturation medium (neurobasal medium supplemented with B27, GDNF, BDNF, cAMP). RNA 
was collected from the cells and sequenced following the same protocol and processing pipeline 
as the DIAN and Knight-ADRC dataset. 
In addition, I accessed RNA-Seq data generated for iPSC-derived neurons from the 
Broad iPSC study[7] (Synapse ID: syn3607401). Forebrain neurons from wild-type background 
were generated using an embryoid body-based protocol to produce neural progenitor cells (day 
17) and mature neurons (day 57 and day 100). RNA was purified using a PureLink RNA mini-kit 
(Life Technologies). RNA-Seq libraries were prepared using Illumina Strand Specific TruSeq 
protocol, and sequenced to obtain an average of 75M reads in pairs reads per sample.  
TRAP-seq mice 
All animal procedures were performed in accordance with the guidelines of Washington 
University's Institutional Animal Care and Use Committee. The Rosa26fsTRAP mice 
(Gt(ROSA)26Sortm1(CAG-EGFP/Rpl10a,-birA)Wtp)[294] (The Jackson Laboratory) were crossed with 
PVCre mice (Pvalbtm1(cre)Arbr)[128] (The Jackson Laboratory) to produce PV-TRAP mice directing 
expression of  EGFP-L10a ribosomal fusion protein in parvalbumin (PV) expressing cells.  
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Purification of cell-type specific mRNA by translating ribosome affinity purification 
(TRAP) was described previously[122] with modifications. Briefly, PV-TRAP mouse brain was 
removed and quickly washed in ice-cold dissection buffer (1× HBSS, 2.5 mM HEPES-KOH (pH 
7.3), 35 mM glucose, and 4 mM NaHCO3 in RNase-free water). Barrel cortex was rapidly 
dissected and flash-frozen in liquid nitrogen, and then stored at -80 C until use. Affinity matrix 
was prepared with 150 μl of Streptavidin MyOne T1 Dynabeads, 60 μg of Biotinylated Protein 
L, and 25 μg of each of GFP antibodies 19C8 and 19F7. The tissue was homogenized on ice in 1 
ml of tissue-lysis buffer (20 mM HEPES KOH (pH 7.4), 150 mM KCl, 10 mM MgCl2, EDTA-
free protease inhibitors, 0.5 mM DTT, 100 μg/ml cycloheximide, and 10 μl/ml rRNasin and 
Superasin). Homogenates were centrifuged for 10 min at 2,000 × g, 4 C, and 1/9 sample volume 
of 10% NP-40 and 300 mM DHPC were added to the supernatant at final concentration of 1% 
(vol/vol). After incubation on ice for 5 min, the lysate was centrifuged for 10 min at 20,000 × g 
to pellet insolubilized material. Then 200 μl of freshly resuspended affinity matrix was added to 
the supernatant and incubated at 4 °C for 16–18 hours with gentle end-over-end mixing in a tube 
rotator. After incubation, the beads were collected with a magnet and resuspended in 1000 μl of 
high-salt buffer (20 mM HEPES KOH (pH 7.3), 350 mM KCl, 10 mM MgCl2, 1% NP-40, 0.5 
mM DTT and 100 μg/ml cycloheximide), and collected with magnet as above. After 4 times of 
washing with high-salt buffer, RNA was extracted using Absolutely RNA Nanoprep Kit (Agilent 
Technologies) following manufacturer’s instruction. RNA quantification was measured using 
Qubit RNA HS Assay Kit (Life Technologies) and the integrity was determined by Bioanalyzer 
2100 using an RNA Pico chip (Agilent Technologies). The cDNA library was prepared with 
Clontech SMARTer and then sequenced by HiSeq3000. Single end reads of 50 base pairs were 
generated for an average of 29.2 million reads per sample (24 samples).  
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iPSC-derived microglia 
The data was accessed from the AMP-AD portal (Synapse ID: syn7203233). This dataset 
is comprised of iPSC-derived microglia (N = 10) from human primitive streak-like cells[77]. 
Within 30 days of differentiation, myeloid progenitors coexpressing CD14 and CX3CR1 were 
generated. These iPSC-derived microglia were able to perform phagocytosis and elicit ADP-
induced intracellular Ca2+ transients that asserted their microglia identity as opposed to 
macrophage. Single-ended RNA-Seq data was generated with the Illumina HiSeq 2500 platform 
following the Illumina protocol. 
2.3.2 RNA-Seq QC and Alignment 
FastQC was applied to DIAN and Knight-ADRC RNA-Seq data to perform quality check 
on various aspects of sequencing quality[231]. Each category of FastQC will be explained with 
pass or fail examples together with summary results ascertained from the DIAN and Knight-
ADRC combined dataset. QC result explanations were obtained from the developer’s 
website[11]. 
The DIAN and Knight-ADRC dataset was aligned to human GRCh37 primary assembly 
using Star (ver 2.5.2b)[74]. I used the primary assembly and aligned reads to the assembled 
chromosomes, un-localized and unplaced scaffolds, and discarded alternative haploid sequences. 
Sequencing metrics, including coverage, distribution of reads in the genome[4], ribosomal and 
mitochondrial contents and alignment quality, were further obtained by applying Picard 
CollectRnaSeqMetrics (ver 2.8.2) to detect sample deviation. QC results from FastQC, Star, 
Picard, and Salmon are merged with multi-QC software to generated integrated summary reports 
(Table 2.3).  
31 
Problematic samples summary: 
 RIN < 5 & DV200 < 75 
o H_VY-82018_S1512310_II.H.40 
o H_VY-83774_S1512313_II.G.39 
 Low Yield 
o H_VY-60410_S1511525_I.D.19 
o H_VY-62240_S1511620_IV 
 High Ribosomal RNA 
o H_VY-83774_S1512313_II.G.39 
o H_VY-82018_S1512310_II.H.40 
o H_VY-9TPSKM_S1512275_I.B.15 
 High Median 5’ to 3’ bias 
o H_VY-60007_S1511546_I.D.21 
o H_VY-83774_S1512313_II.G.39 
 Ethnicity non-Europeans 
o H_VY-83665_S1511508_I.E.31 
o H_VY-61256_S1511537_I.E.31 
o H_VY-62275_S1511542_I.D.19 
o H_VY-11964_S1512298_I.E.29 
o H_VY-23178_S1512475_I.D.19 
o H_VY-62464_S1512484_VI.N 
 Transcriptome-wise outliers  
o H_VY-F1R54Y_D1202616_I.C.18 
o H_VY-1XYTL9_D1202619_I.B.10 
o H_VY-61377_S1511495_I.D.19 
o H_VY-61245_S1512302_IV 
o H_VY-61684_S1512304_IV 
o H_VY-60007_S1511546_I.D.21 
o H_VY-83774_S1512313_II.G.39 
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Table 2.3 Summarized quality check results integrated with Multi-QC
33 
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Per base sequence quality  
Figure 2.1A and Figure 2.1B are passed and failed example for the per base 
sequence quality check. As its name suggested, this analysis summarizes over all 
sequence quality of each sample for each read base. In my case, the read length is 151 
base pairs represented in the x-axis. The y-axis on the graph showed the quality scores. 
The sequence quality is calculated as Q = -10×log10(e) where ‘e’ is the estimated 
probability of the base call being wrong. Thus, higher score indicates higher quality, and 
it ranges from 0 to 40.  A quality score of 20 represents an error rate of 1 in 100, and a 
quality score of 40 represents an error rate of 1 in 10,000 and a call accuracy of 99.99%. 
Green region represents good quality calls from 28 to 40; orange region represents calls 
of reasonable quality from 20 to 28; red represents poor quality calls with quality less 
than 20, with a call accuracy of 99%. The quality of calls on most platforms will degrade 
as the run progresses, so it is common to see base calls falling into the orange area 
towards the end of a read.  
 Each column of box and whisker plot is the summarized quality score of all the 
reads for that particular base position. “The central red line is the median value; the 
yellow box represents the inter-quartile range (25-75%); the upper and lower whiskers 
represent the 10% and 90% points. The blue solid line represents the mean quality”[11]. 
Figure 2.1C is the overall per base sequence quality for all sample, which showed 161 
passed and 9 samples with warning.  
The 9 warning samples are: 
o H_VY-61609_S1512483_VI.N.bam 
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o H_VY-63976_S1511873_VI.M.42.bam 
o H_VY-72221_S1511778_VI.N.bam 
o H_VY-82037_S1511881_II.H.40.bam 
o H_VY-82397_S1511396_I.B.17.bam 
o H_VY-83665_S1511508_I.E.31.bam 
o H_VY-83775_S1511871_II.G.39i.bam 
o H_VY-F11362.1d1B6_Neuron_2_S1512501_VII.O.45.bam 
o H_VY-F11362.1d1F10_Neuron_1_S1512503_VII.Q.47.bam 
 
 
 
Figure 2.1 Sequence quality check. A) Passed sample from H_VY-
1DKYRE_D1202618_I.B.11 and B) Warning sample from H_VY-83775_S1511871_II.G.39i 
and C) Summary sequence quality score showed 161 passed (green lines) and 9 warning 
(yellow lines) for DIAN and Knight ADRC dataset. 
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Per tile sequence quality 
Because we used an Illumina library that retains its original sequence identifiers, the 
sequencing output also documents each read’s flowcell tile information. Thus, for 
Illumina sequencing data FastQC reports quality scores from each tile across all the base 
positions to see if there was a loss in quality associated with any particular part of the 
flowcell. The plot shows the deviation from the average quality for each tile. Cold color 
indicates good quality and warm color indicates bad quality that a tile had worse qualities 
than other tiles for that base. A passed sample plot should be blue all over. FastQC user 
manual explains that “reasons for seeing warnings or errors on this plot could be transient 
problems such as bubbles going through the flowcell, or they could be more permanent 
problems such as smudges on the flowcell or debris inside the flowcell lane”[11]. My 
samples all passed the test except one showed warning (Figure 2.2B). I observed that 
there was a quality drop on the end of the reads in some tiles of the flowcells.  
 
Figure 2.2 Per tile sequence quality. A) passed sample from H_VY-
1DKYRE_D1202618_I.B.11 B) Warning sample from H_VY-62240_S1511620_IV 
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Per sequence quality scores 
The per sequence quality score report allows me to see the overall quality 
distribution of my reads and to detect if I have reads with universally low-quality scores. 
If some reads are poorly imaged, for example, when they are on the edge of the field of 
view, they will have universally poor quality[11]. My samples showed that the majority 
of reads are good quality ranging from 28 to 40 (Figure 2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Per sequence quality scores. A) passed example from 
H_VY-1DKYRE_D1202618_I.B.11 B) summary results for all 
samples showed they all passed for this test. 
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Per Base Sequence Content 
Per Base Sequence Content plots out the proportion of DNA bases for each base 
position, which are the percentage of A, T, C, G. In a random library, I would expect that 
there would be little to no difference between the different bases of a sequence run, so the 
lines in this plot should run parallel with each other. The relative amount of each base 
may not be equally 25% for each type of nucleic acid, but should reflect the overall 
amount of these bases in the sequenced genome and should not be hugely imbalanced 
from each other in any case[11]. 
It is worth noting that some types of library will always produce biased sequence 
composition, normally at the start of the read, which is what is happening in my samples 
with Illumina. “Libraries produced by Illumina priming use random hexamers (including 
nearly all RNA-Seq libraries). Those hexamers were fragmented using transposases, 
which inherit an intrinsic bias in the positions at which reads start. This bias does not 
concern an absolute sequence, but instead provides enrichment of a number of different 
K-mers at the 5' end of the reads. Therefore, it is common for Illumina sequencers to 
have the first 7-9 bases with unbalanced base sequence contents. While this is a true 
technical bias, it can be corrected by trimming, but in most cases, it does not seem to 
adversely affect the downstream analysis”[11]. It will however produce a warning or 
error in this module when the difference between A and T, or G and C is greater than 
10% (warning) and 20% (failed) in any position. After the first nine positions, the lines 
run flat and in parallel with each other indicating balanced and unbiased nucleic acid 
contents (Figure 2.4). Due to the technical bias of Illumina library, this module produced 
38 warning and 132 failed test results for the dataset. 
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Per base N content 
“If a sequencer is unable to make a base call with sufficient confidence then it 
will normally substitute an N rather than a conventional base call. This module plots out 
the percentage of base calls at each position for which an N was called”[11]. My samples 
only showed a very low N content at the beginning of the reads due to unavoidable 
library technical bias, and at 100bp for some samples (Figure 2.5). All samples passed 
this test. 
Figure 2.4 Per base sequence content. The percentage of each DNA nucleic acid type 
for each base position was labeled and color coded respectively.  
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Sequence length distribution 
“Some high throughput sequencers generate sequence fragments of uniform 
length, but others can contain reads of wildly varying lengths. Even within uniform 
length libraries some pipelines will trim sequences to remove poor quality base calls from 
the end. This module generates a graph showing the distribution of fragment sizes in the 
Figure 2.5 Per base N content. A) Passed sample from H_VY-
1DKYRE_D1202618_I.B.11 and B) summary for all samples. 
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file which was analyzed”[11]. In many cases this will produce a simple graph showing a 
peak only at one size, which is the case for my sample shown here (Figure 2.6), but for 
variable length FastQ files this will show the relative amounts of each different size of 
sequence fragment[11].  
Adapter content 
I have adapter contamination due to adapter read-through problem associated with 
fragmented short reads. Adapter source was predicted and my sample showed potential 
adapter contamination from Illumina universal adapter (Table 2.4; Figure 2.7A). All 
samples failed this test (Figure 2.7B). 
 
Figure 2.6 Sequence length distribution. Passed sample from H_VY-
1DKYRE_D1202618_I.B.11 
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Expected observations with adapter dimer contamination[11]: 
 Drop in per base sequence quality after base 60 
 Possible bi-modal distribution of per sequence quality scores 
 Distinct pattern observed in per bases sequence content up to base 60 
 Spike in per sequence GC content 
 Overrepresented sequence matching adapter 
 Adapter content > 0% starting at base 1 
 
 
D501-D508 adapter AATGATACGGCGACCACCGAGATCTACAC[i5]ACACTCTTTCCCTACACGACGCTCTTCCGATCT
D701-D712 adapter GATCGGAAGAGCACACGTCTGAACTCCAGTCAC[i7]ATCTCGTATGCCGTCTTCTGCTTG
i5 index name i5 index bases
D501 TATAGCCT
D502 ATAGAGGC
D503 CCTATCCT
D504 GGCTCTGA
D505 AGGCGAAG
D506 TAATCTTA
D507 CAGGACGT
D508 GTACTGAC
i7 index name i7 index bases
D701 ATTACTCG
D702 TCCGGAGA
D703 CGCTCATT
D704 GAGATTCC
D705 ATTCAGAA
D706 GAATTCGT
D707 CTGAAGCT
Adapter
Index
Table 2.4 Illumina TruSeq Stranded RNA HT adapter and index
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Sequence duplication level 
 “The plot shows the proportion of the library which is made up of the duplicated 
sequences in each of the different duplication level bins. There are two lines on the plot. 
The blue line takes the full sequence set and shows how its duplication levels are 
distributed. In the red plot the sequences are de-duplicated and the proportions shown are 
the proportions of the remained different duplication levels in the original data after 
removing the duplicated sequences. In a properly diverse library most sequences should 
fall into the far left of the plot in both the red and blue lines. A general level of 
Figure 2.7 Adapter content. A) Failed sample from H_VY-
1DKYRE_D1202618_I.B.11 and B) summarized for all samples 
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enrichment, indicating broad over sequencing in the library will tend to flatten the 
lines”[11], lowering the low end and generally raising other categories (Figure 2.8B blue 
line). More specific enrichments of subsets, or the presence of low complexity 
contaminants will tend to produce spikes towards the right of the plot (Figure 2.8A blue 
line). “These high duplication peaks will most often appear in the blue trace as they make 
up a high proportion of the original library, but usually disappear in the red trace as they 
make up an insignificant proportion of the deduplicated set. If peaks persist in the red 
trace then this suggests that there are a large number of different highly duplicated 
sequences which might indicate either a contaminant set or a very severe technical 
duplication. The module also calculates an expected overall loss of sequence were the 
library to be deduplicated shown in the figure headline at the top of the plot, which gives 
a reasonable impression of the potential overall level of loss”[11].  
Note that both biological duplication and technical duplication were not 
differentiated in this analysis and the way to differentiate these two categories is to 
examine if the duplicated reads are mostly from physically connected genome regions 
after alignment[11]. High coverage data has more reads so it is not surprised to see higher 
duplication level. Notice that among the three passed samples, two are low yield samples. 
I would also expect the majority of duplications are from rRNA so the samples with high 
rRNA will have high duplication levels, which is proved by comparing the two figures 
showing one normal rRNA sample (Figure 2.8A) and one high rRNA sample (Figure 
2.8B). In STAR alignment, the default setting for reads aligned to multiple location is 10, 
and when it’s above 20 it will not map to the reference and those will go to unmapped 
category, so from the duplication level plot >10 bin percentage I would be able to have a 
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rough estimation of the percentage of reads that would map to multiple location and 
unmapped percentage of STAR alignment results. For project that look at unmapped 
section of the samples this duplication level information might be extremely important, 
for example circular RNA or microbial RNA focused projects. 
Notice that among the three passed samples, two are low yield samples: 
 H_VY-12152_S1512495.bam 
 H_VY-60410_S1511525_I.D.19.bam (low yield) 
 H_VY-62240_S1511620_IV.bam (low yield) 
 
Figure 2.8 Sequence duplication levels. A) Warning sample from H_VY-
1DKYRE_D1202618_I.B.11 and B) failed sample from H_VY-82018_S1512310_II.H.40 and 
C) summary sample for all samples 
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Per sequence GC content 
“This module measures the GC content across the whole sequence length and 
compares it to a modelled normal distribution of GC content. In a normal random library, 
I would expect to see a roughly normal distribution of GC content where the central peak 
corresponds to the overall GC content of the sequenced genome. An unusually shaped 
distribution could indicate a contaminated library or some other kinds of biased subset. A 
normal distribution which is shifted indicates some systematic bias which is independent 
of base position. If there is a systematic bias which creates a shifted normal distribution 
then this won't be flagged as an error by the module since software doesn't know what the 
sequenced genome's GC content should be”[11].  
This module will indicate a failure if the sum of the deviations from the normal 
distribution represents more than 30% of the reads. Warnings in this module usually 
indicate a problem with the library. Sharp peaks on an otherwise smooth distribution are 
normally the result of a specific contaminant (adapter dimers for example, Figure 2.9A), 
which may well be picked up by the overrepresented sequences module. Broader peaks 
may represent contamination with a different species. In my samples, the distribution 
showed sharp peaks on an otherwise smooth distribution or severely deviated from 
normal distribution may indicate adapter dimers contamination, which might be picked 
by other failed modules, such as overrepresented sequences, adapter content, and kmer 
content. Overall, I have 42 samples with warning and 128 failed samples (Figure 2.9B). 
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Overrepresented sequences 
“A normal high-throughput library will contain a diverse set of sequences, with 
no individual sequence making up a tiny fraction of the whole. Finding that a single 
sequence is very overrepresented in the set either means that it is highly biologically 
significant, or indicates that the library is contaminated, or not as diverse as 
expected”[11]. This module lists all of the sequence which make up more than 0.1% of 
the total (Figure 2.10). “To conserve memory only sequences which appear in the first 
Figure 2.9 Per sequence GC content. A) Failed sample from H_VY-
1DKYRE_D1202618_I.B.11 and B) GC content curves for all sample. 
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100,000 sequences are tracked to the end of the file. For each overrepresented sequence 
the program will look for matches in a database of common contaminants and will report 
the best hit it finds. Hits must be at least 20bp in length and have no more than 1 
mismatch. Finding a hit does not necessarily mean that this is the source of the 
contamination, but may point me in the right direction. Because the duplication detection 
requires an exact sequence match over the whole length of the sequence any reads over 
75bp in length are truncated to 50bp for the purposes of this analysis. Even so, longer 
reads are more likely to contain sequencing errors which will artificially increase the 
observed diversity and will tend to underrepresent highly duplicated sequences”[11].  
Kmer Content 
The Kmer Content module will do a generic analysis of all of the Kmers in my 
sample library to find those which do not have even coverage through the length of my 
reads (Figure 2.11). The top six kmers are plotted in the graph. This can find a number of 
different sources of bias in the library which can include the presence of read-through 
adapter sequences building up on the end of the sequences. The presence of any 
Figure 2.10 Overrepresented sequences. Warning sample from H_VY-
1DKYRE_D1202618_I.B.11. 
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overrepresented sequences in my library (such as adapter dimers) will cause the Kmer 
plot to be dominated by the Kmers these sequences contain. What I have in my samples 
are two folds: 1. Unbalanced sequence content for the first 9 bases which is intrinsic 
technical bias associated with Illumina library. 2. Adapter read through problem at the 
end of the reads which can be corrected with STAR alignment using adapter soft clipping 
option. 
 
 
Figure 2.11 Kmer Content. Failed sample from H_VY-1DKYRE_D1202618_I.B.11. 
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 In summary, my DIAN and Knight ADRC samples have good sequence quality in 
general, reflected in categories such as per base, per tile, per sequence quality scores, and 
per base N content (Table 2.5). Because we used Illumina sequencing, the first nine 
bases of each read have technical bias, therefore, none of the samples passed per base 
sequence content test. However, it does not impact downstream analysis. Due to potential 
rRNA and adapter contamination, several test metrics captured these observations, for 
example, per sequence GC content, sequence duplication levels, overrepresented 
sequences, adapter content, and kmer content. Samples with high rRNA contamination 
were not different from the other samples in terms of deconvolution results, but will be 
excluded from other downstream analysis. Adapter sequences could be soft clipped 
during alignment or trimmed ahead of alignment.  
 
 
 
 
 
 
IGV visualization and IBD to verify sample identity 
Aligned and sorted bam files were loaded into IGV[224] to perform visual 
inspection of target variants. For example, visualization of a PSEN1_S290C delE9 carrier 
in the top red track is compared to a non-carrier in the bottom blue track shown in Figure 
Pass Warning Fail
Basic Statistics 170 0 0
Per base sequence quality 161 9 0
Per tile sequence quality 169 1 0
Per sequence quality scores 170 0 0
Per base sequence content 0 38 132
Per sequence GC content 0 42 128
Per base N content 170 0 0
Sequence Length Distribution 170 0 0
Sequence Duplication Levels 3 148 19
Overrepresented sequences 11 159 0
Adapter Content 0 0 170
Kmer Content 0 0 170
Table 2.5 DIAN and Knight ADRC FastQC summary 
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2.12 using IGV sashimi plot. DelE9 is a mutation (Chr14: 73673093 G>A) in PSEN1 
gene that result in exon 9 exclusion. In this carrier subject, in whom harbors heterozygous 
exon 9 deletion, the peak in the middle represents gene expression level of PSEN1 exon 9 
flanked by exon 8 and exon 10. Because this carrier is heterozygous for delE9, the exon 9 
peak is half in height compared to its neighbors on either side, and there are more reads 
(79 reads) that skipped exon 9 and linked exon 8 and exon 10 compared to the non-carrier 
in the bottom track (0 read). Samples carrying unexpected variants or missing expected 
variants were labeled as potential swapped samples. In addition, variants were called 
from RNA-Seq following BWA/GATK pipeline[171, 181]. The identity of the samples 
was later verified by performing IBD analysis against genomic typing from GWAS 
chipsets.  
Figure 2.12 PSEN1 delE9 Sashimi Plot using IGV. Top red track is from sample H_VY-
2968OM_S1512443_I.B.13, a PSEN1_S290C delE9 carrier, in whom harbors heterozygous exon 
9 deletion. Bottom blue track is from a non-carrier subject.   
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GWAS PCA and Ethnicity Check 
 GWAS principal component analysis (PCA) components were extracted for 
matched RNA-Seq subjects to check ethnic identity. Among RNA-Seq subjects there are 
6 subjects are African Americans, while the rest are European Americans (Figure 2.13).  
 
 
Figure 2.13 GWAS PCA of ethnicity check. HapMap Europeans are color coded as 
yellow; HapMap Africans are color coded as blue; HapMap Asians are color coded as 
red. My samples are color coded as black, which mostly fall into the European ethnic 
group except six subjects labeled with their IDs. 
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2.3.3 Expression quantification 
I applied Salmon transcript expression quantification (ver 0.7.2)[208] to infer the 
gene expression for all samples included in the reference panel and participants in the 
Mayo, MSBB, DIAN and Knight-ADRC. I quantified the coding transcripts of Homo 
Sapiens included in the GENCODE reference genome (GRCh37.75). Similarly, I 
quantified the expression of the mice samples included in the reference panel using the 
Mus Musculus reference genome (mm10). 
2.3.4 Reference panel 
Reference Samples 
I assembled a cell-type specific reference panel from publicly available RNA-Seq 
datasets comprised of both immunopanning collected or iPSC derived neurons, 
astrocytes, oligodendrocytes, and microglial cells from human and murine samples.  For 
immunopanning collected cells, antibodies for cell-type specific antigens were utilized to 
bind and immobilize their targeted cell types in order to immunoprecipitate and purify 
each cell type from the suspensions[290]. cDNA synthesis was accomplished using 
Ovation RNA-Seq system V2 (Nugen 7102) and library prepared with Next Ultra RNA-
Seq library prep kit from Illumina (NEB E7530) and NEBNext® multiplex oligos from 
Illumina (NEB E7335 E7500). TruSeq RNA Sample Prep Kit (Illumina) was used to 
prepare library for paired-end sequence on 100ng of total RNA extracted from each 
sample. Illumina HiSeq 2000 Sequencer was used to sequence all libraries[290]. 
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Both human adult temporal cortex tissue, collected from patients receiving 
neurological surgeries, and mice cells were disassociated, sorted and sequenced as 
described elsewhere[291], and deposited in the Gene Expression Omnibus GSE73721 
and GSE52564. I also accessed neural progenitor cells (day 17) and mature human 
neurons (day 57 and 100) from Broad iPSC deposited in the AMP-AD portal[7] and  
neural progenitor cells and iPSC-derived neurons from[37]. Broad iPSC derived neurons 
accessed from AMP-AD portal were generated using an embryoid body-based protocol to 
differentiate into forebrain neurons[1]. Wild-type cells used in the protocol were obtained 
from UConn StemCell Core.  RNA was purified using PureLink RNA mini-kit (Life 
Technologies) and libraries were prepared by Broad Institute's Genomics Platform using 
TruSeq protocol. Please refer to Table 2.6 for additional information. 
Type Mouse Human iPSC
a
GSM1269905 YZ2-100day
GSM1269906 YZ3-100day
YZ4-100day
YZ5-100day
GSM1901309 GSM1901317 GSM1269903 Astrocyte1
GSM1901310 GSM1901318 GSM1269904 Astrocyte2
GSM1901311 GSM1901319
GSM1901312 GSM1901320
GSM1901313 GSM1901321
GSM1901314 GSM1901322
GSM1901315 GSM1901323
GSM1901316 GSM1901324
GSM1269911
GSM1269912
GSM1269913
GSM1269914
Reference Sample
Neuron
Astrocyte
Oligodendrocyte
Microglia
Table 2.6 Reference samples for each cell type. GEO accession numbers for 
cell-type specific samples. 
a
 Samples accessed from the Broad iPSC cell-lines deposited in the AMP-AD.
GSM1901341
GSM1901340
GSM1901339
GSM1901338
GSM1901336
GSM1901335
GSM1901333
Human
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Marker Genes 
The reference panel was assembled with samples from four distinct cell types. A 
redundant set of well-known cell-type markers was selected from the literature[41, 131, 
291] (Table 2.7). Principal component analysis was performed on the reference panel 
using R function prcomp (version 3.3.3) to verify that the expressions of these gene were 
clustering samples by their cell types (Figure 2.14b; Figure 2.15a).  
Type Human Mouse
a
STMN2 Stmn2
SYN1 Syn1
SYT1 Syt1
GAD1 Gad1
CCK Cck
GFAP Gfap
ALDH1L1 Aldh1l1
AQP4 Aqp4
GJA1 Gja1
SOX9 Sox9
MOG Mog
MOBP Mobp
SOX10 Sox10
GPR37 Gpr37
TLR2 Tlr2
CX3CR1 Cx3cr1
IL1A Il1a
Table 2.7 Gene markers for principal brain cell types. 
a
 Mouse homologous genes were identified from Mouse Genome Database.
Cell Marker
Neuron
Astrocyte
Oligodendrocyte
Microglia
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Figure 2.14 PCA of samples included in the reference panel. a) Transcriptome-wide. Genes included in the reference panel b) PC1 vs PC2 and c) 
PC3 vs PC4. 
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2.3.5 Inference of the cellular population structure 
I ascertained alternative computation deconvolution algorithms implemented in 
the CellMix package (ver 1.6). Based on accuracy and robustness evaluation results I 
compared and reported the following three algorithms that outperformed the others: 
Digital Sorting Algorithm (named “DSA”)[293], which employs linear modeling to infer 
cell distributions; the method population-specific expression analysis (PSEA, also named 
meanProfile in CellMix implementation)[157] that calculates estimated expression 
profiles relative to the average of the marker gene list for each cell type[157]; and a semi-
supervised learning method that employs non-negative matrix factorization (ssNMF in 
CellMix implementation)[103]. I employed a leave-one-out cross-validation procedure to 
evaluate the accuracy provided by each method. The best performing algorithm ssNMF 
integrates cell-type marker genes to resolve the drawbacks of completely unsupervised 
standard non-negative matrix factorization. I followed the standard procedure described 
in the CellMix package, that included the extraction of marker genes from the reference 
samples (function extractMarkers from the CellMix package), and the posterior 
invocation of the function ged to infer cellular population from the gene expression of 
bulk RNA-Seq data. Besides, I tested additional methods which provided considerably 
lower accuracy (least-squares fit[8], quadratic programing[108]) or no significant 
difference (support vector regression[199] or latent variable analysis[51]) to the methods 
presented. 
I selected the reference samples that provide the most faithful transcriptomic 
profile for their respective cell types by following a leave-one-out cross validation 
approach. I trained iteratively deconvolution models using all but one of the samples that 
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was tested.  Only samples predicted with a composition higher than 80% were kept for 
the reference panel (Table 2.6; Figure 2.15b).  
 
 61 
GSM1901338
GSM1901336
GSM1901335
GSM1269912
GSM1269911
YZ5−100day
YZ4−100day
YZ3−100day
YZ2−100day
GSM1901333
GSM1269906
GSM1269905
GSM1901341
GSM1901340
GSM1901339
GSM1269914
GSM1269913
Astrocyte2
Astrocyte1
GSM1901324
GSM1901323
GSM1901322
GSM1901321
GSM1901320
GSM1901319
GSM1901318
GSM1901317
GSM1901316
GSM1901315
GSM1901314
GSM1901313
GSM1901312
GSM1901311
GSM1901310
GSM1901309
GSM1269904
GSM1269903
Gfap Aldh1l1 Aqp4 Gja1 Sox9 Tlr2 Cx3cr1 Il1a Stmn2 Syn1 Syt1 Gad1 Cck Mog Mobp Sox10 Gpr37
R
e
fe
re
n
c
e
 S
a
m
p
le
2 4 6
Log Transformed Gene Expression
GSM1901338
GSM1901336
GSM1901335
GSM1269912
GSM1269911
YZ5−100day
YZ4−100day
YZ3−100day
YZ2−100day
GSM1901333
GSM1269906
GSM1269905
GSM1901341
GSM1901340
GSM1901339
GSM1269914
GSM1269913
Astrocyte2
Astrocyte1
GSM1901324
GSM1901323
GSM1901322
GSM1901321
GSM1901320
GSM1901319
GSM1901318
GSM1901317
GSM1901316
GSM1901315
GSM1901314
GSM1901313
GSM1901312
GSM1901311
GSM1901310
GSM1901309
GSM1269904
GSM1269903
0.00 0.25 0.50 0.75 1.00
Cell Type Astrocyte Microglia Neuron Oligodendrocytea b
Figure 2.15 Leave-one-out evaluation of reference panel. a) Gene expression levels (log-transformed) for reference panel. The cell types of the 
isolated/iPSC-derived samples are color-coded and labeled on the y-axis. b) A leave-one-out procedure to obtain the cellular proportion for each of 
the samples of the reference panel was used. Cell-type proportions are shown as stacked percentage (red: astrocytes; green: microglia; blue: 
neuron; purple: oligodendrocyte). 
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2.3.6 Accuracy and Robustness Evaluation 
Chimeric validation 
 To emulate heterogeneous tissue with known and controlled cellular composition, 
I generated chimeric libraries pooling reads (to a total of 400,000) contributed from the 
human reference samples (See Table 2.6).  This process was repeated 720 times, using 
alternative reference samples to model each cell type. The proportion of reads that the 
libraries of neurons, astrocytes, oligodendrocytes and microglia provided to the chimeric 
libraries varied in predefined ranges (Figure 2.16). As a result, each of the chimeric 
libraries contained reads that followed 32 different distributions (neuronal reads 
contributed between 2 to 36% of reads, astrocytes between 22 to 76%, oligodendrocytes 
between 6 to 62% and microglia between 1 to 5%). Refer to Table 2.8 for detailed 
description of the 32 different distributions. I quantified the chimeric reads using Salmon 
(v0.7.2)[208], and employed the reference samples that did not contribute reads to the 
chimeric library as reference panel for the deconvolution methods.  
Overall, I applied my digital deconvolution analyses to 23,040 (720 × 32) 
chimeric libraries. I evaluated the accuracy using the root-mean-square error (RMSE, 
Equation 2.1 to compare the digital deconvolution cellular proportion estimates (method 
ssNMF) versus the defined proportion of reads specific to each of the chimeric libraries: 
 𝑅𝑀𝑆𝐸 =  √
∑ (?̂?𝑖 − 𝑦𝑖)2𝑛𝑖 = 1
𝑛
         (Equation 2.1) 
 ?̂?𝑖 − 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒, 𝑦𝑖 − 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 
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Figure 2.16 Chimeric library deconvolution simulation. Human cell-type specific reference samples contributed 720 different 
combinations to generate chimeric libraries. Reads were randomly sampled following 32 pre-specified distributions (Neuronal 
reads contributed between 2 to 36% of reads, astrocytes between 22 to 76%, oligodendrocytes between 6 to 62% and microglia 
between 1 to 5%). Each chimeric library was quantified and the cellular distribution estimated using digital deconvolution. These 
estimates were compare to prior distribution. 
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Neuron Astrocyte Oligodendrocyte Microglia
2.31 51.7 43.5 2.49
10 72 15.2 2.81
10.1 44.7 42.9 2.31
18.9 65.9 12.4 2.85
18.9 41.6 37 2.53
25.4 57.6 14.5 2.49
31.6 33.2 33.3 1.9
35.9 46 15.6 2.51
20.3 22.2 55.8 1.75
17.2 34.6 46.2 2.01
33.6 43.1 20.7 2.52
15.6 47.8 34.1 2.53
24.2 56.7 16.5 2.59
19.2 65.5 12.3 2.99
9.81 66.7 20.6 2.95
12.9 76.4 8.1 2.59
18.2 72.2 6.86 2.8
23.3 62.7 11.2 2.87
25 57.3 15.1 2.56
18.2 61.6 17.3 2.94
23.7 49.2 24.6 2.44
20.3 45.5 31.8 2.5
14.7 37.8 45.4 2.13
9.77 26.3 62.2 1.67
17.7 29.9 51.4 1.01
23.8 55.4 19.4 1.38
17.5 41.9 39 1.67
24.7 60.9 12.3 2.01
15 51.2 31.4 2.47
20.1 64.8 12.3 2.71
12.7 48.3 34.9 4.09
21.3 60.6 13.5 4.57
M
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Table 2.8 Simulated chimeric tissue cell-type composition. Percentages of reads 
contributed to the synthetic chimeric libraries.
For each target cell type the distribution was pre-defined to cover a broad range of 
biological viable proportions (highlighted in bold).
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I also tested whether the deconvolution results were dominated by the expression of any 
specific marker gene and ascertained the robustness of the inferred cellular population 
structure to any possibly altered expression of marker genes. To do so, I performed the 
deconvolution analysis discarding each of the marker genes one at a time and evaluated 
how these distributions differed in comparison to the full gene reference panel.  
2.3.7 Statistical Analysis  
Transcriptome PCA and covariate analysis 
Number of reads gene quantification results from Salmon were normalized with 
DeSeq2’s VarianceStabilizingTransformation function after removing genes with total 
reads count less than 10,000. First 10 principle components were extracted from PCA, 
and single and stepwise covariate analysis using linear model were performed to 
investigate what covariates would affect data quality and downstream analysis. RNA 
quality (RIN and DV200), post-mortem index (PMI), sequencing pooling, sex, age at 
death, and brain tissue origin were included in either single covariate and stepwise 
covariate analysis. The results showed RNA quality measurements RIN and DV200, and 
age at death are the most important confounding factors that impact the analysis. 
Covariate correlation was performed to examine any correlation among the factors to 
avoid including highly correlated covariates that lead to over correction of the model, for 
example, RIN and DV200 are associated with quality but they are highly correlated as 
well. Since RIN and DV200 are highly correlated, using RIN only is recommended 
because other publicly ascertained datasets only have RIN measurements. (Figure 2.17). 
Later in Chapter 3, I will replace RIN for transcript integrity number (TIN), which will 
be inferred directly from RNA-Seq data. Notice that ribosomal RNA contents are 
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negatively correlated with uniquely mapped reads, because those rRNA will be mapped 
to multiple locations due to its highly conserved and similar sequences.  Besides, 
uniquely mapped reads also anti-correlated with incorrect strand reads, percentage of 
reads that mapped to multiple loci, and median 5’ to 3’ bias. The neuronal and astrocyte 
proportion I inferred from the RNA-Seq data are also highly negatively correlated. 
Figure 2.17 Covariate correlation. Major covariates of RNA-Seq and inferred cell type 
compositions from deconvolution were correlated to avoid including highly correlated 
covariates in downstream analysis. 
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 Transcriptome-wise PCA showed seven subjects are very different from the rest 
and they appeared as outlier on PC1 vs PC2 plot (Figure 2.18). iPSC samples were 
excluded from this analysis and analyzed separately in another study[143]. Among the 
seven outliers, 60007 and 83774 also have high median 5’ to 3’ bias. The top 30 genes 
that contributed the most to PC1 and top 30 to PC2 were extracted and plotted as a 
heatmap to show the dramatic difference between these outlier subjects and the rest of the 
samples (Figure 2.19). Notice that the left most 5 subjects are the outliers on 
transcriptome-wise PCA, but the other two outliers 83774 and 60007 do not have an 
obvious clustering pattern in the heatmap, suggesting that high median 5’ to 3’ bias also 
contribute variances observed in PC1 and PC2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18 Transcriptome-wise principle component analysis. 
Subject transcriptome-wise PCA were plotted using PC1 and PC2 with 
outliers labeled with subject ID.  
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Figure 2.19 Top 60 Genes for PC1 and PC2 heatmap. The left most 5 subjects are the outliers on transcriptome-wise PCA, and they are 
clustered as a separate group in the top 30 genes contributing the most variance to PC1 and PC2. The other two outliers 83774 and 60007 also 
have high median 5’ to 3’ bias that do not have an obvious clustering pattern in the graph. 
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Cell type proportions and disease status association analysis 
I employed linear regression models to test the association between cell-type 
proportions and disease status (R Foundation for Statistical Computing, ver.3.3.3). 
Stepwise discriminant analysis (stepAIC function of R package MASS, version 7.3-45) 
was used to determine significant covariates, and correct for confounding effects. I 
included RNA integrity number (RIN), batch, age at death and post-mortem interval 
(PMI) as covariates for the Mayo Clinic analyses. For Mount Sinai Brain Bank analyses, 
I corrected for RIN, PMI, race, batch and age at death. I also used linear-mixed models to 
perform multiple-region association analysis, employing random slopes and random 
intercepts grouping by observations and by donors[253], and correcting for the same 
covariates previously described. 
To analyze the DIAN and Knight-ADRC studies I applied linear-mixed models 
(function lmer and Anova, R packages lme4 ver.1.1 and car ver.2.1, respectively), 
clustering at family level to ascertain the effect of the neuropathological status in the cell 
proportion, and corrected for RIN and PMI.  For late-onset specific analyses I also 
corrected for age at death. Cellular composition shown as proportions were plotted using 
R package ggplot2 (ver 2.2.1) 
2.4 Results 
2.4.1 Study design 
To infer cellular composition from RNA-Seq, I firstly assembled a reference 
panel to model the transcriptomic signature of neurons, astrocytes, oligodendrocytes and 
microglia. The panel was created by analyzing expression data from purified cell lines. I 
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evaluated alternative digital deconvolution methods and selected the best performing for 
my primary analyses. I tested the digital deconvolution accuracy on induced pluripotent 
stem cell (iPSC) derived neurons/microglia cells and neuronal Translating Ribosome 
Affinity Purification followed by RNA-Seq (TRAP-seq; Figure 2.20). Finally, I verified 
its accuracy by creating artificial admixture with pre-defined cellular proportions.  
 
 
 
 
 
Figure 2.20 Study design. Development of the brain cell-type transcriptomic reference panel 
(left column): the expression signatures of key cell types of the brain were curated by compiling 
publicly available RNA-Seq data from neurons, astrocytes, oligodendrocytes and microglia. The 
panel was curated iteratively to retain only those samples that showed the most faithful 
expression signature, while evaluating alternative digital deconvolution methods. The accuracy of 
digital deconvolution to estimate brain cellular proportion was validated using additional cell-
type specific samples, and also by generating chimeric libraries. To study cellular population 
structure in AD (right column), I accessed publicly available datasets from the Advanced 
Medicines Partnership-AD knowledge portal (AMP-AD), including Mayo Clinic and Mount 
Sinai Brain Bank datasets. In addition, we generated RNA-Seq from participants of the Knight-
ADRC and The Dominantly Inherited Alzheimer (DIAN) studies. These three studies generated 
RNA-Seq data from pathological aging brains, Alzheimer’s disease cases, and neuropath-free 
controls for a total of six cerebral cortex regions and cerebellum.  I quantified the gene expression 
for all of the samples included in these studies using the same RNA-Seq processing pipeline. 
Using digital deconvolution methods, I estimated the brain cellular proportions of the samples 
and compared the proportion between AD cases and controls.  I study the cell structure of brains 
carriers of Mendelian pathological mutations and variants that confer high-risk to AD. Anterior 
prefrontal cortex – APC; superior temporal gyrus – STG; parahippocampal gyrus – PHG; inferior 
frontal gyrus – IFG; Mount Sinai Brain Bank – MSBB; Alzheimer’s disease – AD; pathological 
aging – PA. 
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Once the deconvolution approach was optimized, I calculated the cell proportion 
in AD cases and controls from the different brain regions of Mayo and MSBB datasets. 
The RNA-Seq data for the Mayo Clinic study (N = 191)[9] and Mount Sinai (MSSM) 
Brain Bank (MSBB; N = 300)[3] are deposited in the Advanced Medicines Partnership-
AD (AMP-AD) knowledge portal (Synapse ID: syn5550404 and syn3157743; Table 
2.1). The Mayo study includes RNA-Seq from the temporal cortex and cerebellum for 
AD affected and non-demented controls, in addition to pathological aging participants 
(Figure 2.20). The MSBB also profiled four additional cerebral cortex areas: anterior 
prefrontal cortex - APC, superior temporal gyrus - STG, parahippocampal gyrus – PHG, 
and inferior frontal gyrus – IFG; Table 2.1; Figure 2.20). I restricted the case-control 
analysis to subjects with definite AD and autopsy confirmed controls. In addition, we 
generated RNA-Seq from parietal lobe for participants of the Knight-ADRC (84 late-
onset cases, carriers of genetic risk factors and 16 controls; Table 2.2) and The 
Dominantly Inherited Alzheimer Network (DIAN; 19 carriers of mutations in APP, 
PSEN1, PSEN2) (Table 2.1; Figure 2.20). I employed the same pipeline to process all of 
the samples in order to avoid any bias. Furthermore, RNA-Seq from the Knight-ADRC 
and DIAN studies allowed us to compare the cell composition from ADAD vs LOAD 
brains, and similarly to test for differences in brain of controls, sporadic AD who do not 
carry any known high-risk variant, carriers of high-risk variants in TREM2 (N = 20), 
PLD3 (N = 33), and APOE 4 allele.  
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2.4.2 Development of a reference panel to estimate brain cellular 
population structure  
Due to limited availability of brain cell-type specific transcriptomic data, I 
compiled reference samples from different sources, including single-population RNA-
Seq from mice and human (immunopan-purified oligodendrocytes, neurons, astrocytes 
and microglia and iPSC-derived neurons and astrocytes).  
I selected 17 well accepted genes that tag brain cell types based on literature 
reviews[41, 131, 291] . A visual inspection of the expression of these marker genes in the 
samples I compiled suggested a divergent transcriptomic profile among the cell types 
(Figure 2.15a). The PCA showed that their expression was sufficient to cluster samples 
of neurons, astrocytes, oligodendrocytes and microglia with their respective cell types, 
regardless of the species of the reference samples (Figure 2.14b; Table 2.6). I observed 
that first principal component (PC) captured the expression profile of astrocytes; as 
shown by the significant association of the expression of astrocyte marker genes with (p 
< 8.05×10-03). The second PC captured the expression of genes whose expression is 
characteristic to oligodendrocytes (p < 2.52×10-02). The third PC was negatively 
associated with neuronal genes (p < 1.11×10-05) and positively with microglia (p < 
1.42×10-02). Overall, the principal component analysis (Figure 2.14b) indicated that these 
genes can effectively cluster samples by their cell-type.  
Given the technical and biological heterogeneity of the samples I compiled for 
reference panel, I carried out an optimization phase to identify those samples that showed 
the most faithful expression profile to represent their respective cell types (See 
Methods). From the leave-one-out cross-validation results, I noticed that not all of the 
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cell-type specific samples were predicted as expected (defined with a correct prediction 
proportion higher than 80%). Samples failed this criteria were due to various reasons, for 
example, the expression profile of immunopan-purified astrocytes collected from 
mice[291], human fetal[291] or human sclerotic hippocampal[291]  brains were reported 
with altered expression[38, 291] that differed to an extent that could not be accurately 
ascertained by deconvolution methods. Similarly, neuronal proportion inferred from 
iPSC-derived neurons from schizophrenic donors[38] and iPSC-derived neurons 
collected at early stages of differentiation (< 100 days; Synapse ID: syn3607401) were 
also lower than 80%. These samples did not cluster with their expected cell types in the 
marker gene PCA either, and coincidently the leave-one-out cross-validation indicated 
that these samples had an expression signature that differed from the other samples of the 
same cell type.  
To evaluate the performance of reference panel performance and test out different 
deconvolution algorithms, I employed and compared six digital deconvolution methods 
implemented in the CellMix package (ver 1.6) to infer cellular composition from 
reference samples RNA-Seq data, including qprog[108], cs-qprog, DSA[293], 
ssFrobenius[103], meanProfile[157], deconf[221]. The deconvolution performance of 
reference panel was evaluated by following a leave-one-out cross-validation procedure to 
compare the predicted cellular composition with its expected cellular identity of each 
cell-type specific sample. The accuracy of this comparison was quantified using the root-
mean-squared error (RMSE) calculation. A semi-supervised method adapted from non-
negative matrix factorization[103] (ssNMF – named ssFrobenius in CellMix) generated 
the most accurate predictions; and I verified that similar results were obtained by the 
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method population-specific expression analysis[157] (PSEA – named meanProfile in 
CellMix).  
I ascertained the effect that sequencing depth has in the accuracy of 
deconvolution.  I generated low-coverage versions (Picard DownsampleSam ver 2.8.2) of 
the samples that included a reduced number of randomly sampled reads (400,000 reads 
per sample), quantified the gene expression, inferred their cellular population 
proportions, and compared the distribution estimates with their full-depth libraries 
sequencing (more than 30 million reads per sample). I observed that the deconvolution 
was robust to the sequencing coverage, as shown by a correlation r2=0.98 (p < 2.2×10-16; 
Figure 2.21).  My final reference panel (Table 2.6; Table 2.7) had a very high 
confidence to predict cell types with a mean predicted accuracy = 95.2%; s.d. = 4.3, and a 
root-mean-square error (RMSE) = 0.06 (Table 2.9). 
 
 
 
76 
 
Figure 2.21 Comparison of cell proportions estimated from full-depth and down-
sampled RNA-Seq data. Each sample of the reference panel sample was down-sampled 
(400,000 reads) and cellular population structure inferred following leave-one-out 
procedure. Cell-type proportions of the samples inferred using the full-depth RNA-Seq 
data are presented along the X-axis, and along the Y-axis the counterparts inferred using 
shallow RNA-Seq. 
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Algorithm Overall Neuron Astrocyte Oligodendrocyte Microglia
ssNMF
a 0.064 0.054 0.055 0.028 0.017
PSEA
b 0.089 0.08 0.052 0.058 0.025
DSA
c 0.465 0.32 0.328 0.291 0.295
Table 2.9 Evaluation of deconvolution accuracy. Overall and cell-type specific root-mean-squared error (RMSE) 
for reference panel, calculated using the leave-one-out approach for three deconvolution algorithms implemented in 
CellMix package.
a 
ssNMF: semi-supervised learning non-negative matrix factorization. 
b 
PSEA: population-specific expression analysis (also named meanProfile in CellMix implementation). 
c 
DSA: Digital sorting algorithm.
 78 
2.4.3 Optimization, validation and accuracy estimation of the reference 
panel and digital deconvolution method 
 Once I identified the optimal approach to perform digital deconvolution from 
brain RNA-Seq, I benchmarked it by using three sets of independent pure cell 
populations and simulated chimeric libraries. 
I firstly validated the accuracy to predict neuronal composition by generating 
RNA-Seq for eight iPSC-derived cortical neurons (see Methods). I observed an accurate 
prediction in these independent cell lines (mean neuronal proportion = 94.8% and s.d. = 
1.1%; Figure 2.22a).  I also ascertained the cellular composition of mRNA extracted 
from the barrel cortex neurons isolated by Translating Ribosome Affinity Purification 
(TRAP) in 24 mice. TRAP is a method that captures cell-type specific mRNA translation 
by purifying tagged ribosomal subunit and capturing the mRNA it bound to[122]. I 
observed an average of neuronal proportion = 96.7% and s.d. = 1.2% (Figure 2.22b). 
Similarly, I assessed the RNA-Seq data generated for iPSC-derived microglia (N = 10) 
deposited in the AMP-AD portal (Synapse ID: syn7203233) and inferred their cellular 
population structure and observed a mean microglia proportion = 86.6% and s.d. = 7.1% 
(Figure 2.22c).
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Figure 2.22 Cellular population structure of cell-type specific samples. Cell-type proportions shown as stacked 
percentage (red: astrocytes; green: microglia; blue: neuron; purple: oligodendrocyte). a) iPSC derived cortical neurons 
(N = 8). b) mouse barrel cortex neurons isolated by Translating Ribosome Affinity Purification (TRAP) procedure (N = 
24). c) iPSC derived microglia (N = 10). 
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To evaluate the accuracy of digital deconvolution for measuring cell-type 
proportion from cell-type admixtures, I simulated RNA-Seq libraries by pooling reads 
from individual cell types into well-defined proportions. I combined randomly sampled 
reads from neurons, astrocytes, oligodendrocytes and microglia to create chimeric 
libraries that mimic bulk RNA-Seq from brain, but with a range of pre-defined cell-type 
distributions (Figure 2.16).  I then quantified the gene expression for the chimeric 
libraries and inferred the cell-type distribution (employing for the reference panel 
samples that did not contribute reads to the chimeric libraries). This process was repeated 
23,040 times, choosing distinct human samples to represent each cell type and varying 
the proportions in 32 alternative distributions (See methods and Table 2.8). The overall 
error (RMSE) compared to known proportions = 0.08.  
Finally, I evaluated whether any gene included in the reference panel was 
dominating the inference of cell proportions. I re-calculated the cell-type distributions of 
the chimeric libraries, but dropping each of the genes from the reference panel one at a 
time. I observed a negligible difference between the cellular population structure inferred 
using the full reference and the gene-dropped panels (average RMSE = 0.022, s.d. < 
0.01). In this way, I verified that the proportions inferred using the reference panel are not 
driven by the expression of a single gene. This reassured us the inference should be 
robust to any bias introduced by the potential association of a single gene included in the 
reference panel with a particular trait.  
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2.4.4 Deconvolution of bulk RNA-Seq of non-demented and AD brains 
shows a characteristic signature for neurodegeneration 
Pathologically, AD is associated with neuronal death and gliosis specifically in 
the cerebral cortex. I evaluated whether I could exploit deconvolution methods using my 
reference panel to detect altered cellular population structure from the bulk RNA-Seq, 
and whether this corresponded to known pathological alterations.  
I initially analyzed the RNA-Seq from the Mayo Clinic Brain Bank that includes 
bulk RNA-Seq from the temporal cortex (TC) and cerebellum (CB) for 191 
participants[9] (Table 2.1). In the TC, I observed a significant higher astrocyte relative 
proportion (β = 0.23; p = 5.01×10-09; Table 2.10; Figure 2.25; Table 2.11) in AD brains 
compared to controls brains. I also found a significant lower relative proportion of 
neurons (β = -0.17; p = 1.58×10-07; Table 2.10; Figure 2.25; Table 2.11) and 
oligodendrocytes (β = -0.07; p = 1.8×10-02; Table 2.10; Figure 2.23; Table 2.11). As 
expected, given the absence of pathology, I did not observe a significant difference in the 
cell-type composition in the CB (Table 2.10). 
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Brain Regions Sample Size
AD vs Control N Effect P-value Effect P-value Effect P-value Effect P-value
  Cerebellum 119 -0.03 2.74×10
-01 0.05 8.65×10
-02 -0.02 1.07×10
-01
-3.19×10
-04
9.19×10
-01
  Temporal Cortex 119 -0.17 1.58×10
-07 0.23 5.01×10
-09 -0.07 1.8×10
-02
-2.03×10
-03
5.48×10
-01
AD vs Control
  Anterior Prefrontal Cortex 184 -0.04 8.14×10
-04 0.06 8.11×10
-05 -0.01 3.36×10
-02
-3.18×10
-03
1.12×10
-02
  Superior Temporal Gyrus 167 -0.08 3.49×10
-07 0.1 1.45×10
-07 -0.01 5.8×10
-02
-3.17×10
-03
5.78×10
-02
  Parahippocampal Gyrus 160 -0.11 1.35×10
-08 0.13 5.48×10
-10 -0.02 1.79×10
-03
-3.18×10
-03
1.35×10
-01
  Inferior Frontal Gyrus 159 -0.04 3.12×10
-03 0.06 3.58×10
-04 -0.01 4.39×10
-02
-3.98×10
-03
1.64×10
-02
  Anterior Prefrontal Cortex 184 -0.02 9.38×10
-04 0.02  2.07×10
-04
-3.43×10
-03
 1.25×10
-01
-1.46×10
-03
 4.95×10
-03
  Superior Temporal Gyrus 167 -0.03  1.87×10
-06 0.04 3.33×10
-07 -0.01   2.1×10
-02
-1.02×10
-03
 1.49×10
-01
  Parahippocampal Gyrus 160 -0.04  8.56×10
-06 0.04  2.85×10
-06 -0.01  8.7×10
-02
-1.94×10
-03
 2.53×10
-02
  Inferior Frontal Gyrus 159 -0.02  8.29×10
-05 0.03 1.4×10
-05
-4.64×10
-03
 6.7×10
-02
-1.46×10
-03
 3.11×10
-02
Braak Staging
  Anterior Prefrontal Cortex 173 -0.01  1.21×10
-02 0.01  1.27×10
-03
-3.09×10
-03 
2.77×10
-02
-7.04×10
-04 
3.12×10
-02
  Superior Temporal Gyrus 158 -0.02  2.22×10
-07 0.02  2.77×10
-07
-2.91×10
-03
 1.17×10
-01
-5.47×10
-04
 1.97×10
-01
  Parahippocampal Gyrus 147 -0.02  1.83×10
-06 0.03  9.6×10
-08 -0.01 1.49×10
-03
-3.71×10
-04
 4.97×10
-01
  Inferior Frontal Gyrus 152 -0.01  1.01×10
-02 0.01 8.56×10
-04
-3.55×10
-03
 2.37×10
-02
-1.01×10
-03
 1.74×10
-02
Mean Amyloid Plaques
  Anterior Prefrontal Cortex 184 -1.88×10
-03
 3.6×10
-03
2.82×10
-03
 1.03×10
-04
-7.99×10
-04
 2.13×10
-03
-1.46×10
-04 
1.72×10
-02
  Superior Temporal Gyrus 167 -4.2×10
-03
 7.73×10
-08 0.01  4.63×10
-08
-6.08×10
-04
 9.01×10
-02
-2.04×10
-04 
1.5×10
-02
  Parahippocampal Gyrus 160 -4.96×10
-03
 5.05×10
-09 0.01  1.26×10
-10
-9.99×10
-04
 1.85×10
-03
-2.1×10
-04
 2.58×10
-02
  Inferior Frontal Gyrus 159 -2.58×10
-03
 3.82×10
-04
3.53×10
-03
 1.96×10
-05
-7.41×10
-04
 1.51×10
-02
-2.04×10
-04
 1.26×10
-02
Table 2.10  Comparison of the cellular population structure (AD vs. neuropath-free controls) from the brains in the Mayo Clinic and Mount Sinai Brain Bank.
The cell-type proportions from AD cases and control were inferred from bulk RNA-seq using the ssNMF method. Effects of AD and associations with additional clinical and pathological 
phenotypes in cell-type distributions were estimated using linear regression model.
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The distribution of microglia was similar in the TC and CB from AD and control 
brains (Table 2.10; Figure 2.23). The proportion of microglia was lower than any other 
cell types. The Mayo dataset also includes brains from individuals with pathological 
aging (PA; Table 2.1); which is neuropathologically defined by amyloid β (Aβ) senile 
plaque deposits but little or no neurofibrillary tau pathology[9, 192]. I observed a 
significant lower relative proportion of microglia in PA brains compared to AD in both 
TC and CB (Table 2.12; Figure 2.24)[169]. Therefore, I speculated that the lack of 
changes in the AD microglial population was neither due to low statistical power nor the 
inability of my method to estimate the microglial proportions, but reflected unaltered 
neuropathological observations in AD brains. 
 
Figure 2.23 Microglia and oligodendrocyte proportions inferred from 
RNA-Seq of Mayo Clinic and Mount Sinai Brain Bank (MSBB) studies. 
Mean microglial (green) and oligodendrocyte (purple) proportion for AD cases 
and neuropath-free controls (bars indicate the standard deviation). The 
numbers of subjects are indicated below x-axis. 
 84 
Figure 2.24 Cellular population structure for Alzheimer’s disease (AD) and Pathological Aging (PA) subjects included in the Mayo 
Clinic study. Columns height represent the mean proportions. The numbers of subjects for each group is reported below x-axis. 
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I also analyzed data from the MSBB, which contains bulk RNA-Seq for four 
additional cerebral cortex areas (APC, STG, PHG, IFG). Replicating my findings from 
the Mayo dataset I observed a significant lower relative proportion in neurons and 
increase in astrocytes in all four areas (Table 2.10; Figure 2.25; and Table 2.11). The 
strongest effect size was detected in the parahippocampal gyrus and superior temporal 
gyrus (p < 3.49×10-07) (Table 2.10; Table 2.13). Neuropathological studies have 
described that the parahippocampal gyrus in one of the first brain areas in which AD 
pathology occurs[33, 78, 267]. I also observed a significant and strong correlation 
between neuronal and astrocyte relative proportions and last ascertained clinical status 
(Clinical Dementia Rating - CDR), and number of amyloid plaques and Braak staging 
(Table 2.10; Figure 2.25; Figure 2.26).  
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Figure 2.25 Cell-type distributions of the samples included in the Mayo Clinic and Mount 
Sinai Brain Bank. Mean neuronal (blue) and astrocytic proportion (red) for a) Alzheimer’s 
disease affected brains (AD) and controls (bars indicate standard deviations). The numbers of 
subjects for each group are shown below the x-axis. Distribution for additional clinical and 
pathological phenotypes reported for the Mount Sinai Brain Bank (MSBB): b) clinical dementia 
rating scores (CDR) and c) Braak and Braak staging.  d) Brain cell-type proportions (x-axis) 
plotted against the mean number of amyloid plaque (values greater than 0; y-axis). Standard 
errors were depicted in shaded area with LOESS smooth curve fitted to cell-type proportions 
derived from deconvolution. (** P< 0.01; *** P< 1.0×10-3; and **** P< 1.0×10-4). 
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Figure 2.26 Neurons and astrocytes distributions for the brains included in the Mount 
Sinai Brain Bank stratified by CDR and Braak staging. Neuron (blue) and astrocyte (red) 
proportions for the plotted against a) CDR  b) Braak Staging.   
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Brain Regions Sample Size
Mayo N Effect P-value Effect P-value Effect P-value Effect P-value
   Cerebellum 119 -0.04  1.05×10
-01 0.06  2.09×10
-02 -0.02  1.53×10
-01
8.79×10
-04 
6.53×10
-01
   Temporal Cortex 119 -0.17  7.1×10
-08 0.23  8.43×10
-09 -0.07  3.1×10
-02
3.91×10
-04
 8.67×10
-01
Mount Sinai Brain Bank
   Anterior Prefrontal Cortex 184 -0.04  1.75×10
-03 0.06  1.02×10
-04 -0.01  2.68×10
-02
-1.81×10
-03
 2.76×10
-02
   Superior Temporal Gyrus 167 -0.07  2.57×10
-06 0.09  1.06×10
-06 -0.01  8.55×10
-02
-1.77×10
-03
 1.32×10
-01
   Parahippocampal Gyrus 160 -0.1  2.37×10
-08 0.13  2.66×10
-10 -0.02  2.74×10
-03
-1.72×10
-03
 2.44×10
-01
   Inferior Frontal Gyrus 159 -0.04  4.07×10
-03 0.06 5.96×10
-04 -0.01  1.15×10
-01
-2.81×10
-03
 1.84×10
-02
Table 2.11 Comparison of the cellular proportions estimated using the method PSEA in AD and control brains from the Mayo and Mount Sinai Brain Bank.  
MicrogliaOligodendrocyteAstrocyteNeuron
Sample Size
PA vs AD N Effect P-value Effect P-value Effect P-value Effect P-value
   Cerebellum 75 0.05 6.66×10
-02 -0.06 3.83×10
-02 0.02 1.11×10
-01 -0.01 2.29×10
-04
   Temporal Cortex 76 0.19 2.51×10
-06 -0.21 1.02×10
-06 0.03 5.57×10
-02 -0.01 5.05×10
-04
PA vs Control
   Cerebellum 94 0.02 5.38×10
-01 -0.04 1.77×10
-01 0.02 1.7×10
-01
4.65×10
-03
1.73×10
-01
   Temporal Cortex 91 -0.05 1.91×10
-01 -0.03 4.58×10
-01 0.07 2.75×10
-02
5.39×10
-03
1.53×10
-01
Table 2.12 Cell-type proportions comparison of subjects diagnosed with Pathological Aging. The cell-type proportions inferred from RNA-seq data using 
the ssNMF method. Distribution in Pathological Aging (PA) brains, AD cases and neuropath-free controls are compared using linear regression model.
MicrogliaOligodendrocyteAstrocyteNeuron
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2.4.5 The cellular population structure differs between ADAD vs LOAD 
While the loss of neurons is a common feature of AD, it is not clear whether the 
mechanism holds true across different forms of AD or AD cases carrying different 
genetic risk variants. Therefore, I investigated whether AD with distinct etiologies 
showed different cellular compositions. We generated RNA-Seq data from the parietal 
lobe of participants enrolled in Knight-ADRC (84 LOAD, 3 ADAD, and 16 neuropath-
free controls) and DIAN (19 ADAD) studies (Table 2.1; Table 2.2). I selected the 
LOAD and ADAD participants to match for CDR at death, brain weight and sex 
distributions (See Table 2.2). 
Using digital deconvolution, I determined the cellular composition for these 
brains. I observed a significant lower relative proportion of neurons (β = -0.02, p = 
2.66×10-02) and significant higher relative proportion of astrocyte in AD (β = 0.03, p = 
MSBB regions APC STG PHG IFG
APC
a - 7.79×10
-04
9.02×10
-03
<2.22×10
-16
STG
b
4.89×10
-01 - 9.35×10
-01
2.12×10
-11
PHG
c
9.90×10
-01
7.06×10
-01 - 8.53×10
-13
IFG
d
1.28×10
-10
2.23×10
-06
8.86×10
-08 -
d
 IFG - Inferior Frontal Gyrus.
Table 2.13 Effect of AD in the neuronal and astrocytic proportions in distinct cerebral 
cortex areas. Comparison of the effect that AD has in the cell-type distribution in the four 
cerebral cortex areas ascertained in the Mount Sinai Study (ANCOVA). We report p-values for 
the pairwise comparison (upper triangle for neuron and lower triangle for astrocyte). 
Lower Half - Astrocyte
Upper Half - Neuron
a
 APC - Anterior Prefrontal Cortex. 
b
 STG - Superior Temporal Gyrus. 
c
 PHG - Parahippocampal Gyrus. 
90 
5.48×10-03) for the combined LOAD and ADAD brains compared to controls (Table 
2.14; Figure 2.27; Table 2.15), consistent with my findings in the Mayo and MSBB 
datasets. Similarly, the joint analysis of the brains from Knight-ADRC and DIAN showed 
a significant association between the neuronal and astrocyte relative proportions and 
neuropathological measures (Braak staging: β = -0.03, p = 8.51×10-06 for neurons and β = 
0.03, p = 3.83×10-06 for astrocytes; Table 2.14; Figure 2.27b) as well as for clinical 
measures (CDR: β = -0.02, p = 2.66×10-02 for neurons and β = 0.03 and p = 5.48×10-03 
for astrocytes; Table 2.14; Figure 2.27c). I did not observe a significant difference in the 
compositions of microglia or oligodendrocytes (Table 2.14; Fig S8). 
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Disease Status Sample Size
AD Status N Effect P-value Effect P-value Effect P-value Effect P-value
   AD
a
 vs Control 122 -0.11 5.52×10
-04 0.14 2.48×10
-05 -0.03 6.5×10
-02
-2.64×10
-03
2.49×10
-01
   ADAD vs Control 38 -0.19 3.94×10
-07 0.24 1.57×10
-10 -0.04 8.5×10
-03 -0.01 7.77×10
-05
   LOAD vs Control 100 -0.09 5.67×10
-03 0.12 3.34×10
-04 -0.02 1.06×10
-01
-1.70×10
-03
4.57×10
-01
   ADAD vs LOAD
      Braak matched 42 -0.08 1.03×10
-02 0.11 9.26×10
-04 -0.03 7.1×10
-02
-1.46×10
-03
7.01×10
-01
      Braak corrected 91 -0.09 4.71×10
-03 0.11 5.24×10
-04 -0.02 1.77×10
-01
-2.41×10
-03
4.25×10
-01
      CDR corrected 94 -0.12 2.11×10
-03 0.13 6.29×10
-04 -0.02 3.8×10
-01
-3.11×10
-03
2.41×10
-01
Clinical Dementia Rating
   AD
a
 and Controls 110 -0.02  2.66×10
-02 0.03  5.48×10
-03 -0.01  2×10
-01
-4.63×10
-04 
4.77×10
-01
   ADAD and Controls 26 -0.08  4.12×10
-04 0.11  1.78×10
-07 0.01   4.03×10
-03
-1.55×10
-03
 1.75×10
-08
   LOAD and Controls 100 -0.02  3.22×10
-02 0.03  7.01 ×10
-03 -0.01 1.81×10
-01
-4.64×10
-04
 5.11 ×10
-01
Braak Staging
   AD
a
 and Controls 106 -0.03  8.51×10
-06 0.03  3.83×10
-06
-4.24×10
-03
 2.04×10
-01
-2.52×10
-04
 6.81×10
-01
   ADAD and Controls 33 -0.05  2.37×10
-05 0.06  2.45×10
-05 -0.01  2.29×10
-01
-7.2×10
-04
 4.89×10
-01
   LOAD and Controls 88 -0.03  7.41×10
-04 0.03  4.63×10
-04
-3.72×10
-03
 3.29×10
-01
-1.66×10
-04
 7.86×10
-01
The cellular population structure was inferred using the ssNMF method. Effects and p-values for the association with disease status, clinical dementia 
rating and Braak staging using generalized mixed models. We identified similar trends with approximately the same significance levels. 
Table 2.14 Cellular population structure altered in the parietal lobe from AD brains in the DIAN study and Knight-ADRC brain bank. 
MicrogliaOligodendrocyteAstrocyteNeuron
a
 AD includes both autosomal dominant AD (ADAD) and late-onset AD (LOAD). 
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 Disease Status Sample Size
N Effect P-value Effect P-value Effect P-value Effect P-value
AD
a
 vs Control 122 -0.1 1.41×10
-03 0.12 7×10
-05 -0.02 1.97×10
-01
-1.84×10
-03
2.4×10
-01
ADAD
b
 vs Control 38 -0.18 2.35×10
-06 0.22 3.03×10
-10 -0.05 3.47×10
-02
-3.77×10
-03
1.56×10
-04
LOAD
c
 vs Control 100 -0.08 1.16×10
-02 0.1 6.82×10
-04 -0.02 2.5×10
-01
-1.12×10
-03
4.91×10
-01
ADAD vs LOAD 106 -0.09 9.47×10
-04 0.12 1.1×10
-05 -0.03 6.23×10
-02
-1.14×10
-04
9.38×10
-01
b
 ADAD: autosomal dominant AD, carriers of pathogenic mutation in APP , PSEN1  or PSEN2 . 
c
 LOAD: late-onset AD patients not carrying any autosomal dominant mutation.
Table 2.15 Comparison of the cellular proportions estimated using the method PSEA in AD and control brains from the DIAN and 
Knight-ADRC
MicrogliaOligodendrocyteAstrocyteNeuron
a
 AD Includes all of the AD affected subjects from the Knight-ADRC and DIAN studies. 
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Figure 2.27 Neuron and astrocyte distributions from the DIAN and Knight-ADRC brains. a) Mean neuronal 
(blue) and astrocytic (red) proportions for carriers of pathogenic mutations in APP, PSEN1 or PSEN2 (ADAD), late-
onset AD (LOAD) and neuropath-free controls (bars indicate standard deviations). Neuronal and astrocytic 
proportions plotted against b) Braak Staging; c) by Clinical Dementia Rating. d) Cell-type distributions for carriers of 
AD genetic risk factors. Lines indicate significance levels (*P< 0.05; ** P< 0.01; *** P< 1.0×10-3; **** P< 1.0×10-4). 
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Next, I compared the cell proportion of LOAD vs ADAD and found that the cell 
composition differs between them. I firstly selected the LOAD brains (N = 25) to match 
the Braak staging distribution of ADAD brains (N = 17). The ADAD brains showed a 
significant lower neuronal proportion compared to LOAD brains (β = -0.08; p = 1.03×10-
02; Table 2.14), and increased relative astrocyte proportion (β = 0.11; p = 9.26×10-04; 
Table 2.14). Then, I analyzed the entire Knight-ADRC LOAD brains, by extending the 
model to correct for Braak stages. I also observed significant lower relative neuronal 
proportion (β = -0.09; p = 4.71×10-03; Table 2.14; Figure 2.27a; Table 2.15) and 
increased relative astrocyte proportion (β = 0.11; p = 5.24×10-04; Table 2.14; Figure 
2.27a; Table 2.15 in ADAD brains compared to LOAD. I observed the same cellular 
differences when I corrected for CDR at death (β = -0.12; p = 2.11×10-03 for neurons and 
β = 0.13; p = 6.29×10-04 for astrocytes; Table 2.14; Figure 2.27bc).  In summary, my 
results indicate that ADAD individuals present a higher neuronal death even in the same 
stage of the disease, suggesting that in ADAD neuronal death play a more important role 
in pathogenesis than sporadic AD, in which other factors such as inflammation or 
immune response may be involved. 
2.4.6 Specific genetic variants confer a distinctive cell composition 
profile 
A variety of genetic variants increase risk of LOAD; however, it is unclear if the 
cellular mechanisms are the same across these distinct risk factors. Therefore, I tested the 
hypothesis that distinct genetic causes of LOAD have characteristic cellular population 
signatures. 
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I initially ascertained the effect of APOE ε4 on the cell-type composition. I 
observed a significant lower relative proportion of neurons (β = -0.06 for each of the ε4 
alleles; p = 9.91×10-03) and increase of relative proportion of astrocytes (β = 0.10; p = 
4.15×10-02) from the TC included in the Mayo Clinic dataset (Table 2.20; Figure 2.28a; 
Figure 2.29a). This finding was replicated when I performed a multi-region analysis of 
the MSBB dataset (β = -0.04; p = 2.60×10-03 and β = 0.05; p = 1.31×10-03 for neurons and 
astrocytes respectively; Table 2.16; Figure 2.28a; Table 2.20; Figure 2.29a). Given the 
strong risk conferred by the APOE ε4 allele[56], I studied its effects on the cell-type 
composition by restricting my analysis to AD brains. I observed a significant association 
in the multi-area analysis of the MSBB dataset (β = -0.03 p = 4.01×10-02; Table 2.16; 
Figure 2.28b; Table 2.21; Figure 2.29b) and also a significant increase in relative 
proportion of astrocytes (β = 0.03; p = 1.23×10-02; Table 2.16; Figure 2.28b; Table 
2.21; Figure 2.29b). I also observed a significant decrease in relative proportion of 
neurons (β = -0.06; p = 2.11×10-02; Table 2.16; Figure 2.28c) when I analyzed the 
LOAD and control brains from the Knight-ADRC. When I restricted the analysis to AD 
brains from the Knight-ADRC and compared the APOE ε4 carriers (N = 46) to non-
carriers (N = 41) I also observed decreased relative neuronal proportion (β = -0.06; p = 
2.69×10-02; Table 2.16; Figure 2.28d). I extended the models to correct for the Braak 
stages, and observed a significant association for the relative proportion of neurons with 
the APOE ε4 allele in the Knight-ADRC dataset (β = -0.06; p = 3.66×10-02; Table 2.16), 
and a significant association for the relative proportion of astrocytes in the MSBB (β = 
0.04; p = 4.89×10-02; Table 2.16). Furthermore, I performed a meta-analysis to combine 
the evidence of both studies and observed a significant association of the relative 
96 
neuronal proportion with APOE ε4 allele (p=1.86×10-02) and marginally significant 
association for the relative astrocytic relative proportion (p=0.09). 
 
 
 
 
 
 
 
 
 
 
Figure 2.28 Effect of the APOE ε4 allele and TREM2 coding variants on the cellular 
population structure. Mean neuronal (blue) and astrocytic (red) proportions for a) AD cases and 
controls in the Knight-ADRC brains categorized by APOE ε4 carriers vs. non-carriers and b) AD 
cases of Knight-ADRC brain bank (bars indicate standard deviations). c) AD cases and controls 
in the Mayo Clinic and MSBB d) AD cases in the Mayo Clinic and MSBB. e) Neuronal (blue) 
and astrocyte (red) distributions for samples included in the Mount Sinai brain bank stratified by 
TREM2 genetic status. APC: Anterior Prefrontal Cortex; STG: Superior Temporal Gyrus; PHG: 
Parahippocampal Gyrus; IFG: Inferior Frontal Gyrus; (n.s. P > 0.05; * P < 0.05; **** P < 1.0×10-
4) 
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Figure 2.29 Neurons and astrocytes distributions for samples included in the Mayo Clinic and Mount Sinai Brain Bank (MSBB) 
stratified by APOE ε4 allele. Neuronal (blue) and astrocyte (red) proportions.  a) AD Cases and controls. b) Restricted to AD cases 
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Variant Carriers Sample Size
Knight-ADRC N Effect P-value Effect P-value Effect P-value Effect P-value
   PLD3  vs Control 49 -0.1 1.6×10
-04 0.13 2.84×10
-03 -0.03 6.17×10
-02
7.05×10
-04
7.89×10
-01
   TREM2  vs Control 36 -0.07 7.93×10
-02 0.11 1.05×10
-02 -0.03 4.9×10
-02
1.65×10
-03
5.84×10
-01
   Sporadic AD vs Control 45 -0.11 5.45×10
-03 0.13 2.95×10
-04 -0.02 4.55×10
-01
-3.48×10
-03
1.13×10
-01
   APOE ε4+ vs APOEε4- LOAD cases & controls100 -0.06 2.11×10
-02 0.05 5.35×10
-02 0.01 3.72×10
-01
-8.09×10
-04
6.31×10
-01
   APOE ε4+ vs APOEε4-  LOAD cases only 84 -0.06 2.69×10
-02 0.03 2×10
-01 0.03 1.4×10
-02
-8.31×10
-04
6.21×10
-01
       CDR corrected 84 -0.06 2.78×10
-02 0.03 2.05×10
-01 0.03 1.16×10
-02
-1.05×10
-03
5.37×10
-01
       Braak corrected 73 -0.06 3.66×10
-02 0.03 3.72×10
-01 0.03 4.51×10
-03
-1.14×10
-03
5.93×10
-01
Mount Sinai Brain Bank - Multi-region
   AD TREM2  carriers vs Control 301 -0.03 3.57×10
-01 0.03 3.19×10
-01
-2.08×10
-03
7.87×10
-01
-2.68×10
-03
8.67×10
-02
   AD non-carriers TREM2  vs Control 882 -0.07 1.91×10
-08 0.08 1.25×10
-08
-3.36×10
-03
4.79×10
-01
-2.89×10
-04
7.97×10
-01
   AD TREM2  vs AD non-TREM2 673 0.05 1.98×10
-02 -0.05 1.58×10
-02
2.12×10
-03
7.76×10
-01
-2.13×10
-03
1.74×10
-01
       CDR corrected 673 0.04 5.83×10
-02 -0.04 4.46×10
-02
1.68×10
-03
8.19×10
-01
-1.92×10
-03
2.22×10
-01
       Braak corrected 642 0.05 1.3×10
-02 -0.05 2.7×10
-02
-1.82×10
-03
8.13×10
-01
-2.66×10
-03
1.28×10
-01
       Mean plaque counts corrected 673 0.05 2×10
-02 -0.05 1.59×10
-02
1.73×10
-03
8.15×10
-01
-2.2×10
-03
1.5×10
-01
   APOEε4 counts all samples 556 -0.04 2.6×10
-03 0.05 1.31×10
-03 -0.01 4.47×10
-02
-3.58×10
-04
6.53×10
-01
   APOE ε4 counts AD cases 225 -0.03 4.01×10
-02 0.03 4.23×10
-02
-4.52×10
-03
3.73×10
-01
-5.13×10
-04
6.78×10
-01
       CDR corrected 225 -0.03 2.02×10
-02 0.03 2.03×10
-02
-4.86×10
-03
3.19×10
-01
-4.91×10
-04
6.93×10
-01
       Braak corrected 198 -0.03 7.35×10
-02 0.04 4.89×10
-02 -0.01 8.54×10
-02
-1.08×10
-03
4.12×10
-01
Table 2.16 Gene specific cellular proportion analysis for Knight-ADRC and Mount Sinai Brain Bank studies 
MicrogliaOligodendrocyteAstrocyteNeuron
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Next, I analyzed the cellular composition in PLD3 carriers (N = 33). PLD3 carriers 
exhibited significantly lower relative proportion of neurons compared to controls (β = -0.10; p = 
1.60×10-04; Figure 2.27d) and a significant higher relative proportion of astrocytes (β = 0.13; p = 
2.84×10-03; Table 2.16; Figure 2.27d).  Sporadic AD non-carrier cases also exhibited 
significantly lower relative proportion of neurons compared to controls (β = -0.11; p = 5.45×10-
03) and significant higher relative proportion of astrocytes (β = 0.13; p = 2.95×10-04; Table 2.16; 
Figure 2.27d). The cell proportion between sporadic AD non-carriers and PLD3 carriers did not 
show any significantly difference (p > 0.05). 
Finally, I performed similar analyses with TREM2 carriers. TREM2 is involved in the 
immune response and its role in amyloid-β deposition or clearance remain controversial[263]. 
My analysis on the Knight-ADRC data showed significantly higher relative astrocytic proportion 
in AD affected TREM2 carriers (N = 20) compared to controls (β = 0.11; p = 1.05×10-02; Table 
2.16; Figure 2.27d). Despite TREM2 carriers presented lower neuron relative proportion 
compared to controls, this difference was not statistically significant (p>0.05; Table 2.16; 
Figure 2.27d). I analyzed whether the TREM2 carriers provided sufficient power to detect a 
significant association. My empirical estimates showed that TREM2 sample size provides 96% of 
power to detect an association with an effect size comparable to that observed for sporadic AD (β 
= -0.11). I also investigated the cellular proportion of the eleven TREM2 carriers in the MSBB 
dataset. The multi-region analysis showed TREM2 carriers do not show a significant difference 
in relative neuronal proportion compared to controls (p > 0.05; Table 2.16; Figure 2.28e), 
whereas in the AD TREM2 non-carriers the relative neuronal and astrocytic proportions are 
significantly different from controls (β = -0.07; p = 1.91×10-08 and β = 0.08; p = 1.25×10-08 
respectively; Table 2.16; Figure 2.28e).  
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In fact, my analyses indicate that TREM2 carriers have a unique cellular brain 
composition distinct than the other AD cases. TREM2 brains showed significantly higher relative 
neuronal proportion (β = 0.05; p = 1.98×10-02) and significantly lower relative astrocyte 
proportion than the AD non-carries (β = -0.05; p = 1.58×10-02; Table 2.16). The distribution of 
CDR, mean number of amyloid plaques and Braak staging do not differ between strata. 
Nonetheless, I verified that the cellular proportions were still significant after correcting for each 
of those variables (Table 2.16). These results suggested that the mechanism that lead to disease 
in TREM2 carriers is less neuron-centric than in the general AD population. 
2.5 Discussion 
I have developed, optimized and validated a digital deconvolution approach to infer cell 
composition from bulk brain gene expression that integrates publicly available cell-type specific 
expression data while addressing the heterogeneity of the phenotypic differences of samples and 
technical characteristics of transcriptome ascertainment. I acknowledge that the accuracy of this 
platform might be affected by the phenotypic diversity of the reference panel or the disease-
induced dysregulation of genes it includes. However, the deconvolution approach proved to be 
robust to the genes included in the reference panel, as I demonstrated that the proportions it 
inferred are not driven by the expression of any single gene. This platform produced reliable cell 
proportion estimates, as was shown by the evaluation of independent datasets of iPSC-derived 
neurons and microglia, mice cortical neurons (Figure 2.22) and simulated chimeric libraries. 
I used this approach to deconvolve studies that include large number of 
neuropathologically defined AD and control brains with their transcriptome ascertained in 
distinct brain regions and observed consistently significant lower relative neuronal proportion 
and increased relative astrocyte proportions in the cerebral cortex suggesting neuronal loss and 
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astrocytosis. Compatible with other studies, I also identified that the altered cellular proportion is 
also significantly associated with decline in cognition and Braak staging[239]. In contrast, I did 
not identify a significant difference in the cellular population structure in the cerebellum, a 
region not affected in AD (Table 2.10; Figure 2.25a).  
We generated RNA-Seq data from brains carrying pathogenic mutations in APP, PSEN1, 
PSEN2, which cause alterations in Aβ processing and lead to ADAD, and also generated RNA-
Seq from brains of LOAD and neuropath-free controls. I observed altered cell composition in 
both ADAD and LOAD compared to controls. However, I identified that ADAD brains have a 
different cell-type composition than disease-stage-matched LOAD, as the ADAD has a 
significantly lower relative neuronal proportion and more pronounced astrocytosis. Given the 
specific cellular population structure of the TREM2 carriers, I compared the neuronal and 
astrocytic relative proportion of ADAD to that of LOAD non-carriers of variants in TREM2 and 
observed significant differences (β = -0.09 and p = 6.89×10-03 for neurons and β = 0.10; p = 
1.49×10-03 for astrocytes). This indicates that the difference of the relative proportion between 
ADAD and LOAD are not driven by TREM2 carrier brains. Based on my results, I would 
hypothesize that this change in Aβ processing of ADAD would lead to more direct to neuronal 
death than the pathological processes of LOAD. Similarly, decreased neuronal and increased 
astrocyte relative proportions were significantly associated with APOEε4 allele. It has been 
reported APOE ε4 allele increase the risk for AD by affecting APP metabolism or Aβ 
clearance[44, 151], suggesting a direct link between APP metabolism and neuronal death. 
In contrast, the analysis of the Knight-ADRC brains showed that the neuronal relative 
proportion decrease is less pronounced in TREM2 carriers than in other LOAD cases. I replicated 
this finding in a multi-area analysis from the MSBB dataset. These results may implicate that 
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TREM2 risk variants lead to a cascade of pathological events that differ from those occurring in 
sporadic AD cases, which is also consistent with the known biology of TREM2. Further 
longitudinal neuroimaging analysis are required to validate my findings. TREM2 is involved in 
AD pathology through microglia mediated pathways, implicated on altered immune response and 
inflammation[54]. Recent studies in TREM2 knock-out animals showed that fewer microglia 
cells were found surrounding Aβ plaques with impaired microgliosis[275]. Furthermore, TREM2 
deficiency was reported to attenuate tauopathy against brain atrophy[168]. I found no significant 
difference in the proportion of microglia between AD cases and controls. However, I found 
significantly decreased microglia in brains exhibiting pathological aging (Table 2.12; Figure 
2.24), proving that these studies are sufficiently powered to identify significant differences. In 
any case, I cannot rule out the possibility of a change in the activation stage of microglia in these 
individuals.  Overall, these results suggest that TREM2 affects AD risk through a slightly 
different mechanism to that of ADAD or LOAD in general. Therefore, other pathogenic 
mechanisms should contribute to disease.  I believe that a detailed modeling of immune response 
cells, reflecting the alternative microglia activation states, will generate more accurate profiles to 
elucidate the immune cell distribution in AD.  
2.6 Conclusions 
There is a large interest in the scientific community to use brain expression studies to try 
to identity novel pathogenic mechanism in AD and to identify novel therapeutic targets. These 
efforts are generating a large amount of bulk RNA-Seq data, as single-cell RNA (scRNA-Seq) 
from human brain tissue in large sample size is not feasible. Single-cell sorting needs to be 
performed with fresh tissue[115], which restrains the analysis of highly characterized fresh-
frozen brains collected by AD research centers. My results indicate that digital deconvolution 
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methods can accurately infer relative cell distributions from brain bulk RNA-Seq data, but I 
recognize the importance of obtaining traditional neuropathological measures to validate the 
results I observed. Having this approach validated for AD can have an important impact in the 
community,  because digital deconvolution analyses 1) can reveal distinct cellular composition 
patterns underlying different disease etiologies; 2) can provide additional insights about the 
overall pathologic mechanisms underlying different mutations carriers for variants as in genes 
such as TREM2, APOE, APP, PSEN1 and PSEN2; 3) can correct the effect that altered cell 
composition and genetic statuses have in addition to downstream transcriptomic analyses and 
lead to novel and informative results; 4) can help the analysis of highly informative frozen brains 
collected over the years. 
In conclusion, my study provides a reliable approach to enhance our understanding of the 
fundamental cellular mechanisms involved in AD and enable the analysis of large bulk RNA-Seq 
data that may lead to novel discoveries and insights into neurodegeneration. 
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Chapter 3: The TMEM106B rs1990621 
protective variant is associated with 
increased neuronal proportion 
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3.1 Abstract 
Background: In previous studies, I observed decreased neuronal and increased astrocyte 
proportions in AD cases in parietal brain cortex by using a deconvolution method for bulk RNA-
Seq. These findings suggested that genetic risk factors associated with AD etiology have a 
specific effect in the cellular composition of AD brains. The goal of this study is to investigate if 
there are genetic determinants for brain cell compositions. 
Methods: Using cell type composition inferred from transcriptome as a disease status proxy, I 
performed cell type association analysis to identify novel loci related to cellular population 
changes in disease cohort. We imputed and merged genotyping data from seven studies in total 
of 1,669 samples and derived major CNS cell type proportions from cortical RNA-Seq data. I 
also inferred RNA transcript integrity number (TIN) to account for RNA quality variances. The 
model I performed in the analysis was: normalized neuronal proportion ~ SNP + Age + Gender + 
PC1 + PC2 + median TIN.  
Results: A variant rs1990621 located in the TMEM106B gene region was significantly 
associated with neuronal proportion (p=6.40×10-07) and replicated in an independent dataset. The 
association passed genome-wide multiple test correction in the multi-tissue meta-analysis 
(p=9.42×10-09) and joint analysis (p=7.66×10-10). This variant is in high LD with rs1990622 (r2 = 
0.98) which was previously identified as a protective variant for FTD with TDP-43 inclusion. 
Further analyses indicated that this variant is associated with increased neuronal proportion in 
participants with neurodegenerative disorders, not only in AD cohort but also in cognitive 
normal elderly cohort. However, this effect was not observed in a younger schizophrenia cohort 
with a mean age of death < 65. The second most significant loci for neuron proportion was 
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APOE, which suggested that using neuronal proportion as an informative endophenotype could 
help identify loci associated with neurodegeneration. 
Conclusion: This result suggested a common pathway involving TMEM106B shared by aging 
groups in the present or absence of neurodegenerative pathology may contribute to cognitive 
preservation and neuronal protection. 
3.2 Introduction 
3.2.1 Alzheimer’s disease in the context of multi-cell type interactions  
Although neuronal loss and synapse dysfunction are the preceding events of cognitive 
deficits in Alzheimer’s disease (AD), neurons do not work or survive by themselves. These 
delicate organelles require supports through intimate collaborations within themselves and with 
other cell types[125]. The microenvironment of cellular crosstalk, interaction, balance, and 
circuits maintained by neurons, astrocytes, microglia, oligodendrocytes, and other vascular cells 
are essential for the brain to carry out functions and fight against insults.  
AD associated risk factors identified across the genome also point to the involvements of 
multi-cell types apart from neurons[125, 161]. APOE4 is related to lipid metabolism and mostly 
expressed in astrocyte and microglia[56]. Other lipid metabolism related risk genes are ABCA7 
identified in all cell types[130, 161], CLU in astrocyte and oligodendrocyte precursor cells[119, 
160, 161], and SORL1 in astrocyte[161]. Research interests in the roles of inflammatory response 
to toxic stimuli or microbial infection have been escalating recently, and AD risk genes 
associated with immune response including TREM2[114, 144, 246], PLCG2[246], ABI3[246], 
CR1[160, 161], CD33[130, 161], HLA-DRB5–HLA-DRB1[161], and INPP5D[161] are mostly 
expressed in microglia and macrophages. BIN1 expressed in microglia, oligodendrocyte, and 
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neurons[161], and PICALM expressed in microglia and endothelial cells[119, 161] are associated 
with endocytosis.  
 In a normal functional brain, astrocytes, microglia, and oligodendrocytes provide trophic 
supports to neurons and various cell type specific functions. Astrocytes confer multiple functions 
to fulfill neurons’ metabolic needs[250] including but not limited to providing substrates for 
oxidative phosphorylation[210], exerting regulation of excitatory CNS neurotransmitter 
glutamate[76, 93], and serving as bidirectional communication nodes that talk to both neurons 
and blood vessels and modulate their activities in an arrangement of functional entities named 
neurovascular units[227, 244, 260]. Microglia surveil in the extracellular space and look for 
pathogens or debris to engulf through phagocytosis. Oligodendrocyte provides insulation to 
neurons by wrapping around the axons with myelin sheath. However, in an AD diseased brain, 
these supporting cells may become double-edged swords that play beneficial and/or harmful 
roles as disease progresses. Amyloid-β accumulation and clearance are the central events of the 
amyloid cascade hypothesis. Both astrocyte and microglia have been involved in response to the 
toxic stimuli of amyloid plaques. During the early stage, microglia[124, 126, 127] and 
astrocytes[126, 209, 225] accumulate around plaques to phagocytose or degrade those in a 
protective manner. However, as disease progresses, the chronic and prolonged activation of 
microglia and astrocytes will be provoked into a damaging pro-inflammatory state and a vicious 
circle that exacerbate pathology in a harmful manner. Evidence suggested that increased 
inflammatory cytokine secretion in microglia, and increased production of complement cascade 
components, and impaired glutamate regulation (unregulated glutamate activity can cause 
neuronal excitatory cell death)[76] may contribute to synaptic loss which ultimately leads to 
cognitive deficits. Disrupted neuronal plasticity due to myelin loss and dysfunctional 
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neurovascular units further exacerbate the dreadful situation and destroy the harmony of the 
multi-cell type microenvironment.  
3.2.2 Cell type composition inferred from bulk RNA-Seq deconvolution 
Apart from disturbed homeostatic processes and impaired circuits integrity, cell type 
composition or proportion is also altered. Brains affected by AD exhibits neuronal loss, 
oligodendrocyte loss, astrocytosis, and microgliosis. However, the specific effects that 
pathological mutations and risk variants have on brain cellular composition are often ignored. To 
investigate the changes of cerebral cortex cell-type population structure and account for the 
associated confounding effects in downstream analysis, I developed an in-silico deconvolution 
method to infer cellular composition from RNA-Seq data, which has been documented in my 
previous publication[172], and explained in depth in Chapter 2. In summary, I firstly assembled 
a reference panel to model the transcriptomic signature of neurons, astrocytes, oligodendrocytes 
and microglia. The panel was created by analyzing expression data from purified cell lines. I 
evaluated various digital deconvolution methods and selected the best performing ones for my 
primary analyses. I tested the digital deconvolution accuracy on induced pluripotent stem cell 
(iPSC) derived neurons and microglia, and neurons derived from Translating Ribosome Affinity 
Purification followed by RNA-Seq. Finally, I verified its accuracy with simulated admixture with 
pre-defined cellular proportions.  
Once the deconvolution approach was optimized, I calculated the cell proportion in AD 
cases and controls from different brain regions of LOAD and ADAD datasets. I found that 
neuronal and astrocyte relative proportions differ between healthy and diseased brains, and also 
differ among AD cases that carry different genetic risk variants. Brain carriers of pathogenic 
mutations in APP, PSEN1 or PSEN2 presented lower neuronal and higher astrocytes relative 
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proportions compared to sporadic AD.  Similarly, APOE ε4 carriers also showed decreased 
neuronal and increased astrocyte relative proportions compared to AD non-carriers.  In contrast, 
carriers of variants in TREM2 risk showed a lower degree of neuronal loss than matched AD 
cases in multiple independent studies. These findings suggest that different genetic risk factors 
associated with AD etiology may have gene specific effects in the cellular composition of AD 
brains. 
3.2.3 Use cell type composition in cell type QTL (cQTL) to identify novel loci 
for AD risk 
In a recently published study named PsychENCODE[272], a very similar deconvolution 
approach as reported in my previous study[172] was taken to infer cell type composition from 
RNA-Seq data predominantly drawn from psychiatric disorder cohorts. From the cell fractions 
inferred from bulk RNA-Seq data, they found that cell type composition differences can account 
for more than 88% of bulk tissue expression variation observed across the population with a ±4% 
variance on a per-subject level. Using cell type compositions as quantitative traits, the authors 
identified a non-coding variant closed to the FZD9 gene that is associated with both FZD9 gene 
expression and the proportion of excitatory layer 3 neurons[272]. Interestingly, deletion variants 
found previously upstream of FZD9 were associated with cell composition changes in Williams 
syndrome[45], a developmental disorder exhibits mild to moderate intellectual disabilities with 
learning deficits and cardiovascular problems. This observation re-emphasized the importance of 
incorporating cell type composition into RNA-Seq analysis pipeline even in psychiatric disorder 
cohorts without dramatic changes in cellular composition, not mention the necessity of such 
practice in neurodegeneration disorders that have significant changes in cell type composition. It 
also demonstrated the great potential of using relative abundance of specific cell types in 
 111 
identifying novel variants and genes implicated in disease. However, it is unclear if this finding 
is only applicable to psychiatry-relate traits or it is a more general finding. 
In this study, I utilized cell-type proportions inferred from my deconvolution 
method[172] to perform cell type QTL analysis in a dataset enriched for AD cases in search for 
potential new loci that are associated with neurodegeneration disorders. We imputed and merged 
genotyping or whole genome sequencing data from seven studies - five centered on 
neurodegeneration (N = 1,125), one schizophrenia cohort (N = 414), and GTEx multiple tissue 
controls (N = 130). From cortical RNA-Seq data, I derived cell fractions of four major CNS cell 
types, including neuron, astrocyte, microglia, and oligodendrocyte. Using normalized neuronal 
proportion as quantitative trait, I identified a variant rs1990621 located in the TMEM106B gene 
region significantly associated with neuronal proportion variation in all cohorts except 
schizophrenia subjects. This variant is in high LD with rs1990622 (r2 = 0.98), which was 
previously identified as a protective variant in FTD cohorts[266]. Variants in this region have 
also been found to be associated with AD with TDP-43 pathology[229], and downregulation of 
TMEM106B is observed in AD brains[234] . In conclusion, I have identified a variant associated 
with neuronal proportion with potential protective effect in neurodegeneration disorders.  
3.3 Methods 
3.3.1 Study participants 
The participants were sourced from seven studies with a total sample size of 1,669 
(Table 3.1). Among those, five studies are mainly focused on neurodegenerative disorders 
including Alzheimer’s disease (N = 681), frontotemporal dementia (N = 11), progressive 
supranuclear palsy (N = 82), pathological aging (N = 29), Parkinson Disease (N = 1), as well as 
cognitive normal individuals (N = 540). These samples come from the Mayo, MSSM, Knight 
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ADRC, DIAN, and ROSMAP studies as described in table 3.1. To compare with the 
neurodegenerative disorders, I also included schizophrenia (N = 210) and bipolar disorders (N = 
34) participants from the CommonMind study (Table 3.1). Additionally, two studies, MSSM and 
GTEx, contain multi-tissue data that include some participants contribute more than one tissue 
(Table 3.1).  
3.3.2 Standard protocol approvals, registrations and patient consents 
The protocol of DIAN and Knight-ADRC studies have been approved by the review 
board of Washington University in St. Louis. The protocol of Mayo dataset was approved by the 
Mayo Clinic Institutional Review Board (IRB).  All neuropsychological, diagnostic and autopsy 
protocols of MSSM dataset were approved by the Mount Sinai and JJ Peters VA Medical Center 
Institutional Review Boards. The religious orders study and the memory and aging project of 
ROSMAP was approved by the IRB of Rush University Medical Center. The NIH Common 
Fund’s GTEx program protocol was reviewed by Chesapeake Research Review Inc., Roswell 
Park Cancer Institute’s Office of Research Subject Protection, and the institutional review board 
of the University of Pennsylvania. Within CommonMind consortium, the MSSM sample 
protocol was approved by Icahn School of Medicine at Mount Sinai IRB; the Pitt sample 
protocol was approved by the University of Pittsburgh’s Committee for the Oversight of 
Research involving the Dead and IRB for Biomedical Research; the Penn sample protocol was 
approved by the Committee on Studies Involving Human Beings of the University of 
Pennsylvania. All participants were recruited with informed consent for research use.
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Dataset Brain Region Library Type Read Length mRNA Enrichment Sequencer Mean Coverage DNA type Reference
Bennett 2012;
Bennett 2012
Mayo TCX Paired end 101 ploy-A selection HiSeq 2000 158.31 ± 34.04 Genotype Allen 2016
MSSM BM10 BM22 BM36 BM44 Single end 100 rRNA depletion HiSeq 2500 35.96 ± 10.04 WGS Wang 2018
Knight-ADRC PAR Paired end 150 rRNA depletion HiSeq 4000 137.87 ± 21.81 Genotype Li 2018
DIAN PAR Paired end 150 rRNA depletion HiSeq 4000 149.82 ± 19.68 Genotype Li 2018
GTEx 2013;
Battle 2017
CommonMind BM9 Paired end 100 rRNA depletion HiSeq 2500 86 ± 21.12 Genotype Fromer 2016
Paired endBM24 CTX FCXGTEx WGS48.28 ± 13.2HiSeq 2000ploy-A selection76
Replication
Discovery
Table 3.2 General information of seven studies evolved in the analysis.  TCX: temporal cortex; PAR: parietal cortex; CTX: cortex; FCX: frontal cortex; DLPFC: dorsal lateral 
prefrontal cortex. BM9: dorsal lateral prefrontal cortex; BM10: Anterior prefrontal cortex; BM22: superior temporal gyrus; BM24: ventral anterior cingulate cortex; BM36: 
parahippocampal gyrus; BM44: inferior frontal gyrus. Mean coverage unit is million.
ROSMAP DLPFC Paired end 101 ploy-A selection HiSeq 2000 99.2 ± 29.29 WGS
N Region Age % Male RIN TIN Control AD FTD PSP PA PD SCZ BP OTH
ROSMAP 523 1 86.6 ± 4.59 35.4 7.07 ± 0.99 73.2 ± 5.13 114 338 0 0 0 0 0 0 71
Mayo 260 1 80.4 ± 8.37 48.1 8.16 ± 0.903 77.4 ± 5.94 69 80 0 82 29 0 0 0 0
MSSM 219 4 84 ± 7.32 35.6 6.42 ± 1.77 76.4 ± 2.52 49 170 0 0 0 0 0 0 0
Knight ADRC 108 1 83.1 ± 12 42.6 6.44 ± 1.2 79.4 ± 1.91 13 77 11 0 0 1 0 0 6
DIAN 15 1 50.9 ± 7.08 73.3 5.55 ± 1.09 78.9 ± 0.99 0 15 0 0 0 0 0 0 0
GTEx 130 3 58.2 ± 9.91 67.7 6.92 ± 0.846 73.8 ± 2.97 125 1 0 0 0 0 0 0 4
CommonMind  414 1 64.6 ± 18 62.3 7.67 ± 0.899 50 ± 7.21 170 0 0 0 0 0 210 34 0
Replication Total 1,146 426 343 11 82 29 1 210 34 10
Merged Total 1,669 540 681 11 82 29 1 210 34 81
Table 3.1 Demographic information for cohorts included in the study. AD: Alzheimer’s Disease; FTD: frontal temporal dementia; PSP:  progressive supranuclear palsy; PA: pathological 
aging; PD: Parkinson’s Disease; SCZ: schizophrenia; BP: bipolar disease; OTH: other unknown dementia or no diagnosis information.  
Discovery
Replication
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3.3.3 Data collection and generation 
Cortical tissues from various locations of post-mortal brains were collected (Table 3.2). 
RNA was extracted from lysed tissues and prepared into libraries of template molecules ready 
for subsequent next-generation sequencing steps. Ribosomal RNAs constitute 80%-90% of total 
RNAs, which are not the targets of this study. To focus on mRNA quantification usually 
researchers would either remove excessive rRNAs or enrich for mRNAs during RNA-Seq library 
preparation. In this study, DIAN[172], Knight ADRC[172], MSSM[274], and CommonMind[95] 
took a rRNA depletion approach to removed ribosomal RNA from total RNAs to retain a higher 
mRNA content.  Whereas, Mayo[9], ROSMAP[27, 28], and GTEx[6, 24] took a poly-A 
enrichment approach to enrich mRNAs from total RNAs. Genotype information were also 
collected and sequenced correspondingly. RNA-Seq paired with genotype data for each 
participant were either sequenced at Washington University for DIAN and Knight-ADRC studies 
or downloaded from public database for all the other studies. Please see Table 3.2 and each 
study reference(s) for more data collection and generation specifications.  
3.3.4 Data QC and preprocessing 
Genetic Data 
Stringent quality control (QC) steps were applied to each genotyping array or sequence 
data. The minimum call rate for single nucleotide polymorphisms (SNPs) and individuals was 
98% and autosomal SNPs not in Hardy-Weinberg equilibrium (p-value < 1×10-06) were 
excluded. X-chromosome SNPs were analyzed to verify gender identification. Unanticipated 
duplicates and cryptic relatedness (Pihat ≥ 0.25) among samples were tested by pairwise 
genome-wide estimates of proportion identity-by-descent. EIGENSTRAT[215] was used to 
calculate principal components. The 1000 Genomes Project Phase 3 data (October 2014), 
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SHAPEIT v2.r837[67], and IMPUTE2 v2.3.2[134] were used for phasing and imputation. 
Individual genotypes imputed with probability < 0.90 were set to missing and imputed genotypes 
with probability ≥0.90 were analyzed as fully observed. Genotyped and imputed variants with 
MAF < 0.02 or IMPUTE2 information score < 0.30 were excluded. WGS data quality is 
censored by filtering out reads with sequencing depth DP < 6 and quality GQ < 20 followed by 
similar QC approaches as described above for genotyping data. After the QC, all studies 
including imputed genotype and WGS data was merged into a binary file using Plink for 
downstream analysis. PCA and IBD analyses were performed on the merged binary files using 
Plink to keep European ancestry and unrelated participants (Figure 3.1 and Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Genomic PCA analysis. Genotype data PCA analysis was performed to select European 
ancestry subjects with PC1 < -0.002 and PC2 < 0.008 with red dotted cut-off lines. HapMap_CEU: 
HapMap Utah residents with Northern and Western European ancestry; HapMap_JPT: HapMap 
Japanese in Tokyo, Japan; HapMap_YRI: HapMap Yoruba in Ibadan, Nigeria; MayoADGS: Mayo 
Clinic study participants; MSBB: MSSM study participants; GTEX: GTEx study participants; 
DIAN: DIAN study participants; MAP: Knight-ADRC participants; NIALOAD: Knight-ADRC 
participants; CMC: CommonMind participants; ROSMAP: ROSMAP participants. 
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Expression Data 
FastQC was applied to RNA-Seq data to examine various aspects of sequencing 
quality[231]. Outlier samples with high rRNA contents or low sequencing depth were removed 
from the pool. The remaining samples were aligned to human GRCh37 primary assembly using 
Star with 2-Pass Basic mode (ver 2.5.4b)[74]. Alignment metrics were ascertained by applying 
Picard CollectRnaSeqMetrics[4] including reads bias, coverage, ribosomal contents, coding 
bases, and etc. Following which, transcript integrity number (TIN) for each transcript was 
calculated on aligned bam files using RSeQC tin.py[273] (ver 2.6.5).  RNA-Seq coding gene and 
transcript expression was quantified using Salmon transcript expression quantification (ver 0.7.2) 
with GENCODE Homo sapiens GRCh37.75 reference genome[208].  
Figure 3.2 Genomic IBD analysis. IBD analysis was performed to select unrelated 
subjects with Z0 > 0.8 and Z1 < 0.2 with red dotted cut-off lines. When there are related 
individuals, one individual will be dropped from the related pair. 
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Four major central nerve system cell type proportions were inferred from RNA-Seq gene 
expression quantification output as documented in my previous deconvolution study[172]. To 
briefly explain the deconvolution process, I firstly assembled a reference panel to model the 
transcriptomic signature of neurons, astrocytes, oligodendrocytes and microglia from purified 
single cell tissue sources respectively. Using the reference panel and the method population-
specific expression analysis[157] (PSEA, also named meanProfile in CellMix 
implementation[102]), I calculated four cell type proportions for each subject bulk RNA-Seq 
data. For each brain tissue collection site of each study, outlier values for each cell type 
proportion were removed. Mean values for each cell type of each tissue in each study were 
subtracted from the deconvolution results to center all the distributions to zero mean (Figure 
3.3). Phenotype information from all studies were merged and unified to the same coding 
paradigm to enable downstream joint analysis; for example, males are all coded as 1 and females 
are 2.
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Figure 3.3 Major CNS cell type proportions derived from RNA-Seq datasets with each row representing each tissue of each study. A) raw 
cell type proportions inferred from the data with vertical bars indicating quantiles within each tissue and each cell type.  B) cell type proportions 
were normalized by subtracting the mean from each tissue deconvolution result after removing outliers. 
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3.3.5 Data analysis 
For the discovery phase, ROSMAP dataset was analyzed with linear regression model 
employed in Plink[217] using normalized neuronal proportion to run quantitative trait analysis. 
Age, sex, PC1, PC2, and median TIN were used as covariates to account for potential genetic, 
phenotypic or technical heterogeneity. TIN is calculated directly from post-sequencing results 
that captures RNA degradation by measuring mRNA integrity directly[273]. Results were 
depicted as Manhattan plots using R (ver 3.4.3) qqman package[261] (ver 0.1.4).  
For the replication phase, all the other studies except ROSMAP were combined and 
prepressed to run meta-tissue QTL analysis because MSSM and GTEx contain samples with 
multiple cortical tissues. Meta-Tissue software installation and data preprocessing were 
conducted following a four-step instruction documented in the developer website: 
http://genetics.cs.ucla.edu/metatissue/install.html.  Meta-tissue[253] processing pipeline calls 
two main functions, firstly MetaTissueMM[253] and then followed by Metasoft[117].  
MetaTissueMM applies a mixed model to account for the heterogeneity of multiple tissue QTL 
effects. Metasoft performs the meta-analysis while proving a more accurate random effect p-
value for multiple tissue analysis and a m-value based on Bayesian inference to indicate how 
likely a locus is a QTL in each tissue. Similarly, results were depicted as Manhattan plots and 
visually examined.  
For the final merging phase, both discovery and replication studies were combined to 
maximize sample size. Apart from meta-tissue analysis by each tissue of each study, a split by 
disease status analysis was also performed in the final merging phase. Samples from each tissue 
of each study were also split into disease categories. Resultant subcategory with less than 20 
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subjects were removed from the analysis to avoid false results due to too small sample size. 
Similar data preparation and analysis pipeline were enforced as documented above.  
QTL analysis results were uploaded to Fuma (v1.3.3d)[276] to annotation significant 
SNPs (p-value < 10-06) with GWAScatalog (e91_r2018-02-06) and ANNOVAR (updated 2017-
07-17). Gene-based analysis was also performed by Magma (v1.06)[63] implemented in Fuma.  
3.3.6 Data availability 
Mayo: https://www.synapse.org/#!Synapse:syn5550404 
MSSM: https://www.synapse.org/#!Synapse:syn3157743 
ROSMAP: https://www.synapse.org/#!Synapse:syn3219045 
CommonMind: https://www.synapse.org/#!Synapse:syn2759792 
GTEx: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000424.v7.p2 
Knight-ADRC: https://www.synapse.org/#!Synapse:syn12181323 
According to the data request terms, DIAN data are available upon request: http://dian.wustl.edu 
 
3.4 Results 
3.4.1 Study design 
The ROSMAP study containing 523 subjects will be the discovery dataset, and the other 
six studies are collapsed into replication dataset with 1,146 subjects. Altogether, I have 
assembled a set of cortical RNA-Seq data comprised of 1,669 participants predominantly 
focused on neurodegenerative disorders from seven sources (Figure 3.4, Table 3.1). 
Collectively, Mayo, MSSM, Knight ADRC, and ROSMAP studies contributed 664 sporadic AD 
cases. Apart from sporadic AD, 15 subjects from DIAN study and 2 from Knight-ADRC also 
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harbor PSEN1, PSEN2, and APP mutations that exhibit familial AD inheritance pattern. Other 
neurodegenerative disorders, including progressive supranuclear palsy (PSP), pathological aging 
(PA), frontal temporal dementia (FTD), and Parkinson’s Disease (PD), are mainly drawn from 
Mayo and Knight ADRC datasets. Other psychiatric disorders including schizophrenia and 
bipolar disorders are contributed by the CommonMind study. Besides, 540 control subjects 
cleared of cognitive dementia or neuropsychiatric symptoms were also included. MSSM and 
GTEx also included multiple tissue data, which were collected from multiple regions of the same 
subjects that allow us to perform region specific comparison within the same cohort.  
Discovery analysis was performed in ROSMAP study. In the replication phase, all the 
other studies were merged to replicate signals identified from the discovery ROSMAP set. 
Because GTEx and MSSM contain multiple cortical regions collected from the same subjects, I 
also applied meta-tissue software[253] specifically designed for multi-tissue QTL analysis to 
perform a mixed model analysis with random effects that account for correlated measurements 
from multi-tissue individuals. To attain the largest available sample size for this study, the 
discovery and replication sets were merged to perform the merged multi-tissue QTL analysis in a 
search for additional signals hidden in previously separated discovery or replication analysis due 
to lack of power. After merged analysis, the cohorts were split into four major disease status 
groups (AD, control, schizophrenia, other non-AD neurodegenerative disorders) to explore how 
different disease strata could impact the results.  
 
 
 
 
 122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Study design. RNA-Seq and paired genotype or WGS data were 
accessed and preprocessed for downstream analysis. Genotype data was censored 
based on my quality control criteria and imputed as needed. WGS and imputed 
genotype were merged and followed by PCA and IBD procedures to select 
unrelated European ancestry subjects. RNA-Seq data was quality checked with 
FastQC and aligned to human GRCh37 primary assembly with Star, from which 
TIN was inferred with RSeQC to account for RNA integrity variances that I later 
incorporated into the analysis. Gene expression were quantified from unaligned 
RNA-Seq with psedo-aligner Salmon for deconvolution procedure. Cell type 
composition comprised of four major CNS cell type proportions were inferred by 
performing deconvolution procedure on gene expression quantification results. 
Using cell type proportions as quantitative traits, I identified loci in TMEM106B 
gene region associated with neuronal proportion in my assembled dataset.  
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3.4.2 TMEM106B variants associated with neuronal proportion 
During discovery phase, ROSMAP dataset (N = 484 after removing outliers from total 
number of 523 subjects) was used to perform cell type proportion QTL analysis. Using 
normalized neuronal proportion as a quantitative trait, the QTL analysis identified more than 10 
peaks that passed genome wide suggestive threshold (<1.0×10-05, Figure 3.5AB, Table 3.3). 
However, only one signal rs1990621 (chr7: 12283873) were replicated with p-value = 7.41×10-04 
in the replication dataset (N = 1,052) combining all the other datasets except ROSMAP (Figure 
3.5CD). When the discovery and replication datasets were merged to attained a larger sample 
size (N = 1,536), rs1990621 major allele C is negatively associated with neuronal proportion 
with p-value = 9.42×10-09 (Figure 3.6AB, Figure 3.7AC), which means the minor allele G is 
associated with increased neuronal proportion in my assembled datasets focusing on 
neurodegenerative disorders. 
 
 
Dataset Brain Region Ref Allele Sample Size Beta SE P-value
Discovery DLPFC C 484 -0.3 0.06 6.40×10
-07
Replication Multiple C 1,052 -0.13 0.04 7.41×10
-04
Merged meta-tissue Multiple C 1,536 -0.16 0.05 9.42×10
-09
 
Table 3.3 rs1990621 (chr7:12283873) major allele C is significantly associated with decreased neuronal 
proportions. Therefore, G allele (MAF = 0.4658) is significantly associated with increased neuronal proportions. 
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Figure 3.5 Discovery and replication phases Manhattan and QQ plots. Loci located in chromosome 7 were 
associated with neuronal proportion in ROSMAP discovery dataset and replicated in replication dataset. A) Discovery 
set Manhattan plot showed seven peaks associated with neuronal proportion at suggestive threshold. The peak located 
in chromosome 7 was labeled, which is for rs1990621 with p-value = 6.4×10-07. B) QQ plot of the discovery phase 
analysis. C) Replication set Manhattan plot showed that the peak located in chromosome 7 replicated the signal 
identified during discovery phase with p-value = 7.41×10-04. D) QQ plot of the replication phase analysis. 
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Figure 3.6 SNP-based and gene-based meta-analysis. rs1990621 located in chromosome 7 TMEM106B gene region was 
significantly associated with neuronal proportion in cortical RNA-Seq dataset. A) Manhattan plot showed SNP-based genome-
wide significant hit located in chromosome 7 with other suggestive SNP hits labeled. B) QQ plot of the SNP-based analysis. C) 
Manhattan plot showed gene-based genome-wide significant hit located in chromosome 7 with other suggestive gene hits labeled. 
D) QQ plot of the gene-based analysis. 
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Figure 3.7 Meta-Tissue analysis results of rs1990621. A) Forest plot showed p-value and confidence interval for 
rs1990621 for each tissue site of each dataset that included in the Meta-Tissue analysis. Summary random effect was 
depicted at the bottom as RE Summary. B) PM-Plot of rs1990621 while combining both p-value (y axis) and m-value 
(x axis). Red dot indicates that the variant is predicted to have an effect in that particular dataset, blue dot means that 
the variant is predicted to not have an effect, and green dot represents ambiguous prediction. C) Forest plot p-value 
and confidence interval for rs1990621 for discovery, replication, and merged datasets. D) Forest plot p-value and 
confidence interval for rs1990621 when splitting the merged dataset into four main disease categories. 
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Noticeably, in both replication and merged analyses, multi-tissue data were involved that 
provided additional power but also posed challenges to the analysis, the same issue faced by the 
GTEx study[24, 55]. Compared to a tissue-by-tissue approach, multiple tissues collected from 
the same subject may help identify QTL by aggregating evidence from multiple tissues, which is 
similar to a meta-analysis of combining each study. However, one violation of such approach is 
that the tissues collected from the same subject are presumably highly correlated since they 
shared the same genetic architecture. Thus, it violates the assumption of independency for 
carrying out a standard meta-analysis[253]. Another challenge of the multi-tissue QTL is the 
heterogeneity of the effects, which means a variant may have different effects on different 
tissues. To resolve these issues, I applied the Meta-Tissue analytic pipeline[253] 
(http://genetics.cs.ucla.edu/metatissue/) specifically designed for multi-tissue QTL, the same 
approach that GTEx took to analyze their multi-tissue data. As shown in Figure 3.7A, Meta-
Tissue analysis results of rs1990621 for the merged analysis were displayed as a forest plot with 
95% confidence interval and p-value labeled for each tissue of each study. Among them, MSSM 
and GTEx are multi-tissue studies while the others are single-tissue studies. Meta-Tissue used a 
linear mixed model to capture the multi-tissue correlation within MSSM and GTEx respectively. 
Regarding the effect heterogeneity, Meta-Tissue calculated a m-value[117] to predict if a variant 
has an effect in a tissue. M-value is similar to the posterior probability of association based on 
the Bayes factor[117] but with differences specifically designed for detecting whether an effect 
is present in a study included in a meta-analysis. Figure 3.7B is a PM-Plot that integrates 
evidences from both frequentist (p-value) and Bayesian (m-value) sides to interpret the 
heterogeneity of multi-tissue QTL effects.  Variant rs1990621 in ROSMAP and Mayo studies 
have m-values greater than 0.9, are predicted to have an effect and color coded with red. In CMC 
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study, the m-value is less than 0.1, so it is predicted to not to have an effect and color coded with 
blue. All the other studies with m-value between 0.1 and 0.9 are predicted with ambiguous effect 
and color coded with green. Based on the forest plot and PM-Plot, the variant does have effect 
heterogeneity across different tissues and studies. In this case, random-effect model will be more 
suitable to account for effect heterogeneity. Therefore, summary random effect and p-value were 
reported for the analysis. 
Apart from multi-tissue QTL, a single-tissue joint analysis was also performed. In this 
case, one tissue region was drawn from the multi-tissue data to avoid violating the independency 
assumption. Specifically, BM36 and frontal cortex tissue were selected to represent MSSM and 
GTEx study respectively. Study sites were coded as dummy variables to account for potential 
batch effects. In this joint analysis, the variant rs1990621 is also the top hit with p-value = 
7.66×10-10.  
3.4.3 Neuronal protective effect of TMEM106B variants observed in 
neurodegenerative disorders and normal aging participants 
To explore the effect in different disease categories, the merged dataset was stratified 
based on disease:  AD, other non-AD neurodegenerative disorders, schizophrenia and control. 
Signification associations between rs1990621 and neuronal proportion were observed in AD (p-
value = 1.95×10-07), other non-AD neurodegenerative (p-value = 8.19×10-04), and cognitive 
normal control (p-value = 2.94×10-02) cohorts, but not in schizophrenic cohort (p-value = 
9.32×10-01, Table 3.4, Figure 3.7D). The effect of the variant was more prominent in 
neurodegenerative cohorts and aging controls with mean age of death greater than 65 years old. 
However, it was absent from younger cohorts such as GTEx controls and CommonMind 
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schizophrenia participants. Thus, this variant seems to be associated with a neuronal protection 
mechanism shared by any aging process in the present or absence of neuropathology.    
 
3.4.4 Functional annotation of rs1990621 
The variant rs1990621 is located in the TMEM106B gene region where other variants in 
high LD linkage are also located and labeled in Figure 3.8A. Although the CADD score and 
RegulomeDB score for this variant are not remarkably high to suggest any functional 
consequences (Figure 3.8BC), this variant is in high LD with rs1990622 (r2 = 0.98), a 
TMEM106B variant previous identified to be associated with FTD risk[266], particularly in 
granulin precursor (GRN) mutation carriers[57, 92]. TMEM106B is expressed in neurons and 
microglia, with highest protein expression detected in the late endosome/lysosome compartments 
of neurons[36, 163, 237, 248]. A nonsynonymous variant rs3173615, which is also in high LD 
with rs1990621 (r2 = 0.98), located in the exon 6 of TMEM106B (the dark blue dot in Figure 
3.8B) produces two protein isoforms (p.T185S) that affect TMEM106B protein level through 
protein degradation mechanism[36, 49, 200]. 
Disease Brain Region Ref Allele Sample Size Beta SE P-value
AD Multiple C 639 -0.26 0.07 1.95×10
-07
Control Multiple C 476 -0.14 0.06 2.94×10
-02
SCZ BM9 C 189 -0.01 0.09 9.32×10
-01
Other TCX C 103 -0.45 0.14 8.19×10
-04
Table 3.4 rs1990621 (chr7:12283873) major allele C is significantly associated with decreased neuronal 
proportions in AD, Control, and other non-AD neurodegenerative disorders. SCZ: schizophrenia; other: 
other non-AD neurodegenerative disorders, including progressive supranuclear palsy and pathological 
aging. BM9: dorsal lateral prefrontal cortex. TCX: temporal cortex.
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Figure 3.8 Variant rs1990621 functional annotation and local plot. A) Local plot showed the zoom-in view of the hit in chromosome 7 with 
the top lead SNP rs1990621 labeled with dark purple. Nearby SNPs were also mainly located in the TMEM106B gene region and color coded with 
LD r2 thresholds. B) Bottom panel showed combined CADD score, RegulomeDB score, and Chromatin state of the region shown in the top panel. 
C) Regulome DB and chromatin state explanation. 
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3.4.5 The impact of other neurodegenerative risk loci on neuronal proportion 
To investigate what other AD or FTD variants might have an effect in neuronal 
proportion QTL analysis, I extracted results for 38 SNPs examined in two large scale genome 
wide association studies, AD focused (Lambert et al.[161]) and FTD focused (Ferrari et al.[87]) 
studies. Among those, only variants located in TMEM106B and APOE gene regions passed 
genome wide significant or suggestive threshold. Both rs1990622 (Figure 3.9A) and rs2075650 
(Figure 3.9B) were found to be associated with FTD reported in Ferrari et al., which were 
associated with neuronal proportion in this study (Table 3.5). The top signals in APOE region 
are rs283815, rs769449, and rs429358 with p-value < 1.22×10-05. Note that rs429358 is one of 
the two SNPs that determine APOE isoforms. Remember that APOE 4 alleles, coded by 
rs429358(C) and rs7412(C), confers the largest effect for AD risk. I observed that the C allele of 
rs429358 was associated with decreased neuronal proportion, but no association observed 
between rs7412 and neuronal proportion.  
In a gene-based analysis of my neuronal proportion QTL, TMEM106B (p-value = 
2.96×10-08) is the only gene that passed genome-wide significant threshold followed by APOE 
(p-value = 3.2×10-05), the most important gene for sporadic AD risk (Figure 3.6CD). Previous 
GWAS for AD risk performed with the International Genomics of Alzheimer’s Project (IGAP) 
data stratified by APOE genotype showed that AD risk is significantly influenced by the 
interaction between APOE and TMEM106B[146]. Together with my observation of cellular 
composition QTL, these results suggest a potential interaction of TMEM106B and APOE may 
play a role in affecting AD risk/vulnerability and cellular composition balance between neurons 
and astrocytes, and the endosome and lysosome compartments might be the location that the 
interaction takes place.
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SNP CHR BP Gene Minor Major MAF SNP proxy Effect (Major) p-value OR (Minor) p-value OR (Minor) p-value OR (Minor) p-value
rs6656401 1 207,692,049 CR1 A G 0.1573 - 0.09 5.59×10-02 1.18 5.7×10-24 - - - -
rs730482 2 127,894,484 BIN1 T A 0.3265 rs6733839 0.03 3.73×10-01 1.22 6.9 × 10−44 - - - -
rs35349669 2 234,068,476 INPP5D T C 0.4256 - 2.33×10-03 9.80×10-01 1.08 3.2×10-08 - - - -
rs190982 5 88,223,420 MEF2C G A 0.3531 - -3.08×10-04 5.88×10-01 0.93 3.2×10-08 - - - -
rs1980493 6 32,363,215 BTNL2 G A 0.1443 - 0.02 7.83×10-01 - - 0.775 1.57×10-08 - -
rs3129871 6 32,406,342 HLA-DRA A C 0.3736 - 0.04 3.72×10-01 - - 0.961 3.43×10-01 - -
rs3129882 6 32,409,530 HLA-DRA G A 0.4353 - 0.06 1.04×10-01 - - 1.086 3.36×10-02 - -
rs9268856 6 32,429,719 DRB5 A C 0.27 - 0.02 8.12×10-01 - - 0.809 5.51×10-09 - -
rs9268877 6 32,431,147 DRB5 A G 0.4268 - 0.05 1.91×10-01 - - 1.204 1.05×10-08 - -
rs9271192 6 32,578,530 HLA-DRB5–HLA-DRB1 C A 0.2677 - 0.04 4.31×10-01 1.11 2.9×10-12 - - - -
rs10948363 6 47,487,762 CD2AP G A 0.2488 - 0.01 8.62×10-01 1.1 5.2×10-11 - - - -
rs1020004 7 12,255,778 TMEM106B G A 0.315 - -0.1 1.35×10-03 - - 1.03 4.59×10-01 0.6 5.00×10−11
rs6966915 7 12,265,988 TMEM106B A G 0.4609 - -0.16 1.24×10-08 - - 1.07 1.21×10-01 0.61 1.63×10−11
rs1990622 7 12,283,787 TMEM106B G A 0.4673 - -0.16 1.44×10-08 - - 1.08 7.88×10-02 0.61 1.08×10−11
rs2718058 7 37,841,534 NME8 G A 0.3861 - -3.76×10-04 9.99×10-01 0.93 4.8×10-09 - - - -
rs1476679 7 100,004,446 ZCWPW1 G A 0.2655 - 0.02 7.71×10-01 0.91 5.6×10-10 - - - -
rs11771145 7 143,110,762 EPHA1 A G 0.3708 - 0 9.67×10-01 0.9 1.1×10-13 - - - -
rs28834970 8 27,195,121 PTK2B C T 0.3318 - 0.07 6.38×10-02 1.1 7.4×10-14 - - - -
rs1532277 8 27,466,181 CLU T C 0.3618 rs9331896 -1.42×10-03 9.92×10-01 0.86 2.8×10-25 - - - -
rs3849942 9 27,543,281 C9orf72/MOB3B T C 0.2253 - -0.01 8.94×10-01 - - 1.166 4.38×10-04 - -
rs10838725 11 47,557,871 CELF1 C T 0.2748 - 0.07 8.60×10-02 1.08 1.1×10-08 - - - -
rs7124974 11 59,906,972 MS4A6A T G 0.3645 rs983392 0.05 2.05×10-01 0.9 6.1 × 10−16 - - - -
rs10792832 11 85,867,875 PICALM A G 0.34 - -0.01 4.50×10-01 0.87 9.3×10-26 - - - -
rs2380093 11 87,803,455 RAB38 T C 0.1323 rs1386330 -0.03 4.87×10-01 - - 1.05 3.35×10-01 - -
rs10128715 11 87,872,076 RAB38/CTSC A G 0.1217 rs74977128 -0.03 7.29×10-01 - - 1.815 3.06×10-08 - -
rs302668 11 87,876,911 RAB38 C T 0.3077 - 0.08 4.57×10-02 - - 0.814 2.44×10-07 - -
rs302665 11 87,879,627 RAB38 G A 0.2464 rs302652 0.07 3.65×10-02 - - 0.73 2.02×10-08 - -
rs7106306 11 87,929,167 RAB38/CTSC G C 0.1146 rs16913634 -0.07 1.85×10-01 - - 0.964 0.71 - -
rs11218343 11 121,435,587 SORL1 C T 0.04487 - -0.12 1.35×10-01 0.77 9.7×10-15 - - - -
rs17125944 14 53,400,629 FERMT2 G A 0.08421 - 0.1 1.71×10-01 1.14 7.9×10-09 - - - -
rs10498633 14 92,926,952 SLC24A4-RIN3 A C 0.2128 - -0.01 8.32×10-01 0.91 5.5×10-09 - - - -
rs242557 17 44,019,712 MAPT A G 0.3558 - -0.01 8.89×10-01 - - 0.853 4.82×10-03 - -
rs8070723 17 44,081,064 MAPT G A 0.2077 - -0.02 7.48×10-01 - - 1.201 2.80×10-04 - -
rs1460595 18 29,045,257 DSG2 A G 0.03763 rs8093731 0.05 3.81×10-01 0.73 1.0 × 10-04 - - - -
rs4147929 19 1,063,443 ABCA7 A G 0.159 - -0.04 4.78×10-01 1.15 1.1×10-15 - - - -
rs2075650 19 45,395,619 TOMM40/APOE G A 0.1407 - 0.2 2.11×10-04 - - 1.304 8.81×10-07 - -
rs3865444 19 51,727,962 CD33 A C 0.2871 - -0.05 2.02×10-01 0.94 3.0×10-06 - - - -
rs7274581 20 55,018,260 CASS4 G A 0.1045 - -0.02 3.01×10-01 0.88 2.5×10-08 - - - -
cQTL AD risk FTD risk
Table 3.5 Neuronal proportion cQTL p-values were reported for variants previously identified in AD risk (by Lambert et al.), FTD risk (by Ferrari et al.), and FTD-TDP risk (by Van Deerlin et al.) studies.
FTD-TDP risk
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Figure 3.9 TMEM106B and TOMM40/APOE regions local plot. A) Local plot showed the zoom-in view of the hit in chromosome 7 with target 
SNP rs1990622 labeled with dark purple, and the top leading SNP is rs1990621. Nearby SNPs were also mainly located in the TMEM106B gene 
region and color coded with LD r2 thresholds. B) Local plot showed the zoom-in view of the hit in chromosome 19 with target SNP rs2075650 
labeled with dark purple, and the top three leading SNPs are rs283815, rs769449, and rs429358. Nearby SNPs were also mainly located in the 
TOMM40/APOE gene region and color coded with LD r2 thresholds. One gene omitted in this region is SNRPD2.  
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3.5 Discussions  
The common variant rs1990622 in TMEM106B was first identified to be associated with 
FTD with TDP-43 inclusions[266]. Hyper-phosphorylated and ubiquitinated TDP-43 is the 
major pathological protein for FTD and ALS[198], which is also present in a broader range of 
neurodegenerative disorders, including AD[10], Lewy body disease[196], and hippocampal 
sclerosis[10].  Recent study also suggested distinct TDP-43 types present in non-FTD brains, 
typical TDP-43 α-type and newly characterized β-type[145]. TDP-43 α-type is the typical form 
conventionally observed in temporal, frontal and brainstem regions. TDP-43 β-type is 
characterized by its close adjacency to neurofibrillary tangles, which is predominantly observed 
in limbic system, including amygdala, entorhinal cortex, and subiculum of the hippocampus. 
These findings suggested that pathologic TDP-43 protein that closely associated with 
TMEM106B variants might be the common pathologic substrate linking these neurodegenerative 
disorders.  Multiple lines of evidence have merged and shown that protective variants in 
TMEM106B are associated with attenuated cognitive deficits or better cognitive performance in 
ALS[268], hippocampal sclerosis[191], presymptomatic FTD[214], and aging groups with 
various neuropathological burden[280] or in the absence of known brain disease[222]. My study 
identified a protective variant rs1990621 of TMEM106B is associated with increased neuronal 
proportion in participants with neurodegenerative disorders and normal aging in non-demented 
controls.  However, this effect is not observed in a younger schizophrenia cohort with a mean 
age of death less than 65 years old. This result suggested a common pathway involving 
TMEM106B shared by aging groups in the present or absence of neurodegenerative pathology 
that may contribute to cognitive preservation and neuronal protection.  
  
135 
My study has demonstrated that a protective variant rs1990621 identified in TMEM106B 
gene region may exert neuronal protection function in aging groups. A protein coding variant 
rs3173615 in high LD with rs1990621 (r2 = 0.98) produces two protein isoforms (p.T185S). The 
S185 allele is protective and the protein carrying this amino acid is degraded faster than the risk 
variant T185. Thus, the risk allele of this coding variant leads to increased TMEM106B protein 
level[36, 49, 200]. TMEM106B overexpression results in enlarged lysosomes and lysosomal 
dysfunction[36, 295]. It has also been shown that TMEM106B may interact with PGRN (the 
precursor protein for granulin) in lysosome[200]. Although rs3173615 is not included in my 
genomic data, it is in complete linkage disequilibrium with rs1990621 and rs1990622. It is worth 
pointing out that the minor allele of rs1990622, which has a protective effect in FTD, is in-phase 
with the minor allele of rs1990621, which is associated with increased neuronal proportion in my 
analysis. Despite the fact that my dataset is focused on neurodegeneration, I only have 11 
verified FTD cases suggesting that TMEM106B might have a general neuronal protection role in 
neurodegeneration apart from FTD.  
This observation suggested that a potential involvement of TMEM106B in the 
endosome/lysosome pathway may play a role in neurodegenerative disorder risk or vulnerability. 
Neuronal survival requires continuous lysosomal turnover of cellular contents through 
endocytosis and autophagy[202]. Impaired lysosomal function reduces lysosomal degradative 
efficiency, which leads to abnormal build-up of toxic components in the cell. Impaired lysosomal 
system has been found to be associated with a broad range of neurodegenerative disorders, 
including AD[201], Parkinson disease[12, 233, 278], Huntington disease[90, 271], FTD[167], 
ALS[90], Niemann-Pick disease type C[154, 204], Creutzfeldt-Jakob disease[166], Charcot-
Marie Tooth disease type 2B[243], Neuronal ceroid lipofuscinoses (Batten disease)[155, 156], 
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autosomal dominant hereditary spastic paraplegia[220], Chediak-Higashi syndrome[159], 
inclusion body myositis[14], and osteopetrosis[141]. Considering the extensive involvements of 
lysosomal/endosomal compartments in neurodegenerative disorders, it has been proposed that a 
long and chronic process of abnormal metabolic changes during aging has led to the 
accumulation of toxic materials[202]. When lifespan increases especially in the sporadic forms 
of neurodegenerative disorders, failures to degrade these waste products break the proteostasis 
and the balance maintained by the multicellular interactions, and trigger subsequent chain 
reactions that lead to neuronal death and outbreaks of various neurodegenerative disorders due to 
different genetic susceptibilities and other disease etiologies. Although each neurodegenerative 
disorder has its own characteristic proteopathy, the boundaries of protein pathology distribution 
are never clear-cut across different disorders. In fact, copathology or nonspecific pathology of 
proteopathy have been observed in most autopsies of neurodegenerative disorders, such as TDP-
43 discussed above, Lewy body, α-synuclein[82], and etc. My observation of lysosomal gene 
TMEM106B associated with neuronal proportion in aging cohorts suggests that the lysosomal 
pathway might be involved in the common mechanism underlying a broad range of 
neurodegenerative disorders or aging process in general that contribute to neuronal cell death.  
My study has demonstrated the great potential of using cell type composition as 
quantitative traits to identify QTLs associated with the changes in cell fractions. This approach is 
more powerful for disorders that involve considerably changes in cellular composition, for 
example, neurodegenerative disorders, and normal conditions during developmental or aging 
processes. The development of recent single cell studies will greatly increase the resolution in 
advancing our knowledge of cellular population changes. More detailed fine mapping of cellular 
composition from single cell studies together with machine learning algorithms, bulk RNA-Seq 
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deconvolution will be more accurately capturing cellular fraction changes in the samples, such as 
different types of neurons or different states of astrocytes or microglia. Regarding scalability, 
this single cell powered bulk deconvolution approach is preferable for carrying out such cell type 
composition QTL analysis, because due to the high cost of performing single cell studies, bulk 
RNA-Seq is more financially feasible to scale up, and with larger sample sizes more hidden 
signals will be unrevealed with increased statistical power. 
To conclude, I have identified a protective variant rs1990621 in TMEM106B associated 
with increased neuronal proportion through bulk RNA-Seq deconvolution and cell type 
proportion QTL analysis. This observation also replicated previous findings of the protective 
variant rs1990622 in FTD risk, which is in high LD with rs19990621[266]. Besides, I also 
observed the C allele of rs429358 (codetermine APOE 4 isoform with rs7412 C allele) 
associated with decreased neuronal proportion as it was hypothesized. It suggested potential 
involvements of both APOE and TMEM106B in neuronal protection mechanisms underlying 
neurodegenerative and normal aging processes, and supported previous observation of 
interactions between these two genes[146] in AD cohort. I speculate that TMEM106B related 
lysosomal changes might be involved in the common pathway underlying neuronal death and 
astrocytosis in neurodegenerative disorders and normal aging cohorts. With larger sample size 
and higher deconvolution resolution, this approach will reveal more biologically relevant and 
novel loci associated with changes in cellular composition that are important for understanding 
both disease etiology and healthy aging. 
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4.1 Abstract 
Background:  Using network analysis approaches, previous studies had revealed several hub 
gene or pathways that were verified or later identified as key players in disease etiology 
underlying AD. In sporadic AD, previous studies from the lab have identified MS4A gene cluster 
significantly associated with soluble TREM2 level in CSF. However, from GWAS result it was 
unclear which MS4A gene is the key regulator of TREM2. In autosomal dominant AD, mutations 
in the APP, PSEN1 and PSEN2 genes and lead to familial early onset AD. However, the 
downstream pathogenic events triggered by these risk and pathogenic variants are still not fully 
understood. By employing an integrative network approach, I aim to more accurately identify 
which gene is the key regulator of TREM2 in sporadic AD and the downstream genes and 
pathways altered by PSEN1 mutation in autosomal dominant AD.  
Methods: To determine which one of the MS4A genes are implicated in TREM2 biology, I 
employed alternative approaches to explore gene regulatory networks from RNA-Seq data. To 
identify causal genes under the genomic locus identified by the CSF TREM2 GWAS, I 
combined weighted correlation network analysis (WGCNA) method to identify a module that 
includes TREM2 co-expressed genes. Then I used Bayesian network inference to learn causality. 
To study the downstream effects of Mendelian mutations in PSEN1 associated with Autosomal 
Dominant Alzheimer’s disease, I applied a seed-based approach to study the genes that are 
significantly co-expressed with PSEN1, and constructed gene networks using WGCNA. This 
analysis includes both PSEN1 mutation carriers, non-carriers and nenuropathological-free 
controls. The network was annotated with gene differential expression, cell type information, and 
functional pathway analysis.  
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Results: My analysis indicated that MS4A4A and MS4A6A are in TREM2 module, and inferred 
that MS4A4A is the key regulator of TREM2. For the downstream events of the Mendelian gene 
PSEN1, I identified 47 genes only present in control cohort that were potentially disrupted in 
PSEN1 mutation carriers; I also found 13 genes only present in PSEN1 mutation carriers but not 
in control cohort that are potentially acquired as downstream transcriptional events altered by 
PSEN1 mutations. Among them, I highlighted the genes LMNA, DOCK1, and DYNC1LI2 and 
discussed them in detail, that were previously associated with Alzheimer’s Disease. 
Conclusions: My study demonstrated the potential of using both system-based and seed-based 
network approaches in replicating and discovering AD related genes and their interactions. In 
sporadic AD cohort, I identified MS4A4A might be a key regulator for TREM2. In autosomal 
dominant AD cohort, I identified total of 60 genes that are lost or acquired in the PSEN1 
associated pathways.  
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4.2 Introduction 
4.2.1 From polygenic to omnigenic - a network interpretation 
To tackle disease etiology, one important theme for diseases with genetic components is 
to figure out how genetic variants explain phenotypic variability. A monogenic theory inspired 
by Gregor Mendel’s work states that one disease could be explained by one mutated gene 
following a Mendelian inheritance pattern. Examples are familial early onset neurodegenerative 
disorders such as autosomal dominant AD, which can be explained by rare mutations in one 
single gene that results in high disease penetrance. However, diseases with complex traits, for 
example late onset sporadic AD, do not follow this pattern. GWAS performed in sporadic AD 
studies have identified dozens of variants across the genome, and many of those are common 
variants with low to medium effects (Figure 1.2)[148]. This pattern is more similar to 
quantitative genetics inspired by Ronald Aylmer Fisher’s infinitesimal model that a quantitative 
trait is influences by an infinitely large number of genes.  Accumulations of large number of 
common variants within multiple genes explain much of the heritability. These polygenic effects 
together with complex interactions with the environment are often observed in diseases with 
complex traits. Based on empirical evidences, the polygenic model has later been expanded to an 
“omnigenic” model for complex traits[31]. They proposed that core genes may have strong and 
direct effects on disease risk, but they only account for a small portion of total heritability. Any 
variants that have disease relevant tissue specific effects may contribute nontrivial effects on 
disease risk. The variants may exert their effects on core genes through highly interconnected 
gene regulatory network such that the collection of the small effects together explain the missing 
heritability[31]. 
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4.2.2 Network analysis as a powerful tool  
Network biology[21, 22, 269] has demonstrated great success in understanding biological 
systems and identifying disease related factors. With large scale data collection and advancement 
in computational powers, various types of networks have been proposed to capture the 
interactions among different elements (zoom-in view) and to gain a systematic view of the 
topological and dynamical properties of a biological system (zoom-out view).  On a gene level, 
gene regulations can be depicted as gene regulatory networks as mentioned above in the 
omnigenic model. The modular and hierarchical organization of gene regulatory networks 
captures the information flow from regulators to their binding sites. On an RNA level, microarray 
and RNA-Seq technologies have enabled generations of transcriptome-wide gene co-expression 
networks to understand associations among transcripts and gene expression synchronicity. On a 
protein level, yeast two-hybrid screens are able to identify protein-protein interactions in 
vivo[89]. On a cellular level, brain neural networks generated from tracer injections have 
captured the topology of neural signaling highways underlying cognitive functions[85].  On a 
system level, networks generated from functional connectivity MRI facilitate understanding of 
how different parts of the brain segregated into functional modules and communicating 
intrinsically without explicit task being performed[213]. On a disease level, human disease 
interactome has been proposed to identify shared pathways among known or unknown 
comorbidities that shed lights on drug repurposing[50, 183]. On a population level, social 
networks could help identify key features of infectious diseases, such as risks for acquisition and 
effective interventions, through learning social aspects of disease transmission.  
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While offering the capability of modeling any type of biological interactions at different 
levels, network analyses provide a unique and powerful approach that can combine elements or 
layers from different modalities and produce integrated models to study interactions among 
multiple networks. One example of an integrative network analysis of combining obesity and 
social network showed that the social ties among friends have a larger effect on obesity risk than 
genetic risk factors (Figure 4.1)[19, 52].  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Network medicine from obesity to the "diseasome". 
Reproduced with permission from Barabasi[19]. Copyright 
Massachusetts Medical Society. 
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4.2.3 Basic concepts in gene co-expression networks 
In biological systems, networks are defined as a collection of biological elements and 
interactions among them. In the context of a gene co-expression network, nodes are genes and 
edges are relations between the expression of a pair of genes, such as Pearson’s correlation. If the 
network is unweighted, an edge means the correlation between a gene pair is above a hard cut-
off, and there will be no edge if the correlation is below the cutoff. If the network is weighted, 
the edge represents weighted magnitude of correlation between a gene pair. In an undirected 
network, such as results from WGCNA, there is no directionality in the connection between two 
nodes. In a directed network, such as directed acyclic network generated from Bayesian network 
inference or structural equation modeling (SEM), information flow will be depicted as directed 
arrow pointing from parent node to child node. This chapter focuses on static and deterministic 
networks that capture network structural topology from a single RNA-Seq snapshot when RNAs 
are extracted from the biological system. Dynamic and stochastic networks can be generated 
with temporal data and data with biological noises. Causal network can also be generated with 
intervention data.  
Regarding the global topology of a network, three common types of networks are showed 
in Figure 4.2. Two important metrics to describe network property are degree distribution and 
adjacency matrix. Degree is the number of edges a node has with other nodes (denoted as k), and 
degree distribution is the probability distribution of these degrees over the whole network 
denoted as p(k). Adjacency matrix is used to represent whether a pair of nodes are connected. It 
is a matrix with 0 and 1; value 1 represents the nodes are connected and adjacent to each other, 
and 0 represents that the nodes are unconnected.  Undirected graph adjacency matrix is 
symmetrical and directed graph adjacency matrix is unsymmetrical. In a random network, the 
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degree distribution p(k) follow a Poisson distribution, and connected nodes are randomly 
distributed in the adjacency matrix. Network path is another important metric, which measures 
how many steps required to connect two nodes in the network, and minimal number of steps is 
called the shortest path length. One important property of a random network is that the shortest 
path length is much smaller than a regular network. Many theoretic and functional works in 
network science are based on random network, however, it has two limitations – first, it does not 
have local clustering structure with its randomly distributed connections depicted in adjacency 
matrix; second, the degree distribution of nodes following a Poisson distribution do not account 
for the formation of hubs that mostly observed in real world networks. To resolve the first 
limitation of lacking local clustering, a Watts-Strogatz model has been proposed to generate 
graphs with small-world property by rewiring edges from a regular lattice network with random 
probabilities[277]. This random rewiring process created long-range connections with small path 
length like a random graph while retaining high local clustering properties of a regular network. 
Thus, the degree distribution of small world network is similar to a random network but with 
high local clustering property shown in adjacency matrix. Later a scale free model is proposed 
based on empirical evidence of real world networks including World Wide Web and citation 
patterns in science[20]. This model explained the hubs observed in many real-world networks 
that a random network model does not explain. They found that large scale complex networks 
exhibit a high degree of self-organizing phenomena that networks expand by adding new vertices 
to already well established highly connected vertices, which explained how hub nodes emerged 
from chaos. In a scale-free network, the degree distribution of nodes decays as a power law. This 
feature holds true in any scales of the network – hence the name “scale-free” network. Rigorous 
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modeling is required to examine the power law distribution of empirical data to determine if a 
network fulfills the criteria[53].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.3 Small-world network generated from Watts-Strogatz 
model.  Image from Watts et al.[277] with permission. 
Figure 4.2 Random, small-world, and scale-free network properties. 
A) random network with 73 connections among 20 nodes assigned 
randomly; B) Small-world network with high local clustering and short 
average path lengths with ‘hub and spoke’ architecture; C) scale-free 
network with ‘hub and spoke’ architecture maintained at multiple spatial 
scales. Image reproduced from Stobb et al.[251] with permission.  
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4.2.4 Network analysis in Alzheimer’s disease 
Gene co-expression network analysis in late-onset AD cohorts had revealed several hub 
gene or pathways that were verified or later identified as key players in disease etiology[184, 
287]. For example, a system based approach using WGCNA had been applied to microarray data 
derived from prefrontal cortex tissues collected from LOAD patients and 173 non-demented 
healthy controls. They identified an immune response related module, which contains an 
important AD risk gene TREM2. Rare variants in TREM2 have been found to be associated with 
sporadic AD risk with moderate effect[114, 144, 148]. The rare TREM2 variant p.R47H 
(rs75932628) carriers exhibit increased AD risk by a range from 1.7-fold to 3.4-fold[112, 212]. 
In the TREM2 module identified from network analysis, Zhang et al. focused on 
TYROBP(DAP12) gene which was identified as an adapter protein for TREM2[30] (Figure 4.4).  
 
 
 
 
 
 
Figure 4.4 TREM2 module 
identified in LOAD cohorts. 
A module enriched for 
immune function and 
pathways contains TREM2, 
TYROBP, and MS4A gene 
clusters. Image from Zhang et 
al.[287] with permission. 
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Our lab has recently identified that the MS4A gene cluster is a key regulator of soluble 
TREM2 in CSF[70]. Using GWAS of a large number of subjects (N = 813) we identified a locus 
in chromosome 7 that shows significant association with CSF TREM2 levels (rs1582763; p=1.15 
×10-15), and replicated in an independent dataset (N = 580). Several members of MS4A gene 
cluster, MS4A4A and MS4A6A are tagged by this signal, which makes difficult the identification 
of the causal MS4A gene affecting CSF TREM2 levels. I envision that transcriptomic data would 
provide additional orthogonal evidence. To identify the relationship between TREM2 and MS4A 
gene cluster, I performed a system-based approach on sporadic AD cohort and focused on the 
module containing TREM2 in the first part of this chapter.  
In the second part of this chapter, I focused on the study of the transcriptomics 
downstream analyses of genetic mutations causal of autosome dominant AD (ADAD). Mutations 
in the amyloid-beta precursor protein (APP) and presenilin genes (PSEN1 and PSEN2)[43] 
cause ADAD which is typically associated with Mendelian inheritance pattern and early-onset 
(30 ~ 50 years old) disease symptoms. Although the disease phenotype may be a consequence of 
an abnormality in a single effector gene product particularly in the Mendelian form of AD, given 
the highly-interactive functional crosstalk within biological organism and the complex disease 
etiology of AD, this dysregulation by a single gene may intertwine with various pathological 
processes and altered downstream events that interact in a complex network. To investigate the 
etiological heterogeneity of AD, I performed a seed-based network analysis in an ADAD cohort, 
carriers of PSEN1 gene mutation, to identify altered downstream transcriptional events triggered 
by this ADAD gene.  By annotating the network with differential gene expression, cell type 
information, and functional pathway analysis, I identified some target genes and related 
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pathways that were either disrupted or emerged in PSEN1 mutation carriers through network 
analysis. 
4.3 Methods 
4.3.1 Samples  
TREM2 Study 
I accessed (AMP-AD portal synapse ID = 3157743) RNA-Seq data from 219 AD and 
non-demented control brains from Mount Sinai School of Medicine (MSSM) ascertained from 
four cortical regions: anterior prefrontal cortex (APC), inferior frontal gyrus (IFG), superior 
temporal gyrus (STG), and parahippocampal gyrus (PHG) (Table 4.1). Data retrieval and 
collection of MSSM, Knight-ADRC, and DIAN have been documented in detail in Chapter 2. 
 
PSEN1 Study 
RNA-Seq was generated for 15 PSEN1 carrier brains from The Dominantly Inherited 
Alzheimer Network (DIAN) and 14 non-demented controls from The Charles F. and Joanne 
Knight Alzheimer's Disease Research Center (Knight ADRC)[153]. We identified three 
additional participants from the Knight-ADRC study with PSEN1 (p.A79V, p.I143T, p.S170F) 
mutations (Table 4.2).   
I accessed (AMP-AD portal synapse ID = 3157743) RNA-Seq data from 67 non-
demented control brains from Mount Sinai School of Medicine (MSSM) ascertained from four 
N Age % Male RIN TIN Control AD
MSSM 219 84 ± 7.32 35.6 6.42 ± 1.77 76.4 ± 2.52 49 170
Table 4.1 TREM2-MS4A  Study Demographic
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cortical regions: anterior prefrontal cortex (APC), inferior frontal gyrus (IFG), superior temporal 
gyrus (STG), and parahippocampal gyrus (PHG). 
GEO replication data was accessed from GSE39420, which is collected from 14 patients 
(7 sporadic EOADs and 7 monogenic familial ADs with PSEN1 mutation) and 7 neurologically 
healthy controls. Samples were hybridized in a Human Gene 1.1 microarray from 
Affymetrix[13].  
 
4.3.2 Data processing and quality control 
TREM2 Study 
Data QC and preprocessing of MSSM dataset have been documented in Chapter 2.3.2. 
MSSM cases and controls gene expressions were derived from Star alignment to human 
GRCh37 primary assembly and quantification using --quantMode TranscriptomeSAM. Because 
low expressed genes tend to reflect noise and produce insignificant correlation, I removed genes 
with gene counts less than 4 in more than 75% subjects. To normalize gene expression respect to 
library size, regularized logarithm transformation was applied to raw counts of the gene 
expression using rlog function from DESeq2 R package. ComBat function was applied to the 
data to remove potential batch effect.  After which, a linear regression model was applied to 
regress out covariate on a per-gene basis. Covariates factors included in the model are PC1, PC2, 
N Age % Male % ApoE4+ Control PSEN1 EOAD
MSSM 67 80.1 ± 8.39 44.8 10.4 67 0 0
Knight-ADRC 17 82.3 ± 18.5 35.3 17.6 14 3 0
DIAN 15 49.1 ± 7.14 66.7 14.3 0 15 0
GEO 21 55.6± 7.65 76.2 14.3 7 7 7
Table 4.2 PSEN1  Study Demographic
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PC3 inferred from genomic PCA analysis to account for ethnic stratification; sex, age at death, 
post-mortem index, RIN to account for general demographics and RNA-Seq tissue pre-
sequencing quality; and RNA-Seq post-sequencing metrics such as ribosomal contents, mapped 
reads number (uniquely mapped and multi-mappers that mapped to multiple loci) to account for 
alignment performances. The residuals from the linear regression were used as inputs to infer 
gene expression correlation. Apart from gene expression values, cognitive performance 
measurement CDR and Tau pathology load measurement Braak staging values were also added 
for computing correlation, from which I could infer what genes are closely correlated with these 
clinical and pathological traits. Besides, cellular composition inferred from the dataset as 
documented in Chapter 2 deconvolution procedure were also added to later correlation 
computing and network construction. Cell type information inferred from the data using 
deconvolution method were also added as nodes. For each region, the top third most variable 
genes were selected. A joint set of the top genes from all four regions accounted for a fifth of the 
whole transcriptome genes. The top fifth most variable genes together with CDR, Braak staging, 
and cell type proportion were selected to run multi-tissue correlation for later network 
construction.  
PSEN1 Study 
Data QC and preprocessing of MSSM, Knight-ADRC, and DIAN have been documented 
in Chapter 2.3.2. For the RNA-Seq data from MSSM gene expression were performed similarly 
as the TREM2-MS4A study as described above, the only difference is that only non-demented 
controls from MSSM were used to construct the network to avoid the confounding factors from 
dramatic neuronal loss or astrocytosis in ADAD as I observed and documented in Chapter 2. 
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For microarray data from GSE39420, probes were mapped to corresponding genes, and 
each gene expression value was derived from averaging probe expression values for each gene. 
Each gene expression level was adjusted for subject sex, age at death, and post-mortem interval 
hours by fitting a linear regression model and the residuals were derived for use in downstream 
analyses. These covariate adjustment procedures were performed for control, FAD-PSEN1, and 
EOAD separately.  
4.3.3 Repeated measures correlation 
I accessed RNA-Seq data MSSM ascertained from four cortical regions: APC, IFG, STG, 
and PHG. Because there is more than one tissue collected from the same subject, the assumption 
of independent observations when applying standard correlation methods is violated. To 
aggregate data collected from multiple tissues in MSSM, I integrated the measures from these 
four brain regions by running repeated measures correlation tool (rmcorr R package)[18] to 
calculate repeated measures correlation (rmcorr) of the MSSM controls, which is a statistical 
technique to determine the overall within-individual relationship among paired measures 
assessed on two or more occasions. 
4.3.4 Network construction 
TREM2 study system-wide network construction 
 With a system-wide approach, Weighted Gene Co-Expression Network Analysis 
(WGCNA)[164] was applied to the transcriptome rmcorr matrix derived from MSSM AD cases 
and control subjects. WGCNA enforces the connectivity to exhibit a power-law distribution. This 
power-law distribution renders a scale-free topology to the network, which will be applied to the 
top fifth most variable genes across all four regions. Both dynamic tree cutting and static tree 
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cutting with signed networks and minimum module size 200 were used, but it has been shown 
that the dynamic tree cutting and signed network might be more biologically relevant compared 
to static tree cut and unsigned network[289]. Raising the correlation to a power will help reduce 
the noise of the correlations in the adjacency matrix. To select the appropriate power value, 
pickSoftThreshold function[288] from the WGCNA package was applied to the rmcorr matrix to 
select the power when the network most resemble a scale-free graph while keeping the highest 
network connectivity.  
TREM2 study Bayesian network construction 
To infer probabilistic relationships between the nodes in a network module, Bayesian 
network analysis was applied to the module derived from the system-wide WGCNA results that 
contains TREM2 gene. Normalized and covariate adjusted gene expression matrix from 
parahippocampal region of MSSM dataset was used, and only genes in the same module with 
TREM2 were included in the Bayesian network construction. Using the discretize function from 
bnlearn R package[193], the continuous gene expression data were transformed into quantiles for 
later network structure and parameter learning. To infer or measure the degree of confidence of 
arc strength of Baysian network, 200 nonparametric bootstrap iterations were applied to the data 
to estimate the relative frequency (strength) of every possible arc[94] using the boot.strength 
function implemented in bnlearn package. Arcs with strength more than 0.38 and probability of 
direction more than 0.5 were kept, and final network was derived from averaging across 200 
bootstraps. The network was plotted using graphviz.plot function with highlighted v-structure 
arcs. Genes related to AD risk and genes related to top pathway results (adjusted p-value less 
than 0.01) were color coded respectively.  
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PSEN1 study seed-based network construction 
Using a seed-based approach, I pre-selected genes that are co-expressed with PSEN1 to 
build a co-expression network. The genes that are correlated with PSEN1 expression are 
potentially linked to AD pathology by assuming ‘guilt-by-association’. In this seed-based 
approach, I used PSEN1 gene as a bait to expand to genes that co-expressed/correlated with 
PSEN1 in PSEN1 variant carriers and/or healthy controls. 
To build upon the MSSM controls co-expression network, I first selected genes that are 
significantly correlated with PSEN1 in the MSSM control rmcorr results at correlation p-value < 
0.05.  Then the genes from parietal PSEN1 carriers and healthy control subjects that overlapped 
with the significant correlated gene in MSSM controls were selected following the two criteria: 
(1) The gene correlation with gene PSEN1 in parietal dataset has to fall into the 95% confident 
intervals of rmcorr results of the MSSM controls; (2) The correlation direction in parietal dataset 
has to be congruent with the direction of the MSSM controls rmcorr correlation. 
4.3.5 Network robustness evaluation 
By applying a bootstrapped version of WGCNA (rWGCNA)[100], it will reduce 
potential bias introduced by outlier samples. I performed 50 iterations of network construction 
with randomly selected 66.66% of the total samples. The resulting 50 networks will be merged 
into one large, final consensus network. The robustness of the networks was evaluated by 
comparing those to the final consensus network.  
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4.3.6 Network functional annotation 
Differential gene expression analysis using DESeq2 R package, and various pathway 
analysis and gene enrichment analysis were applied to annotation the genes in the network, such 
as Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology Enrichment Analysis 
(GO term), and PANTHER implemented in Enrichr online interactive tool[47, 158]. Cell type 
composition derived from deconvolution, CDR, and Braak staging were labeled in the network 
to examine cell-type specific enriched modules and modules related to cognitive and 
pathological measurements. To annotate the genes, the list of interested genes were queried with 
FUMA’s GENE2FUNC online tools[276] to investigate tissue specificity, reported GWAS 
catalog genes, TF targets, microRNA targets, and etc.  
Differential gene expression and correlation analyses were repeated in the independent 
PSEN1 dataset (GSE39420) collected from 14 patients (7 EOAD and 7 FAD-PSEN1) and 7 
neurologically healthy controls.  
4.4 Results 
4.4.1 Study design 
TREM2 Study  
For the TREM2 study, both AD sporadic cases (N = 170) and cognitive normal controls 
(N = 49) were included to build the network (Table 4.1). Tissues from four brain regions 
(Figure 4.5) were collected and followed by RNA-Seq data generation. The same extensive QC 
and quantification processes were applied as documented in Chapter 2. Repeated measure 
correlation was applied to gene expression quantification results from four regions to derive a 
gene expression correlation matrix. With a system-based approach, top 1/5 most variable genes 
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across the four regions were used to construct networks with scale free topology using WGCNA. 
The module containing TREM2 gene was further analyzed with Bayesian network inference and 
functionally annotated with pathway analysis.  
PSEN1 Study 
As discussed in Chapter 2, I observed brain carriers of pathogenic mutations in APP, 
PSEN1 or PSEN2 presented lower neurons and higher astrocytes relative proportions compared 
to sporadic AD and controls. With such extensive neurodegeneration, I concerned that the 
network built with PSEN1 mutation carriers would be confounded by the destructive 
consequence of neurodegeneration. To investigate early transcriptional events trigged by 
pathogenic mutations in PSEN1, I built the network with cognitive normal controls and genes 
correlated with PSEN1 using a seed-based approach.  First, I selected genes that are correlated 
with PSEN1 in both cognitive normal controls and PSEN1 mutation carriers. Then I built a 
network based on correlations of these selected genes in controls across four different brain 
regions in MSSM to capture a control network topology. Then nodes were annotated in regard to 
its correlation with PSEN1 in either controls or PSEN1 mutation carriers to infer their functional 
roles in early disease progression. I hypothesized that network modules enriched with genes 
correlated with PSEN1 in mutation carriers could be involved in early transcriptome changes in 
PSEN1 mutation carriers.    
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Figure 4.5 Study design. For TREM2 study, network was constructed from MSSM AD sporadic 
cases and controls. For PSEN1 study, network topology was built from MSSM control participants 
and functional modules were annotated in related to PSEN1 variant carriers and healthy controls. 
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4.4.2 MS4A gene clusters are associated with TREM2 in AD sporadic and 
control network analysis 
TREM2 Study WGCNA network construction 
The 20% of most variable genes from four regions of AD sporadic cases and controls 
were selected to construct the network using WGCNA. The network connection or topology was 
built upon gene co-expression patterns. Genes that are connected in a co-expression network are 
correlated or synchronized in their expression pattern[97, 223]. In a gene expression correlation 
matrix, any pair of genes would yield a non-zero value, which means any gene pair could be 
correlated to some extent and perfect independency does not exist. Thus, the challenge is how to 
determine the threshold at which two genes are considered as co-expressed. An intuitive way to 
solve this problem is to select a value as a hard cut-off. A binary value is assigned to each gene 
pair; it will be 1 if the gene pair correlation is above the threshold or 0 if it is below the 
threshold. This binary scenario may occur in certain biological systems such as neuron firing, but 
it does not fit gene expression patterns. Rather than this hard thresholding approach, the 
WGCNA researchers proposed a soft thresholding approach that assigns a weight to each gene 
pair to derive a weighted gene co-expression network. The network also bears a scale-free 
topology, which has been shown to be more biologically relevant by both theoretical and 
empirical evidences[288]. The property of scale-free network is defined as the probability of a 
node that is connected with k other node decays as a power law. This type of network contains a 
few hubs with high degree of connectivity compared to the vast majority of non-hub nodes with 
low connectivity. The network is highly resistant to attacks on non-hub nodes, but removing hub 
nodes will be deleterious or change the network topology dramatically. The hub nodes are 
essential for survival in biological systems proved by yeast protein network studies[118, 142].  
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To build a scale free network using WGCNA, taking my study as an example, the first 
step was to define gene co-expression similarity using repeated measure correlation derived from 
gene expression of four brain regions. Compared to all the other network analysis that use single 
region transcriptional data to build a region-specific network, this study integrated data from four 
brain regions to build a network representing the cerebral cortex. Repeated measure correlation 
was applied instead of Pearson correlation because the four cortical regions are not 
independently collected, thus the assumption of independent observations when applying 
standard correlation methods was violated. Then the similarity (correlation) matrix was 
transformed into an adjacency matrix with appropriate power parameters fitting the power 
adjacency function[288]:  
aij = power(sij, β) ≡ sijβ (Equation 4.1)  
 As discussed above, the scale-free network nodes follow the power law:  
p(k) ~ k-γ   (Equation 4.2) 
To define a scale-free topology criterion, R2 is the model fitting index of the linear model that 
regresses log(p(k)) on log(k) based on Equation 4.2, and higher R2 means a better model fit to 
the scale free topology. R2 increased as power increased (Figure 4.6A), thus higher power would 
yield a network more resembling scale free topology. However, there was also a tradeoff 
between scale free network resemblance and connectivity (Figure 4.6B), and too sparse 
networks forfeit too much connection information. In order to construct a network with scale-
free topology and reasonable connectivity, the first power value that passed R2 = 0.8 was picked 
to fulfill scale-free topology criterion while retaining high enough connections to investigate 
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nodes relationships. To detect modules in the co-expression network, the topological overlap 
dissimilarity was measured and a topological overlap matrix (TOM) was derived to reflect 
relative interconnectedness between two nodes. Based on TOM, hierarchical clustering and 
different tree-cutting approaches were applied to determine module boundaries and gene 
memberships[165]. Figure 4.7A showed different modules derived from dynamic tree cutting on 
hierarchical clustering of the transcriptome wide TOM matrix containing the top 20% most 
variable genes. The dynamic tree cutting is a top-down approach that interactively decomposes 
and combines cluster branches until the assignment of module becomes stable. One problem of 
this dynamic tree cutting method is that it may fail to assign some tree branches, although it was 
not an issue in my TREM2 study (Figure 4.7A). To resolve this potential problem, Figure 4.7B 
showed another module assignment of the same hierarchical clustering tree with a dynamic 
hybrid cutting method, which is a bottom-up approach that improves the detection of any 
unassigned branches. Noticeably, for the module I was interested in containing TREM2 gene 
(Figure 4.7AB labeled with star) the two tree cutting methods produced almost identical 
assignments with only 12 (out of 456) more genes in the hybrid tree cutting.  The TREM2 
modules derived from both methods showed almost identical gene memberships and network 
topology (Figure 4.7CD). TREM2 gene is expressed in microglia and involved in immune 
responses in AD. Not surprisingly AD risk related genes HLA-DRB1 and HLA-DRB5, which 
play central roles in immune system by presenting peptides derived from antigens, were also 
present in the same module with TREM2. Another sporadic AD risk gene in this module is 
DSG2, which is important for cell to cell adhesion functions, and its cytoplasmic domain anchors 
the cytoskeleton by interacting with plaque proteins in the desmosome-intermediate filament 
complex[60]. What really caught my attention is the microglial MS4A gene cluster that was 
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located in the same co-expression module with TREM2, because we have recently observed that 
common variants in the MS4A region were significantly associated with elevated CSF soluble 
TREM2 level (rs1582763; p-value = 1.15×10-15)[70]. 
 
 
Figure 4.6 TREM2 network soft thresholding. A) R2 is the scale-free model fitting index. Higher R2 
means a better model fit to the scale free topology. R2 was plotted for power values ranging from 1 to 20. 
A R2 = 0.8 cut-off line was plotted. B) However, there was also a tradeoff between scale free network 
resemblance and connectivity as the mean connectivity decreases as the power increases.  
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In the previous study of network analysis in LOAD using WGCNA, Zhang et al. 
identified an immune/microglia module from prefrontal cortex microarray data. In this module 
containing TREM2, TYROBP scored the highest based on both regulatory strength and 
differential expression, which is an adaptor protein of TREM2. Apart from these two genes, 
MS4A4A and MS4A6A were also located in the same module. Although I identified MS4A4A and 
MS4A6A in the same module in my analysis, I seemed to have missed an important finding from 
Figure 4.7 TREM2 network TOM clustering and gene module assignment. A) Dynamic tree cutting 
B) Dynamic hybrid cutting. C) TREM2 module derived from dynamic tree cutting. D) TREM2 module 
derived from dynamic hybrid cutting. The module contained TREM2 is starred. 
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Zhang et al., which is TYROBP. Apart from the fact that my data is generated from RNA-Seq 
that is different from their microarray data, my analysis also aggregated samples from non-
independent multiple tissues through repeated measures correlation. To recapitulate their finding 
and to understand why I missed TYROBP in my TREM2 module, I performed a robust WGCNA 
analysis on single tissue region from anterior prefrontal cortex (BM10), which is the same region 
where they identified the TREM2-TYROBP module. The robust WGCNA is a resampling version 
of a regular WGCNA that I randomly resampled two thirds of the total sample size for each 
iteration, and repeated the process for 50 iterations to assess module assignment robustness. In 
this analysis, I focused on four genes that are TREM2, MS4A4A, MS4A6A, and TYROBP. 
MS4A4A and MS4A6A are from the same MS4A gene cluster located nearby on chromosome 11. 
Their expression patterns are highly correlated so they are included in this robustness assessment 
as positive controls. In the full run with all available samples from BM10 (N = 181), MS4A4A, 
MS4A6A, and TYROBP were assigned into module 12, colored as tan module in Figure 4.8 
labeled with star. TREM2 was not assigned to any module in the full-size run. It worth 
mentioning that in the previous study, Zhang et al. also applied Bayesian network analysis and 
pathway analysis to further annotate the submodules from their TREM2-TYROBP network. In 
their pathway analysis, MS4A4A, MS4A6A, and TYROBP were segregated into the complement 
pathway, whereas TREM2 was assigned to a separate pathway named Fc receptor system. This 
observation suggested that compared to TREM2-TYROBP co-expression, there might be a 
stronger relationship within MS4A4A-MS4A6A-TYROBP co-expression pattern. My robust 
WGCNA results supported this hypothesis but more in-depth simulations with 1000 runs are 
required to further validate this hypothesis.
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Figure 4.8 Robust WGCNA of anterior prefrontal cortex. Top hierarchical tree is derived from full dataset with all the 
subjects. Two thirds of the total sample size were randomly sampled for each resampling run. One full size run and total of 50 
resampling runs with consensus module assignment were shown as color bars. The module contained TREM2 is starred.  
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TREM2 MS4A4A MS4A6A TYROBP TREM2 MS4A4A MS4A6A TYROBP
Full data set 0 12 12 12 5713 5770 5769 5808
Resampling 1 12 12 12 12 6741 6745 6744 6798
Resampling 2 37 0 0 0 2513 2558 2559 2486
Resampling 3 12 0 0 12 2569 2541 2540 2574
Resampling 4 0 12 12 12 1309 1354 1353 1450
Resampling 5 30 30 30 30 2538 2536 2535 2525
Resampling 6 0 12 12 27 2694 2766 2765 2645
Resampling 7 0 12 12 12 2028 1892 1950 1972
Resampling 8 0 12 12 12 1529 3569 3568 3583
Resampling 9 0 12 12 12 4876 5171 5177 5196
Resampling 10 0 26 26 26 766 6371 6370 6366
Resampling 11 0 12 12 25 2931 2829 2828 2583
Resampling 12 12 12 12 12 6498 6566 6565 6533
Resampling 13 0 0 12 12 4449 4421 4481 4490
Resampling 14 12 12 12 12 3593 3605 3604 3594
Resampling 15 32 32 32 12 1709 1695 1694 1731
Resampling 16 0 12 12 29 6272 6785 6787 6637
Resampling 17 0 12 12 12 657 4664 4663 4740
Resampling 18 12 12 12 12 2010 2108 2107 2034
Resampling 19 33 33 33 0 2559 2532 2529 2593
Resampling 20 12 12 12 12 4903 4918 4922 4924
Resampling 21 0 0 12 12 1688 1726 1849 1766
Resampling 22 0 0 0 12 3187 3452 3451 3553
Resampling 23 12 12 12 12 2681 2711 2710 2697
Resampling 24 0 12 12 12 5691 5959 5958 5892
Resampling 25 12 0 0 12 4642 4595 4589 4650
Resampling 26 28 28 28 27 2832 2803 2802 2892
Resampling 27 0 29 29 28 2055 2727 2726 2707
Resampling 28 0 0 0 12 1525 2750 2749 2709
Resampling 29 0 12 12 12 1361 1779 1778 1863
Resampling 30 0 12 12 12 1573 2146 2147 2183
Resampling 31 0 12 12 34 1982 2150 2149 2067
Resampling 32 0 12 12 12 1636 1655 1654 1701
Resampling 33 33 0 0 0 2853 2845 2844 2640
Resampling 34 12 12 12 12 6690 6647 6646 6728
Resampling 35 0 12 12 12 4430 4601 4599 4584
Resampling 36 12 0 0 12 6349 6302 6301 6440
Resampling 37 0 0 0 12 5409 5405 5404 5455
Resampling 38 0 25 25 12 2083 2216 2215 2262
Resampling 39 0 12 12 12 6470 6793 6792 6720
Resampling 40 12 12 12 12 6788 6798 6797 6844
Resampling 41 0 0 12 12 4116 4314 4448 4397
Resampling 42 0 12 12 12 6723 6739 6737 6655
Resampling 43 0 12 12 12 3958 4249 4248 4286
Resampling 44 0 12 12 12 5442 5892 5897 5914
Resampling 45 0 12 12 12 4219 4434 4438 4461
Resampling 46 0 0 0 12 3833 4361 4360 4297
Resampling 47 0 12 12 29 4060 4299 4298 4214
Resampling 48 33 0 0 12 6676 6669 6668 6742
Resampling 49 12 12 12 12 3809 3790 3803 3878
Resampling 50 12 12 12 12 4885 4861 4860 4917
Module Assignment Dendrogram Postion
RUN
Table 4.3 Robust WGCNA simulation of TREM2  module
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TREM2 Study Bayesian network construction 
To further infer the relationship between TREM2 and MS4A, Bayesian network inference 
was applied to the WGCNA module containing TREM2 gene. Bayesian network infers factorized 
probability distribution from gene expression, and incorporates it into directed acyclic graphical 
representation of the network. As shown in Figure 4.9, compared to undirected graphs from 
WGCNA, Bayesian network inference produces directed graphs with arrows pointing from 
parent nodes to child nodes. Directed acyclic graph has no directed cycles, which generates a 
topological ordering of nodes. The resultant network was produced from averaging across 200 
bootstraps with both connection strength and direction probability hard cutoffs. In the averaged 
final network, there are numerous singletons, doubletons, and small branches with less than 10 
nodes. The large central branch containing TREM2 was labeled with blue, and previously 
identified AD risk genes were labeled with red. It worth noticing that there was a gene regulatory 
cascade from MS4A6A to MS4A4A to TREM2, suggesting a potential regulatory effect of MS4A 
genes on TREM2. This observation has been supported by our recent in-vitro MS4A knockdown 
study using cultured macrophage[70]. We observed that the soluble TREM2 level in cell culture 
was decreased after MS4A4A knockdown but it does not respond to MS4A6A knockdown. The 
knockdown and Bayesian network results together suggest MS4A4A might be the direct regulator 
of TREM2.  
Pathway analysis was performed to further annotate the function of this TREM2 module, 
and top 8 functional pathways were labeled in the graph. The central large branch containing 
TREM2, MS4A genes, and HLA-DRB genes were involved in immune system related pathways, 
such as bacterial or parasitic infections, autoimmune disease systemic lupus erythematosus, toll-
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like receptors mediated pathogen recognition, phagocytosis and complement cascades. The 
second largest branch next to the blue branch was enriched with ribosomal pathway. Compared 
to the pathway analysis results from Zhang et al. TREM2 module, my top 8 functional pathways 
with many overlapped genes replicated 4 out of 5 pathways that they highlighted for their 
TREM2 network. 
Figure 4.9 TREM2-MS4A Gene Network. AD related and top eight pathways are color coded 
accordingly. The largest branch is color coded in blue. V-structures are labeled in bold. 
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4.4.3 Disrupted and acquired genes identified in network module of PSEN1 
mutation carriers  
PSEN1 study WGCNA network construction 
Similar to the TREM2 study, I accessed RNA-Seq data from four cortical regions of 
MSSM[3], and estimated the gene expression correlation combining all four areas using repeated 
measure correlation. There are two key methodological differences in the approach I employed 
to model PSEN1 network:  first, only non-demented controls were included to construct the 
network; second, instead of a system-based approach selecting most variable genes from the 
whole transcriptome, only genes correlated with PSEN1 expression pattern were included. The 
genes that are correlated with PSEN1 expression are potentially linked to AD pathology by 
assuming ‘guilt-by-association’. With this seed-based approach using PSEN1 as a bait, I pre-
selected genes that are co-expressed with PSEN1 gene in both PSEN1 mutation carriers (N = 18) 
and non-carrier non-demented controls (N = 14) to build a co-expression network (Figure 4.10). 
Collectively, total of 5,809 genes correlated with PSEN1 were selected from PSEN1 non-carriers 
(Figure 4.10A) and mutation carriers (Figure 4.10B) that were jointly overlapped with genes 
correlated with PSEN1 from MSSM non-demented control participants.  
 
Figure 4.10 PSEN1 
seeded network gene 
selection. Select genes 
from PSEN1 mutation 
carriers and non-carriers 
correlated with MSSM 
control PSEN1 gene 
expression.  
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 With similar soft thresholding power selection and hierarchical clustering tree cutting 
approaches, modules containing PSEN1 were produced for both dynamic tree cutting (Figure 
4.11AC) and dynamic hybrid cutting (Figure 4.11BD). Compared to the dynamic tree cutting 
module (Figure 4.11A), the dynamic hybrid cutting (Figure 4.11B) lost branches to the left of 
the module and gained branches to the right of the module labeled by arrow heads. Based on a 
human visual inspection of the hierarchical clustering tree, the gain of the right branches might 
be reasonable but the loss of the left branches seems to be spurious. However, the dynamic 
hybrid cutting subdivided the PSEN1 module and grouped the leftmost branches to the large 
module on the left of PSEN1 module (Figure 4.11B turquoise module), due to which the 
dynamic hybrid cutting PSEN1 module lost BACE1, BIN1, and oligodendrocyte proportion 
measures (Figure 4.11D) compared to dynamic tree cutting (Figure 4.11C). Based on queries of 
PSEN1 in Brain RNA-Seq database of human brain purified cell type specific expression 
analysis[291] (http://www.brainrnaseq.org/; Figure 4.12A) and our single nuclei RNA-Seq 
dataset[66] (http://ngi.pub/snuclRNA-seq/; Figure 4.12B), PSEN1 is mostly expressed in 
oligodendrocyte, which support dynamic tree cutting PSEN1 module assignment. 
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Figure 4.11 PSEN1 network TOM clustering and gene module assignment. A) Dynamic 
tree cutting B) Dynamic hybrid cutting. C) PSEN1 module derived from dynamic tree 
cutting. D) PSEN1 module derived from dynamic hybrid cutting. The module contained 
PSEN1 is starred. 
 
Figure 4.12 PSEN1 is mostly expressed 
in oligodendrocyte. A) PSEN1 
expression in purified cell type specific 
expression analysis[291].  B) PSEN1 
expression in our single nuclei RNA-Seq 
dataset[66]. 
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With the dynamic tree cutting PSEN1 module, I performed differential correlation and 
differential expression analysis and functional annotation to identify genes that are altered in 
PSEN1 mutation carriers. The analysis was replicated in another independent PSEN1 mutation 
dataset. The genes were categorized into five groups and depicted as a Venn diagram[120] to 
show the overlaps among the groups (Figure 4.13). In group A, there were 268 genes that are 
significantly correlated with PSEN1 expression in Knight ADRC non-demented controls. In 
group B, there were 264 genes that are significantly correlated with PSEN1 expression in Knight 
ADRC PSEN1 mutation carriers. In group C, there were 269 genes differentially expressed 
significantly comparing Knight ADRC PSEN1 mutation carriers to non-demented controls. In 
group D, there were 25 genes that were differentially correlated with PSEN1 when comparing 
correlation derived from group A to group B[73]. In group E, there were 64 genes specifically 
replicated in GEO PSEN1 mutation carrier data (removing genes replicated in GEO PSEN1 non-
carrier early onset AD cohort). Genes from combinations of A + C, A + D, and A + C + D (total 
of 47 genes) were potentially disrupted genes that only exist in control cohort but disappeared in 
PSEN1 mutation carrier cohort. Genes from combinations of B + E, B + C + E, and B + C + D + 
E (total of 13 genes) were potentially emerged risk genes that were differentially correlated with 
PSEN1 and/or differentially expressed when comparing PSEN1 mutation carriers to non-carriers, 
and they were not correlated with PSEN1 in control cohort.  
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Pathway analysis were performed to the disrupted (N = 47) gene groups, emerged (N = 
13) gene groups, separately and combined. In the disrupted group, arrhythmogenic right 
ventricular cardiomyopathy (ARVC) pathway reached significance after multiple testing 
correction, which contains JUP, ITGB4, and LMNA. Interestingly, a missense mutation 
(p.Asp333Gly) in PSEN1 were previously reported in severe progressive dilated 
cardiomyopathy[170] suggesting a shared common pathway between heart disease and 
autosomal dominant AD were disrupted in PSEN1 mutation carriers. Among the three ARVC 
related genes, LMNA is particularly interesting because mutation in this gene alone could result 
in an extremely rare disease called Hutchinson-Gilford progeria syndrome (1 in 4 million 
Figure 4.13 PSEN1 module genes annotation. A) Genes correlated with PSEN1 expression in Knight 
ADRC non-demented controls. B) Genes significantly correlated with PSEN1 expression in Knight 
ADRC PSEN1 mutation carriers. C) Genes differentially expressed significantly comparing Knight 
ADRC PSEN1 mutation carriers to non-demented controls. D) Genes differentially correlated with 
PSEN1 when comparing correlation derived from group A to group B. E) Genes specifically replicated in 
GEO PSEN1 mutation carrier data.  
  
173 
newborns worldwide). Patients with this disease went through a rapid “premature aging” process 
with growth failure, fat and hair loss, age-looking skin, and death at average of 14.6 years largely 
due to cardiac disease or cerebrovascular disease[262]. Although due to very limited autopsy 
samples, no pathological signs related to dementia or Alzheimer’s disease was identified, this 
accelerated aging process manifested in this disease is intriguing because aging is the most 
important risk factor for AD. Previously in another independent study, we also observed a 
significant increase of LMNA expression in AD brain and significantly associated with plaque 
load[279]. Notice that Alzheimer’s disease presenilin pathway containing JUP and CD44 was 
also significant in the disrupted group pathway analysis. In the emerged group, ELMO1 and 
DOCK1 are related to shigellosis, bacterial invasion of epithelial cells, and integrin signaling 
pathway (Table 4.4). Interestingly, our group have identified a circular form of DOCK1 
(circDOCK1) was significantly up-regulated in ADAD cohort with predominantly PSEN1 
mutation carriers. DYNC1LI2 encodes light intermediate chain 2 of dynein protein, which is a 
family of cytoskeletal motor proteins. It is not surprised to see this gene is related to Huntington 
Disease pathway. When combing both disrupted and emerged groups, apart from ARVC, 
shigellosis also reached significance after multiple testing correction. Shigella, a type of Gram-
negative bacteria, could induce shigellosis after infection with symptoms including diarrhea, 
fever, and stomach cramps. The infection usually last for 5 to 7 days but there has been evidence 
suggesting Gram-negative bacterial molecules, such as lipopolysaccharide and E coli K99 pili 
protein, are associated with AD risk and colocalized with amyloid plaques[286]. Shigella 
infection related pathway might be involved as an emerged immune response to presenilin 
pathway disruption in PSEN1 mutation carriers or directly related to sporadic AD susceptibility.
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Type Source Term Overlap P-value Adjusted P-value Z-score Combined Score Genes
Arrhythmogenic right ventricular cardiomyopathy (ARVC)_Homo sapiens_hsa05412 3/74 7.01×10
-04
3.51×10
-02 -1.82 13.22 JUP;ITGB4;LMNA
Inositol phosphate metabolism_Homo sapiens_hsa00562 2/71 1.21×10
-02
1.16×10
-01 -1.92 8.47 ITPKB;PLCD1
Biosynthesis of amino acids_Homo sapiens_hsa01230 2/74 1.31×10
-02
1.16×10
-01 -1.71 7.40 CPS1;SHMT1
Hypertrophic cardiomyopathy (HCM)_Homo sapiens_hsa05410 2/83 1.63×10
-02
1.16×10
-01 -1.72 7.08 ITGB4;LMNA
Dilated cardiomyopathy_Homo sapiens_hsa05414 2/90 1.90×10
-02
1.16×10
-01 -1.72 6.80 ITGB4;LMNA
ECM-receptor interaction_Homo sapiens_hsa04512 2/82 1.59×10
-02
1.16×10
-01 -1.62 6.71 ITGB4;CD44
Phosphatidylinositol signaling system_Homo sapiens_hsa04070 2/98 2.23×10
-02
1.16×10
-01 -1.67 6.35 ITPKB;PLCD1
Carbon metabolism_Homo sapiens_hsa01200 2/113 2.90×10
-02
1.32×10
-01 -1.45 5.15 CPS1;SHMT1
Alzheimer disease-presenilin pathway_Homo sapiens_P00004 2/99 2.27×10
-02
6.24×10
-02 -1.28 4.86 JUP;CD44
Arginine biosynthesis_Homo sapiens_P02728 1/6 1.40×10
-02
6.24×10
-02 -0.91 3.88 CPS1
Shigellosis_Homo sapiens_hsa05131 2/65 7.93×10
-04
7.97×10
-03 -1.74 12.45 ELMO1;DOCK1
Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 2/78 1.14×10
-03
7.97×10
-03 -1.76 11.94 ELMO1;DOCK1
Vasopressin-regulated water reabsorption_Homo sapiens_hsa04962 1/44 2.82×10
-02
1.32×10
-01 -1.90 6.78 DYNC1LI2
Integrin signalling pathway_Homo sapiens_P00034 2/156 4.46×10
-03
8.91×10
-03 -1.78 9.64 ELMO1;DOCK1
Huntington disease_Homo sapiens_P00029 1/124 7.77×10
-02
7.77×10
-02 -1.56 3.97 DYNC1LI2
Shigellosis_Homo sapiens_hsa05131 3/65 9.82×10
-04
4.36×10
-02 -1.74 12.07 ELMO1;DOCK1;CD44
Arrhythmogenic right ventricular cardiomyopathy (ARVC)_Homo sapiens_hsa05412 3/74 1.43×10
-03
4.36×10
-02 -1.79 11.70 JUP;ITGB4;LMNA
Inositol phosphate metabolism_Homo sapiens_hsa00562 2/71 1.93×10
-02
1.66×10
-01 -1.89 7.45 ITPKB;PLCD1
Biosynthesis of amino acids_Homo sapiens_hsa01230 2/74 2.08×10
-02
1.66×10
-01 -1.64 6.36 CPS1;SHMT1
Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 2/78 2.30×10
-02
1.66×10
-01 -1.64 6.17 ELMO1;DOCK1
Hypertrophic cardiomyopathy (HCM)_Homo sapiens_hsa05410 2/83 2.58×10
-02
1.66×10
-01 -1.62 5.93 ITGB4;LMNA
ECM-receptor interaction_Homo sapiens_hsa04512 2/82 2.52×10
-02
1.66×10
-01 -1.53 5.63 ITGB4;CD44
Dilated cardiomyopathy_Homo sapiens_hsa05414 2/90 2.99×10
-02
1.66×10
-01 -1.59 5.59 ITGB4;LMNA
Phosphatidylinositol signaling system_Homo sapiens_hsa04070 2/98 3.50×10
-02
1.78×10
-01 -1.55 5.21 ITPKB;PLCD1
Carbon metabolism_Homo sapiens_hsa01200 2/113 4.53×10
-02
1.97×10
-01 -1.38 4.26 CPS1;SHMT1
Integrin signalling pathway_Homo sapiens_P00034 3/156 1.15×10
-02
7.15×10
-02 -1.78 7.95 ITGB4;ELMO1;DOCK1
Alzheimer disease-presenilin pathway_Homo sapiens_P00004 2/99 3.57×10
-02
8.56×10
-02 -1.18 3.93 JUP;CD44
Combined
KEGG
Panther
Table 4.4 PSEN1  module disrupted and emerged genes pathway analysis
Acquired
KEGG
Panther
Disrupted
KEGG
Pather
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4.5 Discussion 
To interrogate highly interconnected complex system, network approach not only 
provides a holistic view of the overall topology but also retains the resolution to the level of each 
pairwise relationship. With this powerful approach, I analyzed sporadic AD cohort using a 
system-based approach focusing on the TREM2 module. Using WGCNA, I reconfirmed the 
observation of MS4A4A and MS4A6A in the TREM2 module, and inferred that MS4A4A might 
be the kay regulator of TREM2 through Bayesian network analysis. This finding replicated 
previous network analysis that observed the same TREM2-MS4A pattern, and also provided a 
network explanation of our recent finding about the strong association between MS4A gene 
cluster and soluble TREM2 level in CSF. I then adapted the approach and applied to ADAD 
cohorts specially with PSEN1 mutation carriers. With tissues collected from multiple cortical 
regions in the context of non-demented controls, I constructed a healthy cortical network 
topology. The network nodes are comprised of genes that are significantly co-expressed with 
PSEN1 in both and PSEN1 mutation carriers and non-demented controls with no PSEN1 
mutation. With functional annotation of the network nodes, I identified 47 genes only present in 
control cohort that were potentially disrupted in PSEN1 mutation carriers; I also identified 13 
genes only present in PSEN1 mutation carriers but not in control cohort that were potentially 
emerged as downstream transcriptional events acquired into the PSEN1 network. In this list of 
genes, I highlighted three genes, LMNA, DOCK1, and DYNC1LI2, that are associated to AD in 
additional studies.  
LMNA encodes lamin protein[281], which is important for nucleoskeleton structure in 
providing mechanical support to nuclear envelope[61, 245]. Apart from the premature aging 
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syndrome mentioned above in Chapter 4.4.3, other disease phenotypes include muscular 
dystrophy, lipodystrophy, and cardiomyopathy. In relation to AD, it has been shown that lamin 
dysfunction has led to neuronal death in tauopathy in Drosophila, which is also conserved in 
human tauopathy[96]. In an interactome study that produced a comprehensive map of molecular 
interactions derived from yeast two-hybrid and literature curated interactions[42, 182], 
Alzheimer’s disease and heart disease are close neighbors in the network by sharing several 
proteins associated with both diseases. Apart from the missense mutation in PSEN1 that leads to 
heart disease as I discussed above in Chapter 4.4.3, co-occurrence of cardiovascular disease and 
AD in elderly suggested additive or synergistic effects on both sides[16].  
DOCK1 encodes a member of the dedicator of cytokinesis protein (Dock) family. 
DOCK3 has been found to be associated with AD[149]. This gene’s protein product was 
originally discovered in a yeast two-hybrid protein-protein interaction screening, which binds to 
presenilin so it was named as PBP (presenilin-binding protein) in the original paper[149]. We 
have recently inferred circular RNAs (circRNAs) from RNA-Seq data, which is a type of 
noncoding RNA that may be involved in AD through a circRNA-mediated “miRNA sponging 
systems”[175]. Although Dock1 does not bind to presenilin directly[149], circular form of 
DOCK1 transcript (circDOCK1) was found to be upregulated in both sporadic and autosomal 
dominant AD. These observations suggested a potential involvement of Dock family in AD 
pathology through the presenilin pathway. 
DYNC1LI2 encodes light intermediate chain of dynein, which is a motor protein that is 
required for retrograde axonal transport along microtubules[236, 264]. Dysfunction of this 
protein leads to disruption of endosomal and lysosomal pathway[257]. Mutations in dynein has 
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been found in several neurodegenerative diseases suggesting its essential role in neuronal 
survival, especially for motor neurons[48, 81, 188, 228]. In relation to AD, accumulation of 
amyloid precursor protein was observed in aged monkey (Macaca fascicularis) brains with 
dynein knockdown[152], and dynein-mediated endocytic dysfunction[256] with increased Rab 
GTPase level might be involved in this process[152].  
With more high-throughput omic data being generated, integrating data from different 
sources and dimensions will be a promising future direction for network analysis. Apart from 
multi-dimensional networks, generating hierarchical network (network of networks) could also 
be an interesting direction. By learning more from the science of complexity, we could gain 
more insights into the complex systems from gene regulation[123] to human brain[173].  To 
conclude, my study demonstrated the potential of using both system-based and seed-based 
network approaches in replicating and discovering AD related genes and their interactions. In 
sporadic AD cohort, I identified MS4A4A might be a key regulator for TREM2. In autosomal 
dominant AD cohort, I identified total of 60 genes that are disrupted or emerged as a 
consequence of PSEN1 mutation, in which I highlighted three genes with intriguing links to AD. 
Many of the remaining genes that are not discussed in detail in this chapter are also found to be 
associated with AD, such as ABCA2[176], GFAP[147], CXorf36[207], suggesting a great 
potential of using network analysis to generate working hypothesis. 
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Chapter 5: Conclusions and future directions 
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5.1 Dissertation work contributed to AD research 
In Chapter 2, a deconvolution pipeline for bulk RNA-Seq was developed to account for 
cell type specific effects in brain tissues. Due to disease pathology, cell type balance is disrupted 
in Alzheimer’s Disease (AD) brain, which is a key feature in neurodegeneration that has often 
been overlooked in transcriptome research. With deconvolution methods to better delineate cell 
population changes in disease condition, it would help interpret results and reveal transcriptional 
changes in a cell type specific manner.    
In Chapter 3, using cell type proportion as quantitative trait, a common pathway 
underlying aging brains has been identified in the presence or absence of neurodegenerative 
disease symptoms. A protective variant of TMEM106B, which was previously identified with a 
protective effect in FTD, was identified to be associated with neuronal proportion in aging 
brains, suggesting a common pathway underlying neuronal protection and cognitive reservation 
in elderly. This extended analysis yield from deconvolution results from Chapter 2 
demonstrated one promising application of deconvolution followed by cell type QTL analysis in 
identifying new genes or pathways underlying neurodegeneration or aging in general. 
In Chapter 4, using network analysis I replicated and reconfirmed the co-expression 
pattern between MS4A gene cluster and TREM2 in sporadic AD, from which further evidence 
was inferred from Bayesian network analysis to show that MS4A4A might be a potential 
regulator of TREM2 that is validated by in-vitro experiments. In Autosomal Dominant AD 
(ADAD) cohort, disrupted and acquired genes were identified from PSEN1 mutation carriers. 
Among the genes, previous identified AD related gene and pathways were revealed together with 
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novel findings. These results demonstrated the great potential of applying network approach in 
identifying disease associated genes and the interactions among them.  
5.2 Aging, proteinopathy, and neurodegeneration 
Apart from clinical criteria, diagnosis of neurodegenerative disorders heavily hinges on 
proteinopathies observed either from longitudinal brain imaging and Cerebrospinal fluid data and 
postmortems neuropathology. Although each disease has its own characteristic protein(s), 
pathological proteins from a different neurodegenerative disorder are also observed in patient 
autopsies. For example, AD is characterized by amyloid β and tauopathy; Parkinson’s Disease is 
characterized by alpha-synuclein; FTD is characterized by TDP-43 pathology. However, in AD 
post-mortem tissues alpha-synuclein and TDP-43 are often detected in. Similarly, amyloid β and 
tau are also present in PD. TDP-43 is not only identified in FTD brains, but it also presents in 
various neurodegenerative disorders, such as AD, ALS, hippocampal sclerosis as I have 
discussed in Chapter 3.5. Based on what I have learnt from the field and observations obtained 
from this dissertation work, a model is summarized and depicted in Figure 5.1.  
Initially, soluble protein substrates in their normal folding states are performing normal 
functions in the brains. However, due to triggering-events that could be genetic, lifestyle or 
environmental factors, such as microbial infection, traumatic brain injury, toxic metal exposure, 
and even lack of sleep, the normal protein substrates become insoluble through a mis-folding 
process and start to aggregate. Regarding the initial formation of protein aggregates, a seeding 
hypothesis has been proposed[139].  Taking amyloid formation as an example, an initial 
nucleation event generates a seed that later initiates the following pathogenic accumulation of 
amyloid β proteins in an exponential way of aggregation. Then this pathogenic aggregation starts 
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to propagate based on well-established prion observations that a diseased protein could convert a 
normal protein into a diseased state so that this process is able to propagate to other unaffected 
proteins. One study also demonstrated that the proteins with prion-like characteristics are also 
transmissible from patient to patient through injection of cadaveric pituitary-derived growth 
hormone[140] that induced AD pathology in patients without genetic risk factors.  
What type of mis-folded proteins are generated depends on the genetic background of the 
individual. For example, if one person carries mutations or risk variants in AD risk genes, such 
as APP, PSEN1, PSEN2, APOE, TREM2, this individual will be susceptible to amyloid β and tau 
aggregation. Carriers of PD risk variants, in genes such as PARK2, LRR2, PINK1, SNCA, will be 
susceptible to alpha-synuclein aggregation. And similarly, carriers of variants in in FTD risk 
genes, such as MAPT, GRN or C9orf72, will be susceptible to tau and TDP-43 aggregation. As it 
was discussed above, different categories of proteinopathies are not mutually exclusive in their 
distribution, which means alpha-synuclein protein aggregation could be observed in AD patients 
with amyloid β and tau pathologies. Thus, a patient as depicted in Figure 5.1 is clinically 
diagnosed with AD, but this individual also harbors multiple other proteinopathies that have not 
reached the threshold for clinical manifestation. This observation could be explained by an 
omnigenic model that apart from core pathways of AD risk genes, a collection of low-effect risk 
genes for other neurodegenerative disorders contribute non-trivial effects to the pathologic 
protein aggregation process. Apart from risk factors, there are also protective factors that could 
help ameliorate the damaging effect brought by toxic proteins that protect individuals with 
protein aggregation pathology but no cognitive deficits. 
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Figure 5.1 Proteinopathy model in neurodegenerative disorders. Triggered by various factors such as familial mutation, 
microbial infection, traumatic brain injury, toxic metal exposure, or general aging process, normal proteins may become different 
types of misfolded proteins based on a subject’s specific genetic or epigenetic architecture as shown in A) that form alpha-
synuclein, amyloid beta, or TDP-43 proteinopathies that belong to different neurodegenerative disease categories. B) Accumulated 
proteinopathies may lead to neuronal loss. C) As disease progresses, the subject may experience cognitive deficit with more 
accumulated proteinopathies. D) A patient diagnosed with AD may have alpha-synuclein and TDP-43 deposition apart from 
amyloid plaques that suggests neurodegeneration shall be considered as a continuous trait rather than distinctive disease categories. 
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5.3 Future directions in developing therapies for AD  
A prevalence study focusing on preclinical and clinical AD prevalence showed that there 
are eight times more people in pre-symptomatic phase than people in clinical phase[39]. People 
with preclinical AD have either amyloidosis or neurodegeneration or both, but have no clinical 
manifestation of symptoms. This data showed great promise for preventive therapies that by 
either slowing down disease progression or delaying onset, it will be possible to protect a large 
number of people from developing AD during their lifetime. Currently, more than half of the 
disease modifying therapies are focusing on anti-amyloid approach, including immunotherapy, 
BASE inhibitor, and anti-aggregation. However, there have no signs of any success so far in this 
path. One problem with some clinical trial designs are the patients recruited for the trials are 
usually in their middle or late stage of AD. As it has been shown above, during the long 
preclinical phase, especially in the sporadic form of neurodegenerative disorders, 
neuropathological and neurodegenerative changes have occurred long before any clinical 
symptoms. However, by the time of clinical manifestation, it is usually too late for any treatment 
due to the extensive brain damage. Clearance of aggregated proteins may not be effective to 
compensate cognitive deficit due to massive neuronal loss. If neuronal loss is not reversible in 
the current situation, early intervention, amyloid clearance or trigger-targeting therapies should 
be performed earlier during disease progression to target people still in their pre-symptomatic 
phases. Apart from the amyloid pathway, other potential pathways to target are the lysosomal 
and autophagy pathway to facilitate toxic protein degradation. In addition, targeting immune 
pathway could prevent vicious cycles of proinflammatory responses and boost immune resilience 
to infections. All these pre-clinical therapies heavily rely on achieving early diagnosis in the 
general population. To advance early diagnosis, the development of non-invasive and accurate 
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diagnosis tools is highly demanded to predict disease at early stages before symptom onset. We 
also need to advance our understanding of genetic and environmental triggers of AD to identify 
and better target susceptible cohorts. 
Given the complexity of neurodegenerative disorders, we also need to tailor therapies 
differently for people with different genetic backgrounds. This idea of precision medicine has 
gained success in other medical fields, for example cancer treatment, from which we can learn. 
With better understanding of AD etiology, test results shall be interpreted in the context of 
person specific genetic architecture. Studies with more diverse cohorts shall be supported to 
understand ethnic and sex differences, which should also be considered in evaluating drug 
responses, dosages and side effects during clinical trials. Last but not least, cognitive or motor 
function improvement therapies and health care facilities specially designed for people with 
dementia or motor deficits are also needed for patients with neurodegenerative disorders. 
Regarding recent interests in finding protective factors, neuronal protection therapies could 
prevent the major detrimental consequence. As documented in this dissertation work, using cell 
type compositions inferred from deconvolution as disease endophenotypes, I identified 
protective variants in TMEM106B gene that may have neuronal protection effect in general aging 
groups independent of disease status, which could help understand the relationship between 
aging and neuronal survival and be a potential target for neuronal protection therapies. 
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